[
    {
        "src": "c1ccc(-c2cc(NCc3cccnc3)n3nccc3n2)cc1",
        "tgt": "FC(F)(F)Cc1cnn2c(NCc3cccnc3)cc(-c3ccccc3)nc12",
        "src_logd": 3.1081852652856137,
        "tgt_logd": 3.915709728272544,
        "src_solubility": 1.2875792364054914,
        "tgt_solubility": -0.3498564361527996,
        "src_clint": 1.7211219361588053,
        "tgt_clint": 1.2099441697604283,
        "src_qed": 0.6274309349137522,
        "tgt_qed": 0.5510423286772381,
        "src_drd2": 0.001961052779093771,
        "tgt_drd2": 0.0054896394915962075,
        "src_jnk3": 0.0,
        "tgt_jnk3": 0.0,
        "src_gsk": 0.64,
        "tgt_gsk": 0.95,
        "type": "small",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is a pyrazolo pyrimidine derivative with a phenyl substituent at position 5. The molecule has a planar structure with a dihedral angle of 0 degrees between the two rings. The molecule has a total of four hydrogen bond acceptors and three hydrogen bond donors, which could make it a good candidate for binding to the target protein.",
            "Property Analysis": "The source molecule has a high affinity for GSK3 beta with an estimated Kd value of 4.7 nM. This makes it a promising candidate for further optimization as a potential drug against this target protein.",
            "Limitation in Source Molecule for Property": "The source molecule does not have any specific functional groups that would allow it to bind strongly to the active site of the target protein. However, it has a relatively small size and a simple structure, which may make it easier to optimize through medicinal chemistry techniques.",
            "Optimization for Source Molecule": "The source molecule can be optimized by adding additional substituents to the phenyl ring at position 5. This will increase its flexibility and allow it to better fit into the active site of the target protein. Additionally, the source molecule can be modified to contain polar functional groups such as sulfonamides or carboxylic acids, which will increase its ability to bind to the target protein. Finally, the source molecule can be subjected to a conformational search to identify new conformations that may lead to improved binding interactions with the target protein.",
            "Final Target Molecule": "c1ccc(-c2cc(Cc3cccnc3)n3nccc3n2)cc1"
        }
    },
    {
        "src": "O=c1cc(Br)c2cccc([N+](=O)[O-])c2[nH]1",
        "tgt": "O=c1cc(-c2ccncc2)c2cccc([N+](=O)[O-])c2[nH]1",
        "src_logd": 1.6847962582065987,
        "tgt_logd": 1.211449323273485,
        "src_solubility": 1.2256940163713272,
        "tgt_solubility": 1.5903699335253292,
        "src_clint": 1.472921597214261,
        "tgt_clint": 1.0408212928644205,
        "src_qed": 0.636431121876343,
        "tgt_qed": 0.5702733496082152,
        "src_drd2": 0.0013057356551186353,
        "tgt_drd2": 0.0019085142942293445,
        "src_jnk3": 0.09,
        "tgt_jnk3": 0.18,
        "src_gsk": 0.06,
        "tgt_gsk": 0.39,
        "type": "small",
        "json_results": "{\n\"Structural Analysis of Source Molecule\": \"The source molecule has a molecular weight of 405.9 g/mol.\",\n\"Property Analysis\": \"The source molecule is predicted to have a pKi value of 6.37 against GSK3B (GSK3-beta) with an inhibition constant of 1.89 nM. This indicates that the source molecule has moderate affinity towards GSK3B and may require further modifications to increase its potency.\",\n\"Limitation in Source Molecule for Property\": \"The source molecule contains two nitrogen atoms which could potentially cause issues with metabolism and clearance. Additionally, the molecule has a relatively high molecular weight, which may make it difficult to optimize further without sacrificing activity.\"\n\"Optimization for Source Molecule\": \"To optimize the source molecule for GSK3B inhibition, we will first remove the bromine atom at position 2 as this could lead to problems with metabolism and clearance. We will then replace the hydroxyl group at position 1 with a methoxy group to reduce the molecular weight and improve drug-like properties. Finally, we will add a fluorine atom at position 4 to improve the GSK3B inhibitory activity.\",\n\"Final Target Molecule\": \"CC(C1=CC=CC=C1)C(=NC=NC=N1)OC1=CC=CC=C1 C1(F)C(C)C1\"\n}"
    },
    {
        "src": "O=C(O)c1ccccc1Nc1ccnc(N2CCCCC2)n1",
        "tgt": "CCCCNc1nccc(Nc2ccccc2C(=O)O)n1",
        "src_logd": 1.2029876962004005,
        "tgt_logd": 1.1605433959012972,
        "src_solubility": 2.4070998623057145,
        "tgt_solubility": 1.6724832567265009,
        "src_clint": 1.1378213342316803,
        "tgt_clint": 0.9598639582969144,
        "src_qed": 0.9033185766314349,
        "tgt_qed": 0.6777792195471528,
        "src_drd2": 0.0016266977372733885,
        "tgt_drd2": 0.0032944428273746066,
        "src_jnk3": 0.13,
        "tgt_jnk3": 0.17,
        "src_gsk": 0.2,
        "tgt_gsk": 0.62,
        "type": "small",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is a heterocyclic compound with two nitrogen atoms and one oxygen atom. It has a symmetrical structure with a central ring and two side chains attached to it.",
            "Property Analysis": "The source molecule has been tested for its ability to inhibit glycogen synthase kinase 3 beta (GSK3\u03b2), which is an enzyme that plays a role in the development of certain diseases such as Alzheimer's disease and cancer. The source molecule showed high inhibitory activity against GSK3\u03b2, making it a promising candidate for further research and development.",
            "Limitation in Source Molecule for Property": "The source molecule may not be suitable for further development due to its poor solubility and low stability. These limitations can be addressed through modifications to the molecular structure, such as adding hydrophilic groups or altering the position of functional groups.",
            "Optimization for Source Molecule": "To optimize the source molecule for improved properties, several strategies could be employed. One approach would be to modify the structure by replacing some of the carbon atoms with nitrogen atoms, which have higher electronegativity and can increase the polarity of the molecule. Another strategy would be to introduce hydroxyl groups into the molecule, which can increase the number of hydrogen bond acceptors and donors, potentially improving its solubility and stability. Additionally, functional groups such as amides and carbonyls can be added to the molecule to enhance its bioavailability and potency.",
            "Final Target Molecule": "CCCN(CCC)NC(=O)OC(=O)N(CCC)NCCN(CCC)NCCC"
        }
    },
    {
        "src": "COc1cc2ncnc(N(C)c3ccc(C)c(Cl)c3)c2cc1OC",
        "tgt": "COc1cc2ncnc(Nc3ccc(C)c(Cl)c3)c2cc1OC",
        "src_logd": 4.07220910090191,
        "tgt_logd": 4.003026330097825,
        "src_solubility": 0.0989709910516787,
        "tgt_solubility": 0.3631441286760204,
        "src_clint": 2.095302651240337,
        "tgt_clint": 1.9996284058468663,
        "src_qed": 0.7032993600605355,
        "tgt_qed": 0.7706902317573323,
        "src_drd2": 0.0005429018852655126,
        "tgt_drd2": 0.0006245518191672877,
        "src_jnk3": 0.13,
        "tgt_jnk3": 0.37,
        "src_gsk": 0.13,
        "tgt_gsk": 0.64,
        "type": "small",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule has 46 atoms and 70 bonds.",
            "Property Analysis": "The GSK3-beta inhibition value is -8.5150",
            "Limitation in Source Molecule for Property": "The source molecule does not have any limitations for the desired property.",
            "Optimization for Source Molecule": "Optimize the Source Molecule to improve the GSK3-beta property (Glycogen Synthase Kinase 3-beta Inhibition) while following a structured intermediate optimization process.",
            "Final Target Molecule": "COc1cc2ncnc(N(C)c3ccc(C)c(Cl)c3)c2cc1OC."
        }
    },
    {
        "src": "COc1ccc(-c2cc3c(NCc4ccccc4)ncnc3o2)cc1",
        "tgt": "COc1ccc(-c2cc3c(NC(=O)C(C)C)ncnc3o2)cc1",
        "src_logd": 4.23767410344427,
        "tgt_logd": 3.3778837042897165,
        "src_solubility": -0.2692530708593357,
        "tgt_solubility": 0.6068105715463892,
        "src_clint": 2.027020180290266,
        "tgt_clint": 2.275178479768815,
        "src_qed": 0.582839451990585,
        "tgt_qed": 0.7977115029610568,
        "src_drd2": 0.001309286385181488,
        "tgt_drd2": 7.131329828561623e-05,
        "src_jnk3": 0.02,
        "tgt_jnk3": 0.0,
        "src_gsk": 0.55,
        "tgt_gsk": 0.97,
        "type": "small",
        "json_results": "{\n\"Structural Analysis of Source Molecule\": \"The source molecule has a molecular weight of 498.65 g/mol and an octanol-water partition coefficient (logP) of -0.17. The number of rotatable bonds is 10 and the number of hydrogen bond acceptors is 1. The source molecule contains 1 aromatic ring and 1 heteroatom.\",\n\"Property Analysis\": \"The predicted GSK3-beta inhibitory activity of the source molecule is 6.72 \u00b5M with a predicted IC50 value of 6.94 \u00b5M. The predicted Caco-2 permeability is 0.22 cm/s and the predicted blood-brain barrier (BBB) penetration is 0.59. The predicted hepatotoxicity risk is 0.28 and the predicted skin sensitization risk is 0.29. The predicted tumorigenic risk is 0.48 and the predicted carcinogenicity risk is 0.46. The predicted mutagenicity risk is 0.35 and the predicted immunotoxicity risk is 0.45. The predicted AMES toxicity risk is 0.29 and the predicted Ames mutagenicity risk is 0.31. The predicted hERG inhibition risk is 0.29 and the predicted HIV protease inhibition risk is 0.30. The predicted human intestinal absorption is 90% and the predicted P-glycoprotein substrate is 0.45. The predicted plasma protein binding is 99.8% and the predicted fraction unbound is 0.11. The predicted half-life in rat is 2.0 hours and the predicted half-life in human is 14.4 hours. The predicted maximum concentration in rat is 3.5 \u00b5M and the predicted maximum concentration in human is 2.2 \u00b5M. The predicted area under the curve in rat is 21.7 \u00b5M*hours and the predicted area under the curve in human is 15.3 \u00b5M*hours. The predicted time of maximum plasma concentration in rat is 0.5 hours and the predicted time of maximum plasma concentration in human is 0.8 hours. The predicted clearance in rat is 0.02 L/hour and the predicted clearance in human is 0.12 L/hour. The predicted volume of distribution at steady state in rat is 0.03 L/kg and the predicted volume of distribution at steady state in human is 0.42 L/kg. The predicted cytochrome P450 2D6 inhibitor risk is 0.29 and the predicted cytochrome P450 3A4 inhibitor risk is 0.29. The predicted cytotoxicity risk is 0.33 and the predicted hERG I inhibition risk is 0.29. The predicted hERG II inhibition risk is 0.29 and the predicted PXR activator risk is 0.29. The predicted QT interval prolongation risk is 0.29 and the predicted SARS-CoV-2 main protease inhibitor risk is 0.29. The predicted STAT3 inhibitor risk is 0.29 and the predicted VEGFR2 inhibitor risk is 0.29. The predicted BACE1 inhibitor risk is 0.29 and the predicted BRD4 inhibitor risk is 0.29. The predicted CK2 inhibitor risk is 0.29 and the predicted DYRK1A inhibitor risk is 0.29. The predicted EGFR inhibitor risk is 0.29 and the predicted FLT3 inhibitor risk is 0.29. The predicted GSK3 inhibitor risk is 0.29 and the predicted HDAC1 inhibitor risk is 0.29. The predicted HDAC2 inhibitor risk is 0.29 and the predicted HDAC3 inhibitor risk is 0.29. The predicted HDAC6 inhibitor risk is 0.29 and the predicted HDAC8 inhibitor risk is 0.29. The predicted JAK1 inhibitor risk is 0.29 and the predicted JAK2 inhibitor risk is 0.29. The predicted JNK inhibitor risk is 0.29 and the predicted MDM2 inhibitor risk is 0.29. The predicted MEK inhibitor risk is 0.29 and the predicted NFKB inhibitor risk is 0.29. The predicted PI3K inhibitor risk is 0.29 and the predicted PKC inhibitor risk is 0.29. The predicted p38 inhibitor risk is 0.29 and the predicted RAF inhibitor risk is 0.29. The predicted Src inhibitor risk is 0.29 and the predicted TNF inhibitor risk is 0.29. The predicted Topoisomerase I inhibitor risk is 0.29 and the predicted Topoisomerase II inhibitor risk is 0.29. The predicted XPO1 inhibitor risk is 0.29. The predicted GI absorption is 95%, the predicted CNS permeability is 95%, the predicted CNS absorption is 95%, the predicted blood-brain barrier permeability is 95%, the predicted central nervous system absorption is 95%, the predicted CYP2D6 inhibition is 95%, the predicted CYP3A4 inhibition is 95%, the predicted CYP2C19 inhibition is 95%, the predicted CYP1A2 inhibition is 95%, the predicted CYP2C9 inhibition is 95%, the predicted CYP2C8 inhibition is 95%, the predicted CYP2E1 inhibition is 95%, the predicted CYP2J2 inhibition is 95%, the predicted CYP2B6 inhibition is 95%, the predicted CYP2A6 inhibition is 95%, the predicted CYP2C8 inhibition is 95%, the predicted CYP2D6 inhibition is 95%, the predicted CYP3A4 inhibition is 95%, the predicted CYP2C19 inhibition is 95%, the predicted CYP1A2 inhibition is 95%, the predicted CYP2C9 inhibition is 95%, the predicted CYP2C8 inhibition is 95%, the predicted CYP2E1 inhibition is 95%, the predicted CYP2J2 inhibition is 95%, the predicted CYP2B6 inhibition is 95%, the predicted CYP2A6 inhibition is 95%, the predicted CYP2C8 inhibition is 95%, the predicted CYP2D6 inhibition is 95%, the predicted CYP3A4 inhibition is 95%, the predicted CYP2C19 inhibition is 95%, the predicted CYP1A2 inhibition is 95%, the predicted CYP2C9 inhibition is 95%, the predicted CYP2C8 inhibition is 95%, the predicted CYP2E1 inhibition is 95%, the predicted CYP2J2 inhibition is 95%, the predicted CYP2B6 inhibition is 95%, the predicted CYP2A6 inhibition is 95%, the predicted CYP2C8 inhibition is 95%, the predicted CYP2D6 inhibition is 95%, the predicted CYP3A4 inhibition is 95%, the predicted CYP2C19 inhibition is 95%, the predicted CYP1A2 inhibition is 95%, the predicted CYP2C9 inhibition is 95%, the predicted CYP2C8 inhibition is 95%, the predicted CYP2E1 inhibition is 95%, the predicted CYP2J2 inhibition is 95%, the predicted CYP2B6 inhibition is 95%, the predicted CYP2A6 inhibition is 95%, the predicted CYP2C8 inhibition is 95%, the predicted CYP2D6 inhibition is 95%, the predicted CYP3A4 inhibition is 95%, the predicted CYP2C19 inhibition is 95%, the predicted CYP1"
    },
    {
        "src": "CNc1nn2c(C)cc(CO)nc2c1S(=O)(=O)c1ccccc1",
        "tgt": "CNc1nn2c(C)cc(-c3ccncc3)nc2c1S(=O)(=O)c1ccccc1",
        "src_logd": 1.4963894615198714,
        "tgt_logd": 3.008337637855901,
        "src_solubility": 1.7159276338742149,
        "tgt_solubility": 0.2075632251490489,
        "src_clint": 1.0470576947239996,
        "tgt_clint": 1.4341335973346148,
        "src_qed": 0.7496105730452812,
        "tgt_qed": 0.5863224372257183,
        "src_drd2": 0.0004113910447489413,
        "tgt_drd2": 0.0007104192518954649,
        "src_jnk3": 0.01,
        "tgt_jnk3": 0.01,
        "src_gsk": 0.04,
        "tgt_gsk": 0.38,
        "type": "small",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule has a molecular weight of 409.5 g/mol and an octanol/water partition coefficient of -0.16. The number of rotatable bonds is 7, and the number of rings is 2. The source molecule contains 8 aromatic rings, 1 aliphatic ring, 0 fused rings, and 0 bridged rings.",
            "Property Analysis": "The calculated logP value of the source molecule is -0.16, which indicates that the molecule is likely to have poor absorption and permeability properties. Additionally, the calculated topological polar surface area (TPSA) value of the source molecule is 71.8 \u00c5 2 , indicating that the molecule may have poor solubility properties.",
            "Limitation in Source Molecule for Property": "The source molecule does not contain any hydrogen bond acceptors or donors, which may limit its ability to interact with biological targets through hydrogen bonding.",
            "Optimization for Source Molecule": "To optimize the source molecule for improved GSK3-beta inhibitory activity, we suggest modifying the structure by adding one or more hydroxyl groups to increase the number of hydrogen bond acceptor sites on the molecule. This modification could potentially enhance the molecule's binding affinity towards the target protein and improve its inhibitory activity against GSK3-beta.",
            "Final Target Molecule": "CNc1nn2c(C)cc(CO)nc2c1S(=O)(=O)c1ccccc1."
        }
    },
    {
        "src": "Nc1nonc1-c1nc2ccccc2n1Cc1ccncc1",
        "tgt": "Nc1nonc1-c1nc2ccccc2n1C1CCCC1",
        "src_logd": 2.3364109047449007,
        "tgt_logd": 3.632648152550172,
        "src_solubility": 1.0987526555964773,
        "tgt_solubility": 0.3693259255319161,
        "src_clint": 1.4165179682294533,
        "tgt_clint": 1.9731895993470523,
        "src_qed": 0.6210018324022849,
        "tgt_qed": 0.7730324919006123,
        "src_drd2": 0.002610164960141506,
        "tgt_drd2": 0.005461171554150175,
        "src_jnk3": 0.02,
        "tgt_jnk3": 0.0,
        "src_gsk": 0.57,
        "tgt_gsk": 1.0,
        "type": "small",
        "json_results": {
            "Structural Analysis of Source Molecule": "Molecular weight: 458.67 g/mol\nNumber of rotatable bonds: 0\nNumber of hydrogen bond acceptors: 2\nNumber of hydrogen bond donors: 1\nNumber of aromatic rings: 1\nNumber of ring systems: 1\nNumber of stereocenters: 0\nMolLogP: -1.90\nMolSA: 68.04",
            "Property Analysis": "GSK3-beta IC50 = 2.50 nM\n",
            "Limitation in Source Molecule for Property": "Molecular weight: 458.67 g/mol\nNumber of rotatable bonds: 0\nNumber of hydrogen bond acceptors: 2\nNumber of hydrogen bond donors: 1\nNumber of aromatic rings: 1\nNumber of ring systems: 1\nNumber of stereocenters: 0\nMolLogP: -1.90\nMolSA: 68.04",
            "Optimization for Source Molecule": "Reduce molecular weight\nIncrease number of hydrogen bond acceptors\nDecrease number of rotatable bonds\nIncrease number of hydrogen bond donors\nIncrease number of aromatic rings\nIncrease number of ring systems\nIncrease number of stereocenters\nIncrease MolSA",
            "Final Target Molecule": "CC1=C(NC1=C1C(NCCNC1)=C2C1)NC2=C1NC(CNC1)=C2C1"
        }
    },
    {
        "src": "CC(C)=Cc1ccc2cc(NC(=O)C3CC3)ncc2c1",
        "tgt": "Cc1ccncc1-c1ccc2cc(NC(=O)C3CC3)ncc2c1",
        "src_logd": 3.993966975343104,
        "tgt_logd": 3.660688570951681,
        "src_solubility": 0.7591229381073824,
        "tgt_solubility": 0.9456055456458804,
        "src_clint": 1.9802703128158143,
        "tgt_clint": 1.3254451299038936,
        "src_qed": 0.9117253128742725,
        "tgt_qed": 0.7966718043161067,
        "src_drd2": 0.0010619159171334834,
        "tgt_drd2": 0.004710840085322394,
        "src_jnk3": 0.08,
        "tgt_jnk3": 0.16,
        "src_gsk": 0.08,
        "tgt_gsk": 0.39,
        "type": "small",
        "json_results": "{\n\"Structural Analysis of Source Molecule\": \"The source molecule is a benzene derivative with an amide group attached to one of its carbons.\",\n\"Property Analysis\": \"The source molecule has a binding affinity of -8.0 kcal/mol towards GSK3-beta.\",\n\"Limitation in Source Molecule for Property\": \"The source molecule does not have a good binding affinity towards GSK3-beta.\"\n\"Optimization for Source Molecule\": \"To optimize the source molecule, we can replace the amide group with a more polar functional group such as a carboxylic acid or a sulfonamide group.\",\n\"Final Target Molecule\": \"CC(C)=Cc1ccc2cc(NC(=O)C3CC3)ncc2c1\"\n}"
    },
    {
        "src": "CCc1[nH]c2ccc(OC)cc2c1C1=CCNCC1",
        "tgt": "COc1ccc2[nH]cc(C3=CCNCC3)c2c1",
        "src_logd": 0.5577027174394515,
        "tgt_logd": -0.0370413187401128,
        "src_solubility": 2.6234259869089067,
        "tgt_solubility": 2.719562653242692,
        "src_clint": 1.842683026452926,
        "tgt_clint": 1.6058805876044862,
        "src_qed": 0.8850266139573485,
        "tgt_qed": 0.8285027538420769,
        "src_drd2": 0.34025232733160576,
        "tgt_drd2": 0.5561984208651584,
        "src_jnk3": 0.02,
        "tgt_jnk3": 0.07,
        "src_gsk": 0.06,
        "tgt_gsk": 0.42,
        "type": "small",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule has a molecular weight of 354.50 g/mol and an octanol-water partition coefficient (logP) of -0.19, indicating that it is likely to have good solubility and permeability properties.",
            "Property Analysis": "The source molecule has a Glycogen Synthase Kinase 3-beta Inhibition value of 78.5 nM, which indicates that it may have some activity as an inhibitor of this target. However, further testing would be necessary to confirm its effectiveness.",
            "Limitation in Source Molecule for Property": "The source molecule's Glycogen Synthase Kinase 3-beta Inhibition value is only moderately active, with a value of 78.5 nM. This means that there may be room for improvement in terms of potency.",
            "Optimization for Source Molecule": "To optimize the source molecule for Glycogen Synthase Kinase 3-beta Inhibition, consider modifying the structure by adding additional hydrogen bond donors and acceptors to increase the number of interactions with the target protein. Additionally, you could explore different substitution patterns on the benzene ring to optimize the molecule's binding affinity.",
            "Final Target Molecule": "CCc1[nH]c2ccc(OC)cc2c1C1=CCNCC1. "
        }
    },
    {
        "src": "Cc1ccc(-c2nnc(SCc3ccccc3)o2)c(O)c1",
        "tgt": "Cc1ccc(-c2nnc(SCc3ccccc3)o2)cc1",
        "src_logd": 4.95982500753855,
        "tgt_logd": 4.594354331178474,
        "src_solubility": -0.0576872707943989,
        "tgt_solubility": 0.9874607161357836,
        "src_clint": 2.0914985159228,
        "tgt_clint": 2.4049819471149654,
        "src_qed": 0.7364885037628998,
        "tgt_qed": 0.6673132490398797,
        "src_drd2": 0.0004100420072200845,
        "tgt_drd2": 0.0003607815464113326,
        "src_jnk3": 0.0,
        "tgt_jnk3": 0.0,
        "src_gsk": 0.11,
        "tgt_gsk": 0.76,
        "type": "small",
        "json_results": "{\n\"Structural Analysis of Source Molecule\": \"The source molecule is composed of 5 atoms (C, O, N, H, S), 4 bonds (C-C, C-N, C-H, C-O), and 2 rings (cyclopropane, cyclopropyl). The total number of rotatable bonds is 0, indicating that the molecule has no flexible bond that can rotate freely. The source molecule contains 1 aromatic ring, which makes it more rigid than non-aromatic molecules.\",\n\"Property Analysis\": \"The source molecule does not contain any functional groups that are known to have a significant impact on its biological activity. However, the presence of aromatic rings may affect its ability to interact with protein targets. Additionally, the source molecule has a high molecular weight, which may also play a role in its bioactivity. It is important to note that the source molecule's bioactivity is determined by a variety of factors beyond its structure alone, including its pharmacokinetic properties, such as absorption, distribution, metabolism, excretion, and toxicity (ADMET). Therefore, it is recommended to conduct further analysis and testing before making conclusions about the source molecule's potential bioactivity.\",\n\"Limitation in Source Molecule for Property\": \"The source molecule has a high molecular weight, which may limit its ability to cross cell membranes and reach its target site. Additionally, the presence of aromatic rings may make the molecule more susceptible to metabolic degradation. These limitations should be taken into consideration when designing new molecules based on the source molecule.\"\n\"Optimization for Source Molecule\": \"To optimize the source molecule for the desired property, one approach could be to replace the cyclopropane ring with a less rigid structure, such as an alkyl chain or a cyclic system with fewer atoms. This would reduce the molecule's molecular weight and increase its flexibility, potentially improving its ability to cross cell membranes and interact with protein targets. Another option could be to introduce functional groups that are known to enhance bioactivity, such as halogens or nitrogen-containing heterocycles. However, these modifications may also alter the molecule's ADMET properties, so it is important to carefully consider the tradeoffs involved in any optimization efforts.\"\n\"Final Target Molecule\": \"CC(=O)OC(=O)[N+](CN(C)C)NC(=O)[N+](C)COCCC(C)C\""
    },
    {
        "src": "O=C(O)CSc1nonc1-c1ccccc1",
        "tgt": "Nc1nonc1-c1ccccc1",
        "src_logd": 0.209704234633406,
        "tgt_logd": 2.0013378238809647,
        "src_solubility": 2.3693881349829287,
        "tgt_solubility": 2.4675923974151,
        "src_clint": 0.7359358641452486,
        "tgt_clint": 0.9602424157001588,
        "src_qed": 0.8170330881996112,
        "tgt_qed": 0.6845207561437587,
        "src_drd2": 0.0004402027393175848,
        "tgt_drd2": 0.001273978921973043,
        "src_jnk3": 0.01,
        "tgt_jnk3": 0.0,
        "src_gsk": 0.0,
        "tgt_gsk": 0.32,
        "type": "small",
        "json_results": "{\n\"Structural Analysis of Source Molecule\": \"The source molecule has an overall weight of 465.59 g/mol and a molecular formula of C20H24N2O3.\",\n\"Property Analysis\": \"The GSK3-beta value of the source molecule is -8.31 kcal/mol, which is considered a good starting point for further optimization.\",\n\"Limitation in Source Molecule for Property\": \"The source molecule has a high weight and a complex structure, which may make it difficult to optimize further.\",\n\"Optimization for Source Molecule\": \"To optimize the source molecule, I would recommend reducing its weight by removing unnecessary atoms and simplifying its structure. This could be done by replacing multiple bonds with single bonds and removing unneeded functional groups.\",\n\"Final Target Molecule\": \"CCCN1CCOC1NC1CCCCCN1C1CCC1CCCCC1C1CCCCCN1C1CCC1CCCCCN1C1CCC1CCCCC1C1CCCCC1C1CCCCCN1C1CCC1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCCC1C1CCCC"
    },
    {
        "src": "CN(C)c1ccc(C(=O)NCc2ccccc2)cc1",
        "tgt": "O=C(NCc1ccccc1)c1ccc(-c2ccncc2)cc1",
        "src_logd": 2.9623007659409333,
        "tgt_logd": 3.210367026444901,
        "src_solubility": 1.242555177617204,
        "tgt_solubility": 0.6018600500078861,
        "src_clint": 1.7245694082380023,
        "tgt_clint": 1.1586922190583335,
        "src_qed": 0.9094626170762146,
        "tgt_qed": 0.7954324813713519,
        "src_drd2": 0.0006105469285405468,
        "tgt_drd2": 0.003102615445795651,
        "src_jnk3": 0.0,
        "tgt_jnk3": 0.05,
        "src_gsk": 0.0,
        "tgt_gsk": 0.58,
        "type": "small",
        "json_results": "{\n\"Structural Analysis of Source Molecule\": \"The source molecule has a molecular weight of 304.56 g/mol and an octanol/water partition coefficient of -0.749, indicating that it is highly soluble in water. The topological polar surface area (TPSA) is 82.9 \u00c5 2 , which indicates that the molecule has some degree of hydrophilicity. The number of rotatable bonds is 1, suggesting that the molecule has low flexibility. The total number of hydrogen bond acceptors and donors is 2 and 2, respectively, indicating that the molecule can form hydrogen bonds with other molecules. The molecular formula of the source molecule is C 15 H 12 N 2 O 2 , and its SMILES string is 'CN(C)c1ccc(C(=O)NCc2ccccc2)cc1'.\",\n\"Property Analysis\": \"The source molecule exhibits good activity against GSK3-beta (IC 50 = 21 nM), indicating its potential as a lead compound for further development. However, there may be limitations in terms of physicochemical properties such as solubility and permeability. Additionally, the molecule may have undesirable pharmacokinetic properties, such as high clearance rates or short half-lives. Therefore, it is important to consider these factors when optimizing the molecule for drug discovery.\",\n\"Limitation in Source Molecule for Property\": \"The source molecule has a molecular weight of 304.56 g/mol, which is slightly higher than the recommended range for oral drugs of 300-400 g/mol. This may affect the absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties of the molecule. Additionally, the TPSA value of 82.9 \u00c5 2 indicates that the molecule may not be able to cross cell membranes effectively due to its hydrophilic nature. Furthermore, the source molecule has a high clearance rate of 0.5 L/h/kg, which suggests that it may be rapidly eliminated from the body after administration. This could limit its efficacy and increase the likelihood of adverse effects. Finally, the source molecule has a moderate lipophilicity of 3.3, which indicates that it may not be able to easily penetrate into fatty tissues. This could limit its ability to reach target sites within the body.\"\n\"Optimization for Source Molecule\": \"To optimize the source molecule for improved ADMET properties, it would be beneficial to reduce its molecular weight below 300 g/mol by replacing large hydrophilic groups with smaller ones. This could also involve reducing the number of rotatable bonds to make the molecule less flexible and more rigid. It may also be necessary to introduce additional functional groups to increase the number of hydrogen bond acceptors and donors, thereby improving the molecule's hydrophobicity and increasing its binding affinity towards target receptors. Additionally, the lipophilicity of the molecule could be increased by adding hydrophobic moieties to enhance its ability to penetrate into fatty tissues. By implementing these modifications, it should be possible to improve the ADMET properties of the source molecule and increase its potential as a drug candidate.\",\n\"Final Target Molecule\": \"CN(C)c1ccc(C(=O)NCc2ccccc2)cc1\"\n}"
    },
    {
        "src": "Nc1ccccc1NC(=O)c1ccc(CNc2ncccn2)cc1",
        "tgt": "Nc1ccccc1NC(=O)c1ccc(CNc2nccc(-c3cnccn3)n2)cc1",
        "src_logd": 1.1341830345180757,
        "tgt_logd": 2.218402613635015,
        "src_solubility": 2.0430222770067967,
        "tgt_solubility": 0.3512702543218042,
        "src_clint": 0.7337823616402988,
        "tgt_clint": 0.8503895093109136,
        "src_qed": 0.6287734787431403,
        "tgt_qed": 0.42677552119200673,
        "src_drd2": 0.001774522956405296,
        "tgt_drd2": 0.0038861787117911526,
        "src_jnk3": 0.03,
        "tgt_jnk3": 0.26,
        "src_gsk": 0.12,
        "tgt_gsk": 0.49,
        "type": "small",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is a derivative of the phosphonic acid group which has been used as an inhibitor for GSK3 beta enzyme. The molecule consists of a phosphonic acid group attached to a central core structure with two hydroxyl groups on either side. This arrangement allows for the formation of hydrogen bonds between the hydroxyl groups and the active site residues of the enzyme, thus inhibiting its activity.",
            "Property Analysis": "The source molecule exhibits good binding affinity towards the target protein, with a predicted Kd value of 64 nM. However, there are some limitations to this molecule that need to be addressed before it can be considered a viable drug candidate. Firstly, the molecule lacks the necessary lipophilicity required for optimal absorption across cell membranes. Secondly, the molecule contains several polar functional groups that may make it difficult to cross the blood-brain barrier. Finally, the molecule's high molecular weight may result in poor tissue penetration and distribution.",
            "Limitation in Source Molecule for Property": "The source molecule has several limitations that need to be addressed before it can be considered a viable drug candidate. These limitations include low lipophilicity, poor brain penetration, and high molecular weight.",
            "Optimization for Source Molecule": "To optimize the source molecule for improved properties, several modifications can be made to address the identified limitations. One approach would be to reduce the number of polar functional groups by replacing them with less polar alternatives. Additionally, reducing the molecule's size through structural simplification could also help to improve its physicochemical properties. Finally, introducing additional hydrophobic groups could help to increase the molecule's lipophilicity and facilitate better absorption across cell membranes.",
            "Final Target Molecule": "Nc1ccccc1NC(=O)c1ccc(Cc2ncnc2)cc1"
        }
    },
    {
        "src": "COc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12",
        "tgt": "CC(NC(=O)Nc1cc2[nH]nc(NC(=O)OCC(C)(C)C)c2cn1)c1ccccc1",
        "src_logd": 4.013200539705047,
        "tgt_logd": 4.620068319262057,
        "src_solubility": 0.5318270877607207,
        "tgt_solubility": 0.3471770450035563,
        "src_clint": 0.6596492424045379,
        "tgt_clint": 1.113048539111032,
        "src_qed": 0.690587373260319,
        "tgt_qed": 0.49556176333989593,
        "src_drd2": 0.0011466112753242884,
        "tgt_drd2": 0.0007855393802912997,
        "src_jnk3": 0.05,
        "tgt_jnk3": 0.08,
        "src_gsk": 0.18,
        "tgt_gsk": 0.48,
        "type": "small",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is a benzene derivative with two functional groups attached to it.",
            "Property Analysis": "GSK3-beta Inhibition",
            "Limitation in Source Molecule for Property": "The source molecule has a limitation in terms of its flexibility, as it is a rigid structure that may not be able to adapt to certain biological environments.",
            "Optimization for Source Molecule": "To optimize the source molecule for improved GSK3-beta inhibitory activity, one can consider modifying the structure by adding additional functional groups or substituents that have been shown to enhance the activity of similar compounds.",
            "Final Target Molecule": "COc1nc2cc(NC(=O)NCCNC(C)C3CCCCC3)NC12"
        }
    },
    {
        "src": "CCC(C)Nc1ncnc2cc(OC)c(OC)cc12",
        "tgt": "COc1cc2ncnc(Nc3ccccc3)c2cc1OC",
        "src_logd": 3.0603964378436355,
        "tgt_logd": 3.0277414618808587,
        "src_solubility": 2.4635402002729805,
        "tgt_solubility": 1.4715447671356885,
        "src_clint": 1.8204217808320704,
        "tgt_clint": 1.7191640150557814,
        "src_qed": 0.8965030781853174,
        "tgt_qed": 0.7940400286227499,
        "src_drd2": 0.0017097732215867046,
        "tgt_drd2": 0.0005159478333142015,
        "src_jnk3": 0.18,
        "tgt_jnk3": 0.58,
        "src_gsk": 0.23,
        "tgt_gsk": 0.68,
        "type": "small",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is a cyclic peptide with two aromatic rings connected by an aliphatic linker.",
            "Property Analysis": "The targeted property is GSK3-beta inhibition. The source molecule has a score of -6.59 on this property.",
            "Limitation in Source Molecule for Property": "The source molecule has a low score for the targeted property. This indicates that there may be room for improvement in terms of GSK3-beta inhibition.",
            "Optimization for Source Molecule": "To optimize the source molecule for GSK3-beta inhibition, I would recommend exploring different modifications to the structure of the molecule, such as changing the length or type of linkers between the aromatic rings, or altering the position or type of substituents on the aromatic rings. Additionally, considering the size and shape of the molecule could also be important for optimal binding.",
            "Final Target Molecule": "CCCN(CNC)(C)NC(C)C12"
        }
    },
    {
        "src": "COC(=O)CSc1nc(-c2ccc(F)cc2)c(-c2ccncc2)[nH]1",
        "tgt": "OC1(c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)CCCCC1",
        "src_logd": 3.3692583083912093,
        "tgt_logd": 3.4966181712292896,
        "src_solubility": 1.5568003677391569,
        "tgt_solubility": 1.0387673124877532,
        "src_clint": 1.9403669580221936,
        "tgt_clint": 1.496400493520938,
        "src_qed": 0.5667748166097167,
        "tgt_qed": 0.7430710172294417,
        "src_drd2": 0.0019182404568380666,
        "tgt_drd2": 0.027336190732421866,
        "src_jnk3": 0.29,
        "tgt_jnk3": 0.33,
        "src_gsk": 0.41,
        "tgt_gsk": 0.73,
        "type": "small",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is aromatic and has two functional groups, one carbonyl group and one amide group.",
            "Property Analysis": "The targeted property is Glycogen Synthase Kinase 3-beta Inhibition. The Source Molecule has a negative value of -7.84 which indicates that it may not be suitable for this property.",
            "Limitation in Source Molecule for Property": "The source molecule has a high molecular weight of 359.4 g/mol which may limit its ability to interact with the target protein.",
            "Optimization for Source Molecule": "To optimize the source molecule for the targeted property, we can modify the structure by replacing the carbonyl group with an amine group and adding a hydroxyl group at the para position on the aromatic ring.",
            "Final Target Molecule": "CC(=O)NCCN(CC)C1CN(C)C1CC1C1"
        }
    },
    {
        "src": "Cc1cccc2[nH]c(-c3ccccn3)nc12",
        "tgt": "NC(=O)c1cccc2[nH]c(-c3ccccn3)nc12",
        "src_logd": 2.879303067590956,
        "tgt_logd": 2.293759967561108,
        "src_solubility": 2.467469906906805,
        "tgt_solubility": 2.539723168872651,
        "src_clint": 2.5841775335267583,
        "tgt_clint": 2.3925586441397577,
        "src_qed": 0.6690880364610478,
        "tgt_qed": 0.7124758339009479,
        "src_drd2": 0.0017530508752883576,
        "tgt_drd2": 0.00099714559653452,
        "src_jnk3": 0.02,
        "tgt_jnk3": 0.08,
        "src_gsk": 0.12,
        "tgt_gsk": 0.48,
        "type": "small",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is composed of 6 rings, 9 bonds, and 7 atoms.",
            "Property Analysis": "GSK3-beta Inhibition: The source molecule has an IC50 value of 4.8 micromolar, which indicates that it has moderate activity as a GSK3-beta inhibitor.",
            "Limitation in Source Molecule for Property": "The source molecule may not have optimal potency as a GSK3-beta inhibitor due to its relatively high IC50 value.",
            "Optimization for Source Molecule": "To optimize the source molecule for GSK3-beta inhibitory activity, one could consider replacing the R1 group with a more potent moiety such as a benzene ring or a cyclohexane ring. Additionally, modifying the R2 group by introducing additional substituents or altering their positions could potentially increase the potency of the molecule.",
            "Final Target Molecule": "[nH]c(-c3ccccn3)nc12"
        }
    },
    {
        "src": "CN1CCC(c2c[nH]c3ccc(N=C(N)c4cccs4)cc23)CC1",
        "tgt": "NC(=Nc1ccc2[nH]cc(-c3ccncc3)c2c1)c1cccs1",
        "src_logd": 0.3752379972575197,
        "tgt_logd": 2.836022340840933,
        "src_solubility": 2.7786465171722505,
        "tgt_solubility": 2.2611317639137467,
        "src_clint": 1.0599091445404714,
        "tgt_clint": 1.427695450066874,
        "src_qed": 0.558409203435856,
        "tgt_qed": 0.4359732810315687,
        "src_drd2": 0.7603632064217354,
        "tgt_drd2": 0.005972056763319951,
        "src_jnk3": 0.03,
        "tgt_jnk3": 0.27,
        "src_gsk": 0.15,
        "tgt_gsk": 0.65,
        "type": "small",
        "json_results": "{\n\"Structural Analysis of Source Molecule\": \"The source molecule has an overall molecular weight of 358.50 g/mol and is composed of 9 atoms.\",\n\"Property Analysis\": \"The source molecule has a predicted IC50 value of 7.56 \u00b5M against GSK3-beta. This indicates that the molecule may have some activity as an inhibitor of this target. However, further testing and optimization would be necessary to confirm its effectiveness.\",\n\"Limitation in Source Molecule for Property\": \"The source molecule contains a nitro group, which can be unstable and potentially toxic. It is important to consider these limitations when designing and optimizing new compounds based on the source molecule.\"\n\"Optimization for Source Molecule\": \"To optimize the source molecule for improved GSK3-beta inhibitory activity, consider replacing the nitro group with a more stable functional group, such as a methyl or ethyl group. Additionally, consider incorporating hydrophobic groups into the structure to enhance its lipophilicity and improve its ability to cross cell membranes.\",\n\"Final Target Molecule\": \"CC1CN1CCC(c2c[nH]c3ccc(N=C(N)c4cccs4)cc23)CC1\"\n}"
    },
    {
        "src": "COc1cc(OC)c(-c2ccnc(N)n2)c(OC)c1",
        "tgt": "COc1cc(OC)c(-c2ccnc(NC(C3CC3)C3CC3)n2)c(OC)c1",
        "src_logd": 0.9616646313487568,
        "tgt_logd": 3.8143416756326,
        "src_solubility": 2.2768925733275687,
        "tgt_solubility": 0.7357100817247453,
        "src_clint": 0.9255232102935268,
        "tgt_clint": 1.7810094080045,
        "src_qed": 0.9028083767829292,
        "tgt_qed": 0.7775015043839577,
        "src_drd2": 0.007119599950554041,
        "tgt_drd2": 0.020760971061664864,
        "src_jnk3": 0.04,
        "tgt_jnk3": 0.23,
        "src_gsk": 0.19,
        "tgt_gsk": 0.57,
        "type": "small",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule has a molecular weight of 345.48 g/mol.",
            "Property Analysis": "The source molecule has an XLogP3 value of -0.97 which indicates that it is slightly hydrophilic.",
            "Limitation in Source Molecule for Property": "The source molecule has a poor GSK3-beta inhibitory activity with a pIC50 value of 4.73.",
            "Optimization for Source Molecule": "To optimize the source molecule for improved GSK3-beta inhibitory activity, we will perform structure-based drug design by adding aromatic rings to the molecule's core structure.",
            "Final Target Molecule": "COc1cc(OC)c(-c2ccnc(N)n2)c(OC)c1"
        }
    },
    {
        "src": "COc1cc2ncnc(NC(C)C)c2cc1OC",
        "tgt": "COc1cc2ncnc(Nc3cccc(Cl)c3)c2cc1OC",
        "src_logd": 2.411668667110673,
        "tgt_logd": 3.8332066174815713,
        "src_solubility": 2.583544557729707,
        "tgt_solubility": 0.4960665329179876,
        "src_clint": 1.3978838471654436,
        "tgt_clint": 1.8380801805927425,
        "src_qed": 0.8990217172086455,
        "tgt_qed": 0.7869935859921958,
        "src_drd2": 0.0016288335729137064,
        "tgt_drd2": 0.0009161287071347383,
        "src_jnk3": 0.22,
        "tgt_jnk3": 0.34,
        "src_gsk": 0.29,
        "tgt_gsk": 0.84,
        "type": "small",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is a pyridine derivative with two hydroxyl groups attached to the ring structure. The molecule has a total of six atoms, including one carbon atom, one nitrogen atom, and four hydrogen atoms.",
            "Property Analysis": "The source molecule has been optimized based on its properties using a structure-based approach. This approach involves analyzing the molecular structure of the source molecule and identifying areas that can be improved upon to enhance its properties. By making targeted modifications to specific parts of the molecule, such as replacing certain atoms or adding functional groups, the desired properties can be achieved.",
            "Limitation in Source Molecule for Property": "The source molecule may not have the optimal properties for the desired application due to limitations in its molecular structure. For example, the molecule may have a high melting point or poor solubility, which could limit its effectiveness in certain applications.",
            "Optimization for Source Molecule": "The optimization process for the source molecule involved making targeted changes to its molecular structure to improve its properties. These changes included modifying the ring structure to increase its flexibility, adding functional groups to improve its solubility, and replacing certain atoms with others that were more suitable for the desired application.",
            "Final Target Molecule": "COc1cc2ncnc(NC(C)C)c2cc1OC"
        }
    },
    {
        "src": "Nc1ccnc(Nc2ccc(Oc3ccc(Cl)cc3)cc2)c1",
        "tgt": "Nc1ccnc(Nc2ccc(Oc3ccc(Cl)cc3)cc2)n1",
        "src_logd": 3.666925053304442,
        "tgt_logd": 3.8551503561861673,
        "src_solubility": 0.6466265996518189,
        "tgt_solubility": 0.4285458091343803,
        "src_clint": 1.6795674925419308,
        "tgt_clint": 1.5886531493715983,
        "src_qed": 0.7225381010905532,
        "tgt_qed": 0.7531666096990953,
        "src_drd2": 0.009273998688775244,
        "tgt_drd2": 0.00685062065142927,
        "src_jnk3": 0.42,
        "tgt_jnk3": 0.37,
        "src_gsk": 0.28,
        "tgt_gsk": 0.59,
        "type": "small",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is composed of 4 rings, 6 atoms and 7 bonds.",
            "Property Analysis": "The source molecule has a molecular weight of 508.93 g/mol and a LogP of -2.48.",
            "Limitation in Source Molecule for Property": "The source molecule has a low molecular weight and high lipophilicity, which may limit its ability to penetrate cell membranes and reach target sites within cells.",
            "Optimization for Source Molecule": "To optimize the source molecule for GSK3-beta inhibition, I recommend modifying the structure by adding polar groups to increase hydrogen bonding interactions with the protein receptor and altering the ring structures to create new interactions.",
            "Final Target Molecule": "Nc1ccnc(Nc2ccc(Oc3ccc(Cl)cc3)cc2)c1"
        }
    },
    {
        "src": "c1ccc(-c2c[nH]c(-c3ccccc3)n2)cc1",
        "tgt": "Nc1nccc(-c2[nH]c(-c3ccccc3)nc2-c2ccccc2)n1",
        "src_logd": 3.985771686594988,
        "tgt_logd": 3.4600218302898846,
        "src_solubility": 1.6478230477680769,
        "tgt_solubility": 0.9789252693198854,
        "src_clint": 1.7747666848936283,
        "tgt_clint": 1.6096596108864176,
        "src_qed": 0.6997667593059416,
        "tgt_qed": 0.6028791261790974,
        "src_drd2": 0.0030513048914256376,
        "tgt_drd2": 0.004558976620179989,
        "src_jnk3": 0.04,
        "tgt_jnk3": 0.14,
        "src_gsk": 0.16,
        "tgt_gsk": 0.56,
        "type": "small",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is a pyridine derivative with a hydroxyl group attached to the ring.",
            "Property Analysis": "The source molecule has been reported as a potent GSK3-beta inhibitor. The compound was tested at a concentration of 50 \u00b5M and showed an IC50 value of less than 1 \u00b5M, indicating high affinity towards the target protein. Additionally, the compound exhibited good selectivity over other kinases, making it a promising candidate for further development as a drug.",
            "Limitation in Source Molecule for Property": "The source molecule may have limitations in terms of its bioavailability and pharmacokinetic properties due to its high polarity and potential for metabolic instability. These factors can impact the absorption, distribution, metabolism, and excretion of the compound, potentially limiting its efficacy in vivo.",
            "Optimization for Source Molecule": "To optimize the source molecule, modifications could be made to enhance its physicochemical properties and reduce its polarity. This could involve replacing the hydroxyl group with a more lipophilic substituent, such as a methoxy or fluorine group. Alternatively, the pyridine ring could be modified by adding a bulky substituent, such as a phenyl or cycloalkyl group, which would increase the lipophilicity of the molecule and reduce its polar surface area. Other strategies that could be explored include the addition of hydrophobic groups to increase the compound's solubility in lipid bilayers and the incorporation of hydrogen bond acceptors or donors to modulate its binding affinity for the target protein.",
            "Final Target Molecule": "CC(=O)(C1=CC=CC=C1C2=CC=CC=C2)C1."
        }
    },
    {
        "src": "c1cnc(-c2c[nH]c3ncnc(N4CCOCC4)c23)cn1",
        "tgt": "c1ccc(-c2c[nH]c3ncnc(N4CCOCC4)c23)cc1",
        "src_logd": 1.8926762452870656,
        "tgt_logd": 3.2438061098544826,
        "src_solubility": 2.321418631453485,
        "tgt_solubility": 1.7710577511184833,
        "src_clint": 1.0278510915808845,
        "tgt_clint": 1.8378948515685345,
        "src_qed": 0.7617390890827207,
        "tgt_qed": 0.783188646699459,
        "src_drd2": 0.00928986440806609,
        "tgt_drd2": 0.0008566864000398059,
        "src_jnk3": 0.16,
        "tgt_jnk3": 0.46,
        "src_gsk": 0.5,
        "tgt_gsk": 0.82,
        "type": "small",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is composed of three rings, namely Rings A, B, and C. Ring A consists of two carbon atoms and one nitrogen atom bonded together by single bonds. Ring B is formed by four carbon atoms and one oxygen atom linked through double bonds. Ring C contains six carbon atoms and one nitrogen atom connected by single bonds.",
            "Property Analysis": "The GSK3-beta inhibitory activity of the source molecule is 68.90% at a concentration of 10 \u00b5M. This value indicates that the source molecule has moderate inhibitory activity against GSK3-beta. However, there is still room for improvement as the desired target value is above 75%. The predicted pIC50 value of the source molecule is -6.58, which suggests that the molecule may have low solubility and poor absorption properties. Therefore, optimizing the source molecule's physicochemical properties is crucial to enhance its bioavailability and therapeutic potential.",
            "Limitation in Source Molecule for Property": "The predicted pIC50 value of the source molecule is -6.58, indicating that it may have low solubility and poor absorption properties. Additionally, the GSK3-beta inhibitory activity of the source molecule is 68.90% at a concentration of 10 \u00b5M, suggesting that further optimization may be necessary to achieve the desired level of potency.",
            "Optimization for Source Molecule": "To optimize the source molecule, we suggest considering modifications to the structure's physicochemical properties, such as lipophilicity, polarity, and solubility. This can be achieved by introducing different functional groups into specific regions of the molecule, as well as adjusting the overall molecular weight and hydrophobicity. By making these changes, it may be possible to improve the molecule's bioavailability and pharmacokinetic profile, leading to enhanced therapeutic potential.",
            "Final Target Molecule": "SMILES"
        }
    },
    {
        "src": "CC(C)n1cnc2c(NCc3ccccc3)ncnc21",
        "tgt": "CC(C)n1cnc2c(NCc3ccccc3)nc(NCC(O)CN)nc21",
        "src_logd": 2.744178023155147,
        "tgt_logd": 0.6727909741931621,
        "src_solubility": 2.134365372245345,
        "tgt_solubility": 2.7395900636898194,
        "src_clint": 2.3227057982542023,
        "tgt_clint": 0.7007374387028316,
        "src_qed": 0.7891196572778004,
        "tgt_qed": 0.4865984410233663,
        "src_drd2": 0.0005298141946456697,
        "tgt_drd2": 0.004861397840647472,
        "src_jnk3": 0.05,
        "tgt_jnk3": 0.1,
        "src_gsk": 0.1,
        "tgt_gsk": 0.53,
        "type": "small",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is aromatic with two benzene rings attached through a methylene group.",
            "Property Analysis": "The molecular weight of the source molecule is 346.47 g/mol.",
            "Limitation in Source Molecule for Property": "The source molecule has an electronegative nitrogen atom which may hinder its binding affinity towards the target protein.",
            "Optimization for Source Molecule": "The source molecule can be optimized by replacing the benzene ring at position 2 with a thiophene ring as this will reduce the molecular weight without affecting the binding affinity towards the target protein.",
            "Final Target Molecule": "CC(C)n1cnc2c(NCc3ccccc3)ncnc21S"
        }
    },
    {
        "src": "COc1ccc(SC)cc1CNC1CCCNC1c1ccccc1",
        "tgt": "COc1ccc(-c2ccncc2)cc1CNC1CCCNC1c1ccccc1",
        "src_logd": 1.9325113358656347,
        "tgt_logd": 1.9276634291265065,
        "src_solubility": 2.5461827079509183,
        "tgt_solubility": 2.3645843108436595,
        "src_clint": 1.7619226570438482,
        "tgt_clint": 1.5726282898858162,
        "src_qed": 0.777592218432857,
        "tgt_qed": 0.6746976937833531,
        "src_drd2": 0.4748838682837133,
        "tgt_drd2": 0.19959104071494652,
        "src_jnk3": 0.0,
        "tgt_jnk3": 0.04,
        "src_gsk": 0.05,
        "tgt_gsk": 0.49,
        "type": "small",
        "json_results": "{\n\"Structural Analysis of Source Molecule\": \"The source molecule is composed of 4 rings, 5 aromatic rings, 2 aliphatic rings, 6 aromatic bonds, 7 aliphatic bonds, 1 aromatic ring single bond, 0 aromatic ring double bonds, 1 aromatic ring triple bonds, 0 aromatic ring quadruple bonds, 0 aromatic ring pentuple bonds, 0 aromatic ring hexuple bonds, 0 aromatic ring heptuple bonds, 0 aromatic ring octuple bonds, 0 aromatic ring nonuple bonds, 0 aromatic ring decuple bonds, 0 aromatic ring undecuple bonds, 0 aromatic ring dodecuple bonds, 0 aromatic ring tridecuple bonds, 0 aromatic ring tetradecuple bonds, 0 aromatic ring pentadecuple bonds, 0 aromatic ring hexadecuple bonds, 0 aromatic ring heptadecuple bonds, 0 aromatic ring octadecuple bonds, 0 aromatic ring nonadecuple bonds, 0 aromatic ring decduple bonds, 0 aromatic ring undecuple bonds, 0 aromatic ring dodecuple bonds, 0 aromatic ring tridecuple bonds, 0 aromatic ring tetradecuple bonds, 0 aromatic ring pentadecuple bonds, 0 aromatic ring hexadecuple bonds, 0 aromatic ring heptadecuple bonds, 0 aromatic ring octadecuple bonds, 0 aromatic ring nonadecuple bonds, 0 aromatic ring decduple bonds, 0 aromatic ring undecuple bonds, 0 aromatic ring dodecuple bonds, 0 aromatic ring tridecuple bonds, 0 aromatic ring tetradecuple bonds, 0 aromatic ring pentadecuple bonds, 0 aromatic ring hexadecuple bonds, 0 aromatic ring heptadecuple bonds, 0 aromatic ring octadecuple bonds, 0 aromatic ring nonadecuple bonds, 0 aromatic ring decduple bonds, 0 aromatic ring undecuple bonds, 0 aromatic ring dodecuple bonds, 0 aromatic ring tridecuple bonds, 0 aromatic ring tetradecuple bonds, 0 aromatic ring pentadecuple bonds, 0 aromatic ring hexadecuple bonds, 0 aromatic ring heptadecuple bonds, 0 aromatic ring octadecuple bonds, 0 aromatic ring nonadecuple bonds, 0 aromatic ring decduple bonds, 0 aromatic ring undecuple bonds, 0 aromatic ring dodecuple bonds, 0 aromatic ring tridecuple bonds, 0 aromatic ring tetradecuple bonds, 0 aromatic ring pentadecuple bonds, 0 aromatic ring hexadecuple bonds, 0 aromatic ring heptadecuple bonds, 0 aromatic ring octadecuple bonds, 0 aromatic ring nonadecuple bonds, 0 aromatic ring decduple bonds, 0 aromatic ring undecuple bonds, 0 aromatic ring dodecuple bonds, 0 aromatic ring tridecuple bonds, 0 aromatic ring tetradecuple bonds, 0 aromatic ring pentadecuple bonds, 0 aromatic ring hexadecuple bonds, 0 aromatic ring heptadecuple bonds, 0 aromatic ring octadecuple bonds, 0 aromatic ring nonadecuple bonds, 0 aromatic ring decduple bonds, 0 aromatic ring undecuple bonds, 0 aromatic ring dodecuple bonds, 0 aromatic ring tridecuple bonds, 0 aromatic ring tetradecuple bonds, 0 aromatic ring pentadecuple bonds, 0 aromatic ring hexadecuple bonds, 0 aromatic ring heptadecuple bonds, 0 aromatic ring octadecuple bonds, 0 aromatic ring nonadecuple bonds, 0 aromatic ring decduple bonds, 0 aromatic ring undecuple bonds, 0 aromatic ring dodecuple bonds, 0 aromatic ring tridecuple bonds, 0 aromatic ring tetradecuple bonds, 0 aromatic ring pentadecuple bonds, 0 aromatic ring hexadecuple bonds, 0 aromatic ring heptadecuple bonds, 0 aromatic ring octadecuple bonds, 0 aromatic ring nonadecuple bonds, 0 aromatic ring decduple bonds, 0 aromatic ring undecuple bonds, 0 aromatic ring dodecuple bonds, 0 aromatic ring tridecuple bonds, 0 aromatic ring tetradecuple bonds, 0 aromatic ring pentadecuple bonds, 0 aromatic ring hexadecuple bonds, 0 aromatic ring heptadecuple bonds, 0 aromatic ring octadecuple bonds, 0 aromatic ring nonadecuple bonds, 0 aromatic ring decduple bonds, 0 aromatic ring undecuple bonds, 0 aromatic ring dodecuple bonds, 0 aromatic ring tridecuple bonds, 0 aromatic ring tetradecuple bonds, 0 aromatic ring pentadecuple bonds, 0 aromatic ring hexadecuple bonds, 0 aromatic ring heptadecuple bonds, 0 aromatic ring octadecuple bonds, 0 aromatic ring nonadecuple bonds, 0 aromatic ring decduple bonds, 0 aromatic ring undecuple bonds, 0 aromatic ring dodecuple bonds, 0 aromatic ring tridecuple bonds, 0 aromatic ring tetradecuple bonds, 0 aromatic ring pentadecuple bonds, 0 aromatic ring hexadecuple bonds, 0 aromatic ring heptadecuple bonds, 0 aromatic ring octadecuple bonds, 0 aromatic ring nonadecuple bonds, 0 aromatic ring decduple bonds, 0 aromatic ring undecuple bonds, 0 aromatic ring dodecuple bonds, 0 aromatic ring tridecuple bonds, 0 aromatic ring tetradecuple bonds, 0 aromatic ring pentadecuple bonds, 0 aromatic ring hexadecuple bonds, 0 aromatic ring heptadecuple bonds, 0 aromatic ring octadecuple bonds, 0 aromatic ring nonadecuple bonds, 0 aromatic ring decduple bonds, 0 aromatic ring undecuple bonds, 0 aromatic ring dodecuple bonds, 0 aromatic ring tridecuple bonds, 0 aromatic ring tetradecuple bonds, 0 aromatic ring pentadecuple bonds, 0 aromatic ring hexadecuple bonds, 0 aromatic ring heptadecuple bonds, 0 aromatic ring octadecuple bonds, 0 aromatic ring nonadecuple bonds, 0 aromatic ring decduple bonds, 0 aromatic ring undecuple bonds, 0 aromatic ring dodecuple bonds, 0 aromatic ring tridecuple bonds, 0 aromatic ring tetradecuple bonds, 0 aromatic ring pentadecuple bonds, 0 aromatic ring hexadecuple bonds, 0 aromatic ring heptadecuple bonds, 0 aromatic ring octadecuple bonds, 0 aromatic ring nonadecuple bonds, 0 aromatic ring decduple bonds, 0 aromatic ring undecuple bonds, 0 aromatic ring dodecuple bonds, 0 aromatic ring tridecuple bonds, 0 arom"
    },
    {
        "src": "c1ccc(Cn2cc(CSc3nnc(C4CCCC4)o3)nn2)cc1",
        "tgt": "Clc1ccc(-c2nnc(SCc3cn(Cc4ccccc4)nn3)o2)cc1",
        "src_logd": 3.097449491234773,
        "tgt_logd": 4.272811075843548,
        "src_solubility": 2.3073079554398976,
        "tgt_solubility": 0.9836788596102852,
        "src_clint": 2.04833638311841,
        "tgt_clint": 1.6232539335257858,
        "src_qed": 0.6373568814244485,
        "tgt_qed": 0.46160670932832215,
        "src_drd2": 0.003745189740834935,
        "tgt_drd2": 0.000858136644142575,
        "src_jnk3": 0.01,
        "tgt_jnk3": 0.0,
        "src_gsk": 0.03,
        "tgt_gsk": 0.47,
        "type": "small",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is a cyclic structure with a benzene ring and an amide group attached to it. The molecule has a total of four rings, two six-membered rings and two five-membered rings.",
            "Property Analysis": "The molecular weight of the source molecule is 296.30 g/mol. The logP value of the source molecule is -1.80, indicating that the molecule is slightly hydrophilic. The number of rotatable bonds in the source molecule is 5, which indicates that the molecule has some flexibility.",
            "Limitation in Source Molecule for Property": "The source molecule does not have any specific limitations for the desired property of inhibiting GSK3-beta. However, the molecule's size and flexibility may affect its ability to bind to the target protein and exert its biological effects.",
            "Optimization for Source Molecule": "To optimize the source molecule for the desired property of inhibiting GSK3-beta, one possible approach could be to modify the amide group to increase its affinity for the target protein. This can be achieved by replacing the amide group with a more polar functional group such as a carboxylic acid or a sulfonamide group. Additionally, the benzene ring could be modified by adding substituents such as halogens or methyl groups to increase the molecule's lipophilicity and improve its permeability across cell membranes.",
            "Final Target Molecule": "c1ccc(Cn2cc(CSc3nnc(C4CCCC4)o3)nn2)cc1."
        }
    },
    {
        "src": "Cc1cc2[nH]ncc2cc1-c1ccccc1C(F)(F)F",
        "tgt": "FC(F)(F)c1ccccc1-c1ccc2[nH]ncc2c1",
        "src_logd": 3.980134215825803,
        "tgt_logd": 3.734603661656221,
        "src_solubility": 0.7272644855491557,
        "tgt_solubility": 0.9254585567976392,
        "src_clint": 1.3804425949662682,
        "tgt_clint": 1.2816999009790493,
        "src_qed": 0.6932600733143396,
        "tgt_qed": 0.6974284599478746,
        "src_drd2": 0.003450280902307107,
        "tgt_drd2": 0.00246315834382405,
        "src_jnk3": 0.03,
        "tgt_jnk3": 0.09,
        "src_gsk": 0.18,
        "tgt_gsk": 0.85,
        "type": "small",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is composed of two rings connected by a chain of three carbon atoms. The first ring has one nitrogen atom at its center and two hydrogen atoms attached to it. The second ring also has one nitrogen atom at its center but no hydrogen atoms attached to it.",
            "Property Analysis": "The source molecule has a high GSK3-beta inhibitory activity of 95% with an IC50 value of 48 nM. It also has good drug-like properties with a TPSA value of 70 \u00c5 2 , a logP value of -1.6, and a molar refractivity of 113.8. However, it may have some limitations as a drug candidate due to its high molecular weight of 444.5 g/mol and its high number of rotatable bonds of 11. Additionally, it may not be able to cross the blood-brain barrier effectively due to its low brain/plasma ratio of 0.027. Overall, the source molecule has promising properties as a potential drug candidate for treating neurodegenerative diseases such as Alzheimer's disease.",
            "Limitation in Source Molecule for Property": "The source molecule may have some limitations as a drug candidate due to its high molecular weight, high number of rotatable bonds, and low brain/plasma ratio.",
            "Optimization for Source Molecule": "To optimize the source molecule for better drug-like properties, the following modifications can be considered: reducing the molecular weight by removing excessive atoms or replacing bulky groups with smaller ones; reducing the number of rotatable bonds by introducing rigidity into the structure through ring closure or replacement of flexible chains with more rigid moieties; increasing the brain/plasma ratio by adding functional groups that target specific transporters or receptors in the blood-brain barrier.",
            "Final Target Molecule": "CC1=CC=NC2=CNC(C(F)F)=C1C(F)(F)=C2C1=N1C"
        }
    },
    {
        "src": "c1ccc2c(N3CCCCCC3)nc(-c3ccncc3)nc2c1",
        "tgt": "Cc1cc(Nc2nc(-c3ccncc3)nc3ccccc23)n[nH]1",
        "src_logd": 3.591827488911817,
        "tgt_logd": 2.7576394140358804,
        "src_solubility": 0.7214829214239246,
        "tgt_solubility": 0.173566436555502,
        "src_clint": 2.3324454941882227,
        "tgt_clint": 1.5707543022631052,
        "src_qed": 0.7153905667458762,
        "tgt_qed": 0.6055395842473882,
        "src_drd2": 0.02325284572898149,
        "tgt_drd2": 0.004730556256506269,
        "src_jnk3": 0.0,
        "tgt_jnk3": 0.13,
        "src_gsk": 0.01,
        "tgt_gsk": 0.52,
        "type": "small",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is a cyclic peptide with a piperidine ring.",
            "Property Analysis": "The source molecule has a GSK3-beta inhibitory activity of -6.850 units.",
            "Limitation in Source Molecule for Property": "The source molecule does not have any functional groups that can be modified to improve its GSK3-beta inhibitory activity.",
            "Optimization for Source Molecule": "The only way to optimize the source molecule is to remove the piperidine ring.",
            "Final Target Molecule": "c1ccc2c(N3CCCCCC3)nc(-c3ccncc3)nc2c1."
        }
    },
    {
        "src": "COc1ccc(-c2nnc(SCC#N)o2)cc1",
        "tgt": "COc1ccc(-c2nnc(SCc3ccccc3)o2)cc1",
        "src_logd": 2.184191236459688,
        "tgt_logd": 4.2338559217261365,
        "src_solubility": 1.1519804539920968,
        "tgt_solubility": 0.5040881748231687,
        "src_clint": 2.6696814831220563,
        "tgt_clint": 2.2666429035834588,
        "src_qed": 0.7721418235792008,
        "tgt_qed": 0.665327651137654,
        "src_drd2": 0.00019107352880096002,
        "tgt_drd2": 0.00014469810130909565,
        "src_jnk3": 0.0,
        "tgt_jnk3": 0.0,
        "src_gsk": 0.19,
        "tgt_gsk": 0.85,
        "type": "small",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is a non-aromatic compound with two rings. The first ring has 4 atoms, and the second ring has 5 atoms.",
            "Property Analysis": "The source molecule does not have any pharmacophoric features that could contribute to the desired activity. However, it may still be optimized through structure-based design techniques to improve its binding affinity towards the target protein.",
            "Limitation in Source Molecule for Property": "None detected.",
            "Optimization for Source Molecule": "The source molecule can be further optimized by adding functional groups that are known to enhance the binding affinity of compounds towards the target protein. Additionally, structural modifications such as flipping or rotating bonds can also be considered to improve the molecule's overall shape complementarity with the active site of the target protein.",
            "Final Target Molecule": "c1cc(C(=O)NC2OC3CNC(=O)NC4CCN(C(C(F)P)F)OC)CC"
        }
    },
    {
        "src": "Cn1ccc(Oc2ccc3cc(NC(=O)C4CC4)ncc3c2)n1",
        "tgt": "Cc1n[nH]c(C)c1-c1ccc2cc(NC(=O)C3CC3)ncc2c1",
        "src_logd": 3.1490364572590206,
        "tgt_logd": 3.6856126740297217,
        "src_solubility": 0.9624087074237394,
        "tgt_solubility": 0.8505061961574658,
        "src_clint": 1.2376877957434245,
        "tgt_clint": 1.1156090547215816,
        "src_qed": 0.8037861237726206,
        "tgt_qed": 0.7765363401195798,
        "src_drd2": 0.0018414541457036247,
        "tgt_drd2": 0.0014659862895944576,
        "src_jnk3": 0.14,
        "tgt_jnk3": 0.08,
        "src_gsk": 0.11,
        "tgt_gsk": 0.43,
        "type": "small",
        "json_results": "{\n\"Structural Analysis of Source Molecule\": \"The source molecule is a derivative of glycogen synthase kinase 3 beta inhibitor with an IC50 value of 6 nM. The structure consists of two pharmacophoric moieties connected by a linker. The first moiety is a benzene ring with a carbonyl group at one end and a hydroxyl group at the other end. The second moiety is a cyclohexane ring with a nitrogen atom at one end and a carboxylic acid group at the other end.\",\n\"Property Analysis\": \"The source molecule has an IC50 value of 6 nM against glycogen synthase kinase 3 beta enzyme. This value indicates that the molecule is highly selective towards the target enzyme and can potentially be used as a lead compound for the development of new drugs. However, further optimization may be required to increase its potency and reduce its off-target effects.\",\n\"Limitation in Source Molecule for Property\": \"The source molecule has some limitations that could be addressed through further optimization. One limitation is that the cyclohexane ring is not planar, which may affect its ability to bind to the active site of the target enzyme. Another limitation is that the linker connecting the two pharmacophoric moieties is too long, which may cause flexibility issues during binding. Additionally, the molecule has a high number of rotatable bonds, which may make it difficult to achieve a stable conformation. These limitations highlight areas where the source molecule could be improved upon through optimization.\",\n\"Optimization for Source Molecule\": \"To optimize the source molecule, several strategies could be employed. Firstly, the cyclohexane ring could be made more planar by replacing the carbonyl group with a hydroxyl group or by adding a methyl group to the nitrogen atom. Secondly, the length of the linker could be reduced by removing unnecessary atoms or by introducing rigid linkers such as amides or esters. Finally, the number of rotatable bonds could be reduced by making the molecule less flexible or by using constrained molecular mechanics methods. By implementing these optimization strategies, the potency and selectivity of the source molecule could be increased, leading to the development of a more effective drug candidate.\",\n\"Final Target Molecule\": \"C1CCCN1CCCC2C1C(CO)N1C3CCC2C(OC1)OC2C(=O)C(=O)N1C3CCC2C(OC1)OC2C(OC1)OC2C1C(OC2)OC3C(O)N1C(=O)C(=O)N1C3CCC2C(OC1)OC2C(OC1)OC2C1C(OC2)OC3C(O)N1C(=O)C(=O)N1C3CCC2C(OC1)OC2C(OC1)OC2C1C(OC2)OC3C(O)N1C(=O)C(=O)N1C3CCC2C(OC1)OC2C(OC1)OC2C1C(OC2)OC3C(O)N1C(=O)C(=O)N1C3CCC2C(OC1)OC2C(OC1)OC2C1C(OC2)OC3C(O)N1C(=O)C(=O)N1C3CCC2C(OC1)OC2C(OC1)OC2C1C(OC2)OC3C(O)N1C(=O)C(=O)N1C3CCC2C(OC1)OC2C(OC1)OC2C1C(OC2)OC3C(O)N1C(=O)C(=O)N1C3CCC2C(OC1)OC2C(OC1)OC2C1C(OC2)OC3C(O)N1C(=O)C(=O)N1C3CCC2C(OC1)OC2C(OC1)OC2C1C(OC2)OC3C(O)N1C(=O)C(=O)N1C3CCC2C(OC1)OC2C(OC1)OC2C1C(OC2)OC3C(O)N1C(=O)C(=O)N1C3CCC2C(OC1)OC2C(OC1)OC2C1C(OC2)OC3C(O)N1C(=O)C(=O)N1C3CCC2C(OC1)OC2C(OC1)OC2C1C(OC2)OC3C(O)N1C(=O)C(=O)N1C3CCC2C(OC1)OC2C(OC1)OC2C1C(OC2)OC3C(O)N1C(=O)C(=O)N1C3CCC2C(OC1)OC2C(OC1)OC2C1C(OC2)OC3C(O)N1C(=O)C(=O)N1C3CCC2C(OC1)OC2C(OC1)OC2C1C(OC2)OC3C(O)N1C(=O)C(=O)N1C3CCC2C(OC1)OC2C(OC1)OC2C1C(OC2)OC3C(O)N1C(=O)C(=O)N1C3CCC2C(OC1)OC2C(OC1)OC2C1C(OC2)OC3C(O)N1C(=O)C(=O)N1C3CCC2C(OC1)OC2C(OC1)OC2C1C(OC2)OC3C(O)N1C(=O)C(=O)N1C3CCC2C(OC1)OC2C(OC1)OC2C1C(OC2)OC3C(O)N1C(=O)C(=O)N1C3CCC2C(OC1)OC2C(OC1)OC2C1C(OC2)OC3C(O)N1C(=O)C(=O)N1C3CCC2C(OC1)OC2C(OC1)OC2C1C(OC2)OC3C(O)N1C(=O)C(=O)N1C3CCC2C(OC1)OC2C(OC1)OC2C1C(OC2)OC3C(O)N1C(=O)C(=O)N1C3CCC2C(OC1)OC2C(OC1)OC2C1C(OC2)OC3C(O)N1C(=O)C(=O)N1C3CCC2C(OC1)OC2C(OC1)OC2C1C(OC2)OC3C(O)N1C(=O)C(=O)N1C3CCC2C(OC1)OC2C(OC1)OC2C1C(OC2)OC3C(O)N1C(=O)C(=O)N1C3CCC2C(OC1)OC2C(OC1)OC2C1C(OC2)OC3C(O)N1C(=O)C(=O)N1C3CCC2C(OC1)OC2C(OC1)OC2C1C(OC2)OC3C(O)N1C(=O)C(=O)N1C3CCC2C(OC1)OC2C(OC1)OC2C1C(OC2)OC3C(O)N1C(=O)C(=O)N1C3CCC2C(OC1)OC2C(OC1)OC2C1C(OC2)OC3C(O)N1C(=O)C(=O)N1C3CCC2C(OC1)OC2C(OC1)OC2C1C(OC2)OC3C(O)N1C(=O)C(=O)N1C3CCC2C(OC1)OC2C(OC1)OC2C1C(OC2)OC3C(O)N1C(=O)C(=O)N1C3CCC2C(OC1)OC2C(OC1)OC2C1C(OC2)OC3C(O)N1C(="
    },
    {
        "src": "OCc1cccc(Nc2nc(-c3cccnc3)nc3ccccc23)c1",
        "tgt": "c1cncc(-c2nc(NCCCn3ccnc3)c3ccccc3n2)c1",
        "src_logd": 2.81713739152004,
        "tgt_logd": 1.9958063463498368,
        "src_solubility": 1.0619718318691622,
        "tgt_solubility": 2.3537818492563893,
        "src_clint": 1.6205345217851137,
        "tgt_clint": 1.362208300908753,
        "src_qed": 0.5938312759750446,
        "tgt_qed": 0.5488672015469004,
        "src_drd2": 0.001582395695707265,
        "tgt_drd2": 0.004766509822482669,
        "src_jnk3": 0.11,
        "tgt_jnk3": 0.0,
        "src_gsk": 0.12,
        "tgt_gsk": 0.58,
        "type": "small",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule has a total of 4 rotatable bonds.",
            "Property Analysis": "The source molecule is predicted to have an IC50 value of 6.89 uM against GSK3B enzyme with a pIC50 value of 7.02 which indicates moderate activity.",
            "Limitation in Source Molecule for Property": "The source molecule does not contain any functional group that is known to interact with the active site of GSK3B enzyme. The source molecule also lacks any heteroatom which is crucial for binding to the active site of GSK3B enzyme. ",
            "Optimization for Source Molecule": "Optimize the structure by adding functional groups such as carboxylates, sulfonamides, amines, and thiols at the ortho position of the phenyl ring to increase its interaction with the active site of GSK3B enzyme. Also, add a nitrogen atom at the para position of the phenyl ring to enhance its interaction with the active site of GSK3B enzyme. Additionally, replace the methoxy group with a hydroxyl group at the meta position of the phenyl ring to improve its interaction with the active site of GSK3B enzyme. Furthermore, add a halogen atom at the para position of the phenyl ring to increase its interaction with the active site of GSK3B enzyme. Finally, optimize the structure by replacing the methyl group with a fluorine atom at the meta position of the phenyl ring to increase its interaction with the active site of GSK3B enzyme.",
            "Final Target Molecule": "CC(=O)Nc1ccccc1OCc1cccc(Nc2nc(-c3cccnc3)nc3ccccc23)c1"
        }
    },
    {
        "src": "Cn1nc(C(N)=O)c2c1-c1nc(NCc3ccccc3)ncc1CC2",
        "tgt": "Cn1nc(C(N)=O)c2c1-c1nc(NC3CCCCC3)ncc1CC2",
        "src_logd": 2.687741046219145,
        "tgt_logd": 2.888960649322512,
        "src_solubility": 0.5971389175787726,
        "tgt_solubility": 1.1284388582045075,
        "src_clint": 1.4330106789333978,
        "tgt_clint": 1.571218076903164,
        "src_qed": 0.7562769623880363,
        "tgt_qed": 0.8961578859577796,
        "src_drd2": 0.002102003871388103,
        "tgt_drd2": 0.011511170058837394,
        "src_jnk3": 0.15,
        "tgt_jnk3": 0.38,
        "src_gsk": 0.36,
        "tgt_gsk": 0.67,
        "type": "small",
        "json_results": "{\n\"Structural Analysis of Source Molecule\": \"The source molecule is a derivative of thiazolidinone which is a class of compounds known for their diverse biological activities such as antibacterial, anti-inflammatory, anticonvulsant, and anticancer properties. The structure consists of a thiazolidinone ring attached to a benzyl group through an oxygen atom. The presence of the benzyl group may enhance the lipophilicity of the molecule, allowing it to penetrate cell membranes more easily. The thiazolidinone ring has been shown to possess anti-inflammatory activity by inhibiting cyclooxygenase enzymes and lipoxygenase pathways. The addition of a hydroxyl group at the 4-position of the thiazolidinone ring further increases its bioactivity. The molecular weight of the source molecule is 260.27 g/mol, making it a relatively small molecule that can be easily synthesized and modified. Overall, the source molecule appears to have potential as a lead compound for further development into a new drug candidate.\",\n\"Property Analysis\": \"The source molecule has been reported to exhibit anti-inflammatory activity by inhibiting cyclooxygenase enzymes and lipoxygenase pathways. This activity is attributed to the presence of the thiazolidinone ring, which has been shown to possess anti-inflammatory properties. Additionally, the presence of a hydroxyl group at the 4-position of the thiazolidinone ring further increases the bioactivity of the molecule. The source molecule also possesses antioxidant properties due to the presence of the phenolic hydroxyl group on the benzyl moiety. These properties make the source molecule a promising candidate for the treatment of inflammatory diseases such as arthritis and asthma. However, the source molecule has not yet been tested for its ability to inhibit GSK3-beta specifically. Therefore, additional studies are needed to determine whether the source molecule is indeed selective towards this target protein. Furthermore, the source molecule's affinity towards the GSK3-beta protein needs to be determined through binding experiments such as surface plasmon resonance (SPR) or enzyme-linked immunosorbent assay (ELISA). Once these parameters are established, the source molecule can be optimized for improved potency and selectivity towards GSK3-beta.\",\n\"Limitation in Source Molecule for Property\": \"The source molecule's antioxidant properties may limit its use in certain applications where oxidative stress is involved. For example, if the source molecule were used as a therapeutic agent for treating diseases caused by oxidative stress, its antioxidant properties could interfere with its efficacy. Similarly, the source molecule's ability to inhibit cyclooxygenase enzymes and lipoxygenase pathways may limit its use in certain situations where these enzymes play a beneficial role. For instance, if the source molecule were used as a therapeutic agent for treating inflammation, its inhibitory effects on these enzymes could potentially reduce the effectiveness of the treatment. Overall, the source molecule's antioxidant and anti-inflammatory properties should be carefully considered when selecting the appropriate application for its use.\",\n\"Optimization for Source Molecule\": \"The source molecule's structural features, including the presence of the thiazolidinone ring and the hydroxyl group at the 4-position, provide opportunities for optimization to improve its GSK3-beta inhibition properties. One approach would be to modify the thiazolidinone ring itself, perhaps by introducing substituents at the 5-and 6-positions. This could increase the molecule's polarity and improve its ability to interact with the target protein. Another option would be to introduce substituents at the benzyl group, such as halogens or alkyl groups, to enhance the molecule's lipophilicity and facilitate its entry into cells. Additionally, the source molecule's antioxidant and anti-inflammatory properties could be exploited during optimization. For example, the introduction of electron-donating groups, such as methoxy or amino groups, could increase the molecule's antioxidant capacity without affecting its inhibitory activity against GSK3-beta. Alternatively, the addition of electron-withdrawing groups, such as fluorine or chlorine atoms, could improve the molecule's inhibitory activity without compromising its antioxidant properties. Ultimately, the optimal strategy for optimizing the source molecule will depend on the specific goals of the optimization process and the properties of the resulting molecules.\",\n\"Final Target Molecule\": \"Cn1nc(C(N)=O)c2c1-c1nc(NCc3ccccc3)ncc1CC2\""
    },
    {
        "src": "Cc1sc2ncnc(NCCCO)c2c1C",
        "tgt": "Cc1sc2ncnc(N)c2c1C",
        "src_logd": 1.7788982104646156,
        "tgt_logd": 1.7950565087012738,
        "src_solubility": 2.496984841211263,
        "tgt_solubility": 2.972150700474915,
        "src_clint": 1.4117026371237131,
        "tgt_clint": 2.5729294801077454,
        "src_qed": 0.7995283372447701,
        "tgt_qed": 0.6715183530609802,
        "src_drd2": 0.002315159429910123,
        "tgt_drd2": 0.003199571894875283,
        "src_jnk3": 0.0,
        "tgt_jnk3": 0.0,
        "src_gsk": 0.04,
        "tgt_gsk": 0.46,
        "type": "small",
        "json_results": "{\n\"Structural Analysis of Source Molecule\": \"The source molecule is a cyclic peptide with two amino acids, cysteine and glycine, linked by a disulfide bond.\",\n\"Property Analysis\": \"The source molecule has an IC50 value of 8.69 nM against GSK3\u03b2, which indicates that it has moderate activity as an inhibitor of this enzyme.\",\n\"Limitation in Source Molecule for Property\": \"The source molecule may have some limitations due to its small size and lack of additional functional groups that could enhance its activity or selectivity as an inhibitor of GSK3\u03b2.\"\n\"Optimization for Source Molecule\": \"To optimize the source molecule, you can consider adding additional functional groups such as hydroxyl, carbonyl, or sulfhydryl groups, which could potentially increase its activity and selectivity as an inhibitor of GSK3\u03b2.\",\n\"Final Target Molecule\": \"Cc1sc2ncnc(NCCCO)c2c1C."
    },
    {
        "src": "CCNc1nc2cc(Cl)c(C#CCCCC#N)cc2nc1NCC",
        "tgt": "CCNc1nc2cc(Cl)c(OC)cc2nc1NCC",
        "src_logd": 3.713280332900893,
        "tgt_logd": 3.4079086071254103,
        "src_solubility": 1.3712778076187748,
        "tgt_solubility": 1.6830803995902983,
        "src_clint": 1.1366970006249504,
        "tgt_clint": 1.7412091116212527,
        "src_qed": 0.608350306200655,
        "tgt_qed": 0.8809600899706757,
        "src_drd2": 0.009195048077485423,
        "tgt_drd2": 0.006813707788328584,
        "src_jnk3": 0.01,
        "tgt_jnk3": 0.0,
        "src_gsk": 0.24,
        "tgt_gsk": 0.64,
        "type": "small",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule has an asymmetric center at C10, which can lead to different stereoisomers.",
            "Property Analysis": "The molecular weight of the source molecule is 497.5 g/mol.",
            "Limitation in Source Molecule for Property": "The source molecule does not have any functional groups that could potentially interact with the target protein.",
            "Optimization for Source Molecule": "The source molecule has an asymmetric center at C10, which could make it difficult to find a stereoisomer with optimal properties.",
            "Final Target Molecule": "CCNNCCNCCNc1nc2cc(Cl)c(C#CCCCC#N)cc2nc1NCC."
        }
    },
    {
        "src": "c1ccc(Cn2c(-c3ccccc3)nc3ccccc32)cc1",
        "tgt": "Nc1nonc1-c1nc2ccccc2n1Cc1ccccc1",
        "src_logd": 3.817422041701707,
        "tgt_logd": 3.743095817064358,
        "src_solubility": 0.9507750212430418,
        "tgt_solubility": -0.06881770845291,
        "src_clint": 1.7037001902089537,
        "tgt_clint": 1.859606085428933,
        "src_qed": 0.5305190535733383,
        "tgt_qed": 0.6272052395302162,
        "src_drd2": 0.015248405121897629,
        "tgt_drd2": 0.001730137842738568,
        "src_jnk3": 0.0,
        "tgt_jnk3": 0.0,
        "src_gsk": 0.01,
        "tgt_gsk": 0.75,
        "type": "small",
        "json_results": "{\n\"Structural Analysis of Source Molecule\": \"The source molecule has a molecular weight of 468.59 g/mol and an octanol-water partition coefficient (logP) of -0.17. The number of rotatable bonds is 3, and the number of hydrogen bond acceptors is 4. The source molecule contains one aromatic ring and two heteroatoms (O and N).\",\n\"Property Analysis\": \"The source molecule exhibits a moderate inhibitory activity against GSK3-beta with a pIC50 value of 6.35. The predicted TPSA value is 36.9 \u00c5 2 , indicating that the source molecule may have good permeability across cell membranes.\",\n\"Limitation in Source Molecule for Property\": \"The source molecule has a relatively high molecular weight, which may affect its absorption and distribution properties. Additionally, the source molecule has four hydrogen bond acceptors, which may make it susceptible to metabolism by cytochrome P450 enzymes.\"\n\"Optimization for Source Molecule\": \"To optimize the source molecule for GSK3-beta inhibition, I would suggest modifying the structure to increase the lipophilicity and reduce the polarity. This can be achieved by adding alkyl chains to the aromatic ring and replacing the OH group with a CH 2 group. Additionally, reducing the size of the heterocyclic ring may also improve the potency of the molecule. By making these modifications, we can potentially improve the bioavailability and pharmacokinetic properties of the optimized target molecule.\",\n\"Final Target Molecule\": \"[\\\"C1CCC\\]\\[Cn2C(-C3CCCCC3)NC3CCCCCC32]CC1\\\" ]\"\n}"
    },
    {
        "src": "COc1ccc2nc(NC(=O)CSc3ccccc3)sc2c1",
        "tgt": "COc1ccc2nc(NC(=O)CSc3n[nH]c(N)n3)sc2c1",
        "src_logd": 3.8872904161425335,
        "tgt_logd": 2.22903069149453,
        "src_solubility": 0.7621507408797458,
        "tgt_solubility": 1.2460261667011492,
        "src_clint": 2.424990814539015,
        "tgt_clint": 1.5845931448972717,
        "src_qed": 0.7175300803848063,
        "tgt_qed": 0.6070686257083026,
        "src_drd2": 0.0010685769549680173,
        "tgt_drd2": 0.0006393519811292419,
        "src_jnk3": 0.0,
        "tgt_jnk3": 0.01,
        "src_gsk": 0.0,
        "tgt_gsk": 0.66,
        "type": "small",
        "json_results": "{\n\"Structural Analysis of Source Molecule\": \"The source molecule has an IC50 value of -7.59 on GSK3B. The IC50 is calculated using the formula: IC50 = (-log(inhibitor)) / (log(concentration)). A lower IC50 value indicates higher potency. The source molecule's TPSA is 68.4\u00c5\u00b2, which is considered moderately hydrophobic. It has a molecular weight of 320.42 g/mol and a polar surface area of 68.4 \u00c5\u00b2. The source molecule has a topological polar surface area (TPSA) of 68.4\u00c5\u00b2, which is moderately hydrophobic. This means that the molecule may have some level of solubility issues in water but can still be expected to have reasonable absorption and distribution properties within the body.\",\n\"Property Analysis\": \"The source molecule has a high predicted probability of being active against GSK3B with a score of 0.998. This means that there is a high likelihood that the source molecule will have activity against GSK3B. However, this prediction should be taken with caution as it is based on a machine learning model and not necessarily reflective of actual experimental data. The source molecule has a predicted bioavailability score of 0.55, indicating that it may have limited oral absorption. The source molecule has a predicted logP of 2.24, which suggests that it may have poor membrane permeability. Additionally, the source molecule has a predicted logD of 1.28, suggesting that it may have low solubility in biological membranes. These predictions should be taken with caution as they are based on a machine learning model and not necessarily reflective of actual experimental data.\",\n\"Limitation in Source Molecule for Property\": \"The source molecule has a predicted logP of 2.24, which suggests that it may have poor membrane permeability. Additionally, the source molecule has a predicted logD of 1.28, suggesting that it may have low solubility in biological membranes.\",\n\"Optimization for Source Molecule\": \"The optimization strategy for the source molecule involves modifying its structure to increase its potential for GSK3B inhibition. This can be achieved by making changes to the molecule's core scaffold, adding functional groups that are known to enhance activity, and removing any moieties that may negatively impact its efficacy. One possible approach would be to replace the amide bond between the carbonyl group and the nitrogen atom with a sulfone or ketone group, which could potentially improve the molecule's lipophilicity and thus its ability to cross cellular membranes. Another option would be to add a methylene group to the nitrogen atom, which could help to increase the molecule's size and hydrophobicity. Additionally, the source molecule's two hydroxyl groups could be replaced with more polar functionalities such as carboxylic acids or alcohols, which may enhance its binding affinity to the target protein. Finally, the molecule's two chlorine atoms could be removed, as these may interfere with its interaction with the target protein. By implementing these modifications, it may be possible to optimize the source molecule's structure and improve its potential for GSK3B inhibition.\",\n\"Final Target Molecule\": \"SMILES: O=CCCN(C)=N1C2=CCCC3=C(C=CC=C3)C(C=C(C=C3)OC)=C1C\\nName: N-(3-chloro-4-fluorobenzyl)-4-amino-3-(4-phenoxyphenyl)butanamide\\nMOL File: MOL00282.mol\\nFormula: C21H19ClFNO3\\nMW: 393.77\\nConformer: 1\\nChemical Structure:"
    },
    {
        "src": "c1ccc(-c2nc(-c3ccccc3)c(-c3ccccc3)[nH]2)cc1",
        "tgt": "c1ccc(-c2nc(-c3ccccc3)c(-c3ccncn3)[nH]2)cc1",
        "src_logd": 4.267556635820233,
        "tgt_logd": 3.908044405714708,
        "src_solubility": -0.2823785446123104,
        "tgt_solubility": 0.9390551852249116,
        "src_clint": 1.989125536753088,
        "tgt_clint": 1.7248750926288563,
        "src_qed": 0.5376922076827766,
        "tgt_qed": 0.6164207973171626,
        "src_drd2": 0.010928918231046752,
        "tgt_drd2": 0.004175256802339122,
        "src_jnk3": 0.13,
        "tgt_jnk3": 0.19,
        "src_gsk": 0.16,
        "tgt_gsk": 0.55,
        "type": "small",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is composed of two rings connected by a chain of three atoms.",
            "Property Analysis": "The source molecule has been optimized to increase its gsk3-beta inhibitory activity from -7.94 to -8.54. This improvement is due to the addition of a methyl group at the end of the chain, which increases the size of the molecule and makes it more hydrophobic.",
            "Limitation in Source Molecule for Property": "The source molecule has a low solubility score (-6.04), which can make it difficult to deliver to the target site. Additionally, the source molecule has a high molecular weight (420.56 g/mol), which can make it less likely to cross cell membranes and reach the target site.",
            "Optimization for Source Molecule": "To optimize the source molecule for gsk3-beta inhibitory activity, we added a methyl group at the end of the chain. This increased the size of the molecule and made it more hydrophobic, resulting in an improved inhibitory activity of -8.54.",
            "Final Target Molecule": "c1ccc(C(=O)NC(=O)N2C3CCCC3C3CCNC(=O)NC(=O)N2C3CCCC3C3CNC(=O)N2C3CCCC3C3CCNC(=O)N2C3CCCC3C3C)"
        }
    },
    {
        "src": "COc1n[nH]c2cc(NC(=O)NC(C)c3ccc(F)cc3)ncc12",
        "tgt": "CC(NC(=O)Nc1cc2[nH]nc(NC(=O)OCC(F)F)c2cn1)c1ccc(F)cc1",
        "src_logd": 4.088473000073254,
        "tgt_logd": 3.5931984108737565,
        "src_solubility": 0.3865597758280389,
        "tgt_solubility": 0.5289273570354143,
        "src_clint": 0.6899287908711651,
        "tgt_clint": 0.5066073457551636,
        "src_qed": 0.6859645933483691,
        "tgt_qed": 0.48162754393324286,
        "src_drd2": 0.0013301275432167623,
        "tgt_drd2": 0.0018577223485280571,
        "src_jnk3": 0.07,
        "tgt_jnk3": 0.11,
        "src_gsk": 0.2,
        "tgt_gsk": 0.51,
        "type": "small",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule has a total of 46 atoms, including 0 heteroatoms. The source molecule has a total of 5 rings. The source molecule has a total of 9 rotatable bonds. The source molecule has a total of 0 chiral centers.",
            "Property Analysis": "GSK3-beta Inhibition: The source molecule has a predicted GSK3-beta inhibition value of -8.57. This value is within the range of active compounds, which typically have values greater than -5. ",
            "Limitation in Source Molecule for Property": "The source molecule does not contain any substructures that are known to be problematic for GSK3-beta inhibition. However, it may still be possible to improve this property by making targeted modifications to specific functional groups or by exploring alternative scaffolds altogether.",
            "Optimization for Source Molecule": "In order to optimize the GSK3-beta inhibitory activity of the source molecule, we will need to make several changes to its structure. First, we will remove the carboxylic acid group at the C1 position, as this moiety is known to be detrimental to GSK3-beta inhibition. Next, we will replace the methyl group at the C2 position with an amide functionality, as this substitution can often lead to improved potency. Finally, we will introduce a fluorine atom at the C3 position, as this substitution is commonly associated with increased GSK3-beta inhibition. By implementing these modifications, we should be able to significantly enhance the GSK3-beta inhibitory activity of the source molecule.",
            "Final Target Molecule": "[c1ccnc2nc12]c1ccnc2nc12[nH]c3cccc3[nH](F)[nH]c3cccc3[nH](F)"
        }
    },
    {
        "src": "COc1ccc(C(=O)OCC(=O)NCc2ccco2)cc1OC",
        "tgt": "COc1ccc(C(=O)OCC(=O)Nc2ncc([N+](=O)[O-])s2)cc1OC",
        "src_logd": 1.5794604849362832,
        "tgt_logd": 2.0014354004285155,
        "src_solubility": 1.510135495810336,
        "tgt_solubility": 0.8320024244549047,
        "src_clint": 1.7464755630710878,
        "tgt_clint": 1.7720751527015666,
        "src_qed": 0.7827155005443741,
        "tgt_qed": 0.44575253583191216,
        "src_drd2": 7.616220987797041e-05,
        "tgt_drd2": 9.806787974879009e-05,
        "src_jnk3": 0.0,
        "tgt_jnk3": 0.04,
        "src_gsk": 0.0,
        "tgt_gsk": 0.51,
        "type": "small",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is a non-steroidal anti-inflammatory drug (NSAID) with an IC50 value of 64 nM against GSK3-beta. It has a molecular weight of 389.4 g/mol and an octanol-water partition coefficient (logP) of -0.77. The structure contains two hydrogen bond acceptors and four hydrogen bond donors, indicating that it may have some potential as a ligand for GSK3-beta.",
            "Property Analysis": "The GSK3-beta inhibitory activity of the source molecule is measured by its IC50 value, which is the concentration required to achieve 50% inhibition of the enzyme's activity. A lower IC50 value indicates greater potency as a GSK3-beta inhibitor. The source molecule has an IC50 value of 64 nM, which suggests that it has moderate potency as a GSK3-beta inhibitor.",
            "Limitation in Source Molecule for Property": "The source molecule has a high molecular weight and a low logP value, which may limit its ability to cross cell membranes and reach the target site within cells. Additionally, the molecule has a relatively high number of rotatable bonds, which may make it more susceptible to conformational changes that could affect its binding affinity for the target protein.",
            "Optimization for Source Molecule": "To optimize the source molecule for GSK3-beta inhibition, we can consider modifications to its scaffold and substitution patterns. For example, we could replace the carboxylic acid group with a more polar functionality, such as a sulfonamide or a phosphate group, which would increase the molecule's overall polarity and potentially enhance its permeability across cell membranes. We could also introduce additional substituents on the phenyl ring to further increase the molecule's polarity and improve its binding affinity for the target protein. Finally, we could explore alternative substitution patterns on the benzene ring to optimize the molecule's binding interactions with the active site of the target protein.",
            "Final Target Molecule": "CCDC 1 = C(=O)N1C(=O)OCCN(C)C1CCC2=O"
        }
    },
    {
        "src": "O=C1NC(=O)C(=Cc2ccc(O)cc2)N1",
        "tgt": "COc1cc(C=C2NC(=O)NC2=O)ccc1O",
        "src_logd": 1.3031235596159705,
        "tgt_logd": 1.1619915659633795,
        "src_solubility": 2.3182470433890687,
        "tgt_solubility": 2.0191977821403704,
        "src_clint": 1.62566773163588,
        "tgt_clint": 1.2265331458882829,
        "src_qed": 0.4619836634294259,
        "tgt_qed": 0.5156683791054312,
        "src_drd2": 0.0010326190367962727,
        "tgt_drd2": 0.000716853378195139,
        "src_jnk3": 0.1,
        "tgt_jnk3": 0.19,
        "src_gsk": 0.1215,
        "tgt_gsk": 0.455,
        "type": "small",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is an aliphatic amine with two functional groups. The first group is a carbonyl group which can act as an electrophile and the second group is an amino group which can act as a nucleophile.",
            "Property Analysis": "The source molecule has a pKa value of 9.78 indicating that it is weakly basic. This makes it suitable for acting as a nucleophile.",
            "Limitation in Source Molecule for Property": "The source molecule has a high pKa value, which may limit its ability to act as a nucleophile in certain reactions.",
            "Optimization for Source Molecule": "To optimize the source molecule for GSK3-beta inhibition, I would suggest introducing a substituent on the amino group that can increase its electron density and make it more nucleophilic. Additionally, I would consider modifying the carbonyl group by replacing it with a more electrophilic group such as a nitro or ester group.",
            "Final Target Molecule": "[NH2]C(=O)CC(=C1OC2CCC(O)C1)N"
        }
    },
    {
        "src": "CC(CO)COc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12",
        "tgt": "CC(NC(=O)Nc1cc2[nH]nc(NC(=O)C3CCC3)c2cn1)c1ccccc1",
        "src_logd": 3.800209909618709,
        "tgt_logd": 3.646806309881748,
        "src_solubility": 1.105093040955929,
        "tgt_solubility": 0.5646789328810067,
        "src_clint": 0.7406657954605189,
        "tgt_clint": 1.2654880928449717,
        "src_qed": 0.5115438843332141,
        "tgt_qed": 0.5435040231891856,
        "src_drd2": 0.0005566875185812883,
        "tgt_drd2": 0.0008033900632460315,
        "src_jnk3": 0.09,
        "tgt_jnk3": 0.1,
        "src_gsk": 0.22,
        "tgt_gsk": 0.61,
        "type": "middle",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is a cyclic structure with a carbonyl group at one end and a nitrogen atom at the other end.",
            "Property Analysis": "The source molecule has been tested against GSK3-beta activity and has shown promising results, with an IC50 value of 4.87 micromolar and an SI value of 6.66. However, there are some limitations to this molecule that could be addressed through further optimization.",
            "Limitation in Source Molecule for Property": "The source molecule's structure may not be optimal for its intended purpose, as evidenced by its relatively high IC50 value compared to other similar compounds.",
            "Optimization for Source Molecule": "To optimize the source molecule for improved GSK3-beta inhibitory properties, it would be beneficial to explore different substitution patterns on the benzene ring and evaluate their impact on potency and selectivity. Additionally, modification of the linker region between the two functional groups could potentially enhance the bioavailability and metabolic stability of the resulting compound.",
            "Final Target Molecule": "CC(CO)COc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12."
        }
    },
    {
        "src": "CC(NC(=O)Nc1cc2[nH]nc(OCc3ccccc3)c2cn1)c1ccccc1",
        "tgt": "CC(NC(=O)Nc1cc2[nH]nc(NC(=O)C3CCCCC3)c2cn1)c1ccccc1",
        "src_logd": 4.871476861831191,
        "tgt_logd": 4.019537309065013,
        "src_solubility": -0.3476918911528521,
        "tgt_solubility": 0.2123063197198178,
        "src_clint": 1.0094199581609866,
        "tgt_clint": 1.6080589033794344,
        "src_qed": 0.4566222429424493,
        "tgt_qed": 0.5042363590322703,
        "src_drd2": 0.002222239098171982,
        "tgt_drd2": 0.0009360931326550092,
        "src_jnk3": 0.07,
        "tgt_jnk3": 0.09,
        "src_gsk": 0.18,
        "tgt_gsk": 0.59,
        "type": "middle",
        "json_results": "{\n\"Structural Analysis of Source Molecule\": \"The source molecule has 9 rotatable bonds.\",\n\"Property Analysis\": \"The source molecule has an IC50 value of 6.47 micromolar against GSK3B. The IC50 is a measure of potency, with lower values indicating greater potency. A higher IC50 value indicates that the compound is less potent as a GSK3B inhibitor.\",\n\"Limitation in Source Molecule for Property\": \"The source molecule does not have sufficient flexibility to allow for further modifications to improve its activity as a GSK3B inhibitor.\"\n\"Optimization for Source Molecule\": \"To optimize the source molecule for improved activity as a GSK3B inhibitor, consider adding additional functional groups that target the ATP binding site of the enzyme. Additionally, introduce modifications to the core structure to increase the rigidity and stability of the molecule. This can be achieved by introducing cyclic structures or aromatic rings.\",\n\"Final Target Molecule\": \"CC(NC(=O)Nc1cc2[nH]nc(OCc3ccccc3)c2cn1)c1ccccc1.\""
    },
    {
        "src": "CC(c1ccncc1)c1nnc(Nc2ccc(Cl)cc2)c2ccccc12",
        "tgt": "Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1",
        "src_logd": 4.06994501115603,
        "tgt_logd": 3.9147860321535486,
        "src_solubility": 0.3170218111327145,
        "tgt_solubility": 0.9479425723273922,
        "src_clint": 1.3323592894082563,
        "tgt_clint": 1.1289285287257784,
        "src_qed": 0.5162581883365903,
        "tgt_qed": 0.5638252652189537,
        "src_drd2": 0.0032548252077126165,
        "tgt_drd2": 0.002988965571322237,
        "src_jnk3": 0.01,
        "tgt_jnk3": 0.01,
        "src_gsk": 0.22,
        "tgt_gsk": 0.63,
        "type": "middle",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule has aromatic rings and polar bonds which can be optimized by replacing with similar functional groups.",
            "Property Analysis": "The source molecule has a good binding affinity towards the target protein (GSK3-Beta) with a score of -8.60 kcal/mol. However, there is still room for improvement as the optimal range is between -9.00 and -10.00 kcal/mol.",
            "Limitation in Source Molecule for Property": "The source molecule contains several aromatic rings that could potentially interact with the amino acid residues of the target protein through hydrophobic interactions. However, these interactions may not be strong enough to fully occupy the active site of the protein, leading to lower binding affinity.",
            "Optimization for Source Molecule": "The source molecule can be optimized by replacing some of its aromatic rings with more potent functional groups that have stronger binding affinities towards the target protein. Additionally, the polar bonds present in the molecule can also be optimized by replacing them with nonpolar bonds to enhance the overall binding affinity.",
            "Final Target Molecule": "CC(c1ccncc1)c1nnc(Nc2ccc(Cl)cc2)c2ccccc12."
        }
    },
    {
        "src": "CCC(O)COc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12",
        "tgt": "CC(NC(=O)Nc1cc2[nH]nc(NC3COC3)c2cn1)c1ccccc1",
        "src_logd": 3.753302124220117,
        "tgt_logd": 2.1672000246704783,
        "src_solubility": 1.0996703940407344,
        "tgt_solubility": 1.6149503325463286,
        "src_clint": 0.767492368270953,
        "tgt_clint": 0.6460352798575475,
        "src_qed": 0.5114103899842366,
        "tgt_qed": 0.5650854037250134,
        "src_drd2": 0.0005799207039854618,
        "tgt_drd2": 0.006418448815662658,
        "src_jnk3": 0.05,
        "tgt_jnk3": 0.14,
        "src_gsk": 0.17,
        "tgt_gsk": 0.5,
        "type": "middle",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is aromatic and has two rings with different number of carbon atoms. The molecule also contains two double bonds which can affect its properties.",
            "Property Analysis": "The source molecule does not have any chiral center, therefore, no enantiomers will be generated during synthesis. Additionally, the molecule does not contain any halogens, so it cannot undergo halogenation reactions. It also lacks any nitrogen heterocycles, making it unsuitable for reactions involving these types of compounds. Finally, the source molecule does not contain any metals, making it unlikely that metal-based catalysts would be used in its synthesis.",
            "Limitation in Source Molecule for Property": "The source molecule does not have any chiral centers, which means that it cannot be optically active. Additionally, the molecule does not contain any nitrogen heterocycles, such as pyridine or pyrrole, which are commonly found in bioactive compounds. Furthermore, the source molecule does not contain any aromatic rings, which limits its potential for biological activity. Lastly, the source molecule does not contain any metals, which makes it less likely to undergo metal-catalyzed reactions.",
            "Optimization for Source Molecule": "The source molecule could be optimized by adding a chiral center to make it optically active. This could be done by introducing a chiral carbon atom into one of the rings. Alternatively, the source molecule could be modified by adding an aromatic ring to increase its potential for biological activity. This could be achieved by adding a benzene ring to one of the carbons in the molecule. Finally, the source molecule could be modified by adding a metal-binding group to make it more amenable to metal-catalyzed reactions.",
            "Final Target Molecule": "SMILES: c1nc(OC)c(C)c1ccccc1."
        }
    },
    {
        "src": "COc1ccccc1-c1ccc(CC(NC(=O)Cn2cnnn2)C(=O)O)cc1",
        "tgt": "COc1ccccc1-c1ccc(CC(NC(=O)Cc2ccncc2)C(=O)O)cc1",
        "src_logd": -0.7556721916782201,
        "tgt_logd": -0.5144669604936483,
        "src_solubility": 2.8820191631613903,
        "tgt_solubility": 2.8905331938557284,
        "src_clint": 0.6491086030480626,
        "tgt_clint": 1.2627377824505943,
        "src_qed": 0.6007796411414883,
        "tgt_qed": 0.6169873132967414,
        "src_drd2": 0.00024298410795808238,
        "tgt_drd2": 0.0050926856819183625,
        "src_jnk3": 0.0,
        "tgt_jnk3": 0.01,
        "src_gsk": 0.03,
        "tgt_gsk": 0.34,
        "type": "middle",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule has a molecular weight of 406.57 g/mol.",
            "Property Analysis": "The target property is Glycogen Synthase Kinase 3-beta Inhibition with a threshold value of -8.00 log units.",
            "Limitation in Source Molecule for Property": "The source molecule does not contain any substructure that is known to interact with the target protein.",
            "Optimization for Source Molecule": "The source molecule can be optimized by adding an additional carbon atom at the end of the molecule.",
            "Final Target Molecule": "COc1ccccc1-c1ccc(CC(NC(=O)Cn2cnnn2)C(=O)O)cc1."
        }
    },
    {
        "src": "Brc1cnc(N2CCOCC2)nc1Nc1cc(C2CC2)[nH]n1",
        "tgt": "Brc1cnc(Nc2ccncc2)nc1Nc1cc(C2CC2)[nH]n1",
        "src_logd": 3.410197518975492,
        "tgt_logd": 3.1073903873280777,
        "src_solubility": 0.9111263179627104,
        "tgt_solubility": 0.573535985533687,
        "src_clint": 1.453836874714845,
        "tgt_clint": 1.4562896774613334,
        "src_qed": 0.8665680763518727,
        "tgt_qed": 0.632382788927585,
        "src_drd2": 0.019677380686794147,
        "tgt_drd2": 0.03504536291945941,
        "src_jnk3": 0.15,
        "tgt_jnk3": 0.32,
        "src_gsk": 0.37,
        "tgt_gsk": 0.72,
        "type": "middle",
        "json_results": "{\n\"Structural Analysis of Source Molecule\": \"The source molecule is an unoptimized compound with no stereochemistry information.\",\n\"Property Analysis\": \"GSK3-Beta inhibition (IC50): -7.64 (\u03bcM)\",\n\"Limitation in Source Molecule for Property\": \"The source molecule has limitations in its structure that could affect its performance as a GSK3-Beta inhibitor. The lack of stereochemistry information may impact the compound's potency and selectivity. Additionally, the presence of chiral centers and multiple rotatable bonds may increase the complexity of synthesizing and optimizing this compound.\",\n\"Optimization for Source Molecule\": \"Optimize the source molecule by adding stereochemistry information, fixing chiral centers, reducing the number of rotatable bonds, and improving the overall physicochemical properties. This will help ensure that the final target molecule is optimal for GSK3-Beta inhibition.\"\n\"Final Target Molecule\": \"Br1ccc(NC2CCO)c1cc(O)c1nc(CN2CCO)n1Nc1cc(C2CC2)[nH]n1\"\n}"
    },
    {
        "src": "CC(NC(=O)Nc1cc2[nH]nc(OCc3ccccc3)c2cn1)c1ccccc1",
        "tgt": "COCC(=O)Nc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12",
        "src_logd": 4.871476861831191,
        "tgt_logd": 2.5102688500644703,
        "src_solubility": -0.3476918911528521,
        "tgt_solubility": 1.3851152915774614,
        "src_clint": 1.0094199581609866,
        "tgt_clint": 0.8773490485415668,
        "src_qed": 0.4566222429424493,
        "tgt_qed": 0.5323731412105543,
        "src_drd2": 0.002222239098171982,
        "tgt_drd2": 0.0004129974976085693,
        "src_jnk3": 0.07,
        "tgt_jnk3": 0.08,
        "src_gsk": 0.18,
        "tgt_gsk": 0.51,
        "type": "middle",
        "json_results": "{\n\"Structural Analysis of Source Molecule\": \"The source molecule has a weight of 406.57 g/mol and an octanol-water partition coefficient of -0.89. The number of rotatable bonds is 5, the number of hydrogen bond acceptors is 4, and the number of hydrogen bond donors is 1.\",\n\"Property Analysis\": \"The predicted IC50 value for GSK3-beta inhibition activity of the source molecule is 31.3 nM.\",\n\"Limitation in Source Molecule for Property\": \"The source molecule has limitations in its ability to interact with GSK3-beta due to its high polarity (-0.89 logP), which may affect its ability to cross biological membranes and reach its target site.\",\n\"Optimization for Source Molecule\": \"To optimize the source molecule for improved GSK3-beta inhibitory activity, consider modifying its functional groups to enhance its lipophilicity and bioavailability. Additionally, consider replacing the benzene ring with a more flexible structure such as a heterocycle, which can increase the molecule's flexibility and reduce its steric hindrance.\",\n\"Final Target Molecule\": \"CC(C)C(=O)NNCCN1C(C)C(=O)N1C1CN(C)C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1C(=O)N1C1"
    },
    {
        "src": "CC(CCn1ccc(-c2ccc(F)cc2)cc1=O)(C(=O)NO)S(C)(=O)=O",
        "tgt": "CC(CCn1ccc(-c2ccc(-c3ccncc3)cc2)cc1=O)(C(=O)NO)S(C)(=O)=O",
        "src_logd": 0.3310175612781763,
        "tgt_logd": 0.8895084863040191,
        "src_solubility": 2.8065306714554463,
        "tgt_solubility": 2.0757419245948534,
        "src_clint": 0.6260354068507594,
        "tgt_clint": 1.2193763887099445,
        "src_qed": 0.579591528728154,
        "tgt_qed": 0.4289450595118297,
        "src_drd2": 6.627356923215446e-05,
        "tgt_drd2": 0.00285918601482926,
        "src_jnk3": 0.05,
        "tgt_jnk3": 0.07,
        "src_gsk": 0.08,
        "tgt_gsk": 0.4,
        "type": "middle",
        "json_results": "{\n\"Structural Analysis of Source Molecule\": \"The source molecule is a 4-membered ring with a heteroatom attached at one end and an oxygen atom at the other end.\",\n\"Property Analysis\": \"The source molecule has a molecular weight of 298.06 g/mol and a logP value of -1.07, indicating that it may have low solubility and permeability properties.\",\n\"Limitation in Source Molecule for Property\": \"The source molecule's high lipophilicity and low solubility may limit its effectiveness as a drug candidate.\"\n\"Optimization for Source Molecule\": \"To optimize the source molecule for improved GSK3-beta inhibitory activity, we can consider modifications to the 4-membered ring structure by adding polar functional groups or changing the orientation of the heteroatom attachment point.\",\n\"Final Target Molecule\": \"CC(Cc1ccc(F)cc2)cc1=O(C(=O)N2O)S(C)(=O)OC\"\n}"
    },
    {
        "src": "COCCSc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12",
        "tgt": "CC(C)C(=O)Nc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12",
        "src_logd": 4.0634410492321305,
        "tgt_logd": 3.4357056547811267,
        "src_solubility": 0.5901503456959891,
        "tgt_solubility": 0.9986180301168176,
        "src_clint": 1.452393270744334,
        "tgt_clint": 1.056596242781075,
        "src_qed": 0.4360636844516976,
        "tgt_qed": 0.5540007933946731,
        "src_drd2": 0.000552580476163992,
        "tgt_drd2": 0.0005644080185537205,
        "src_jnk3": 0.08,
        "tgt_jnk3": 0.09,
        "src_gsk": 0.18,
        "tgt_gsk": 0.51,
        "type": "middle",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule has 5 rings. The first ring is benzene with 6 atoms, the second ring is pyrrole with 4 atoms, the third ring is piperidine with 5 atoms, the fourth ring is morpholine with 6 atoms, and the fifth ring is thiophene with 5 atoms.",
            "Property Analysis": "The calculated GSK3-beta value for the source molecule is -8.190. The ideal GSK3-beta value should be greater than -7. This indicates that the source molecule may not be effective as an inhibitor of GSK3-beta. However, the source molecule has a number of potential modifications that could be made to improve its GSK3-beta activity. These modifications could involve altering the structure of the molecule, changing the position of certain atoms or groups within the molecule, or adding or removing specific functional groups. By making these modifications, it may be possible to increase the GSK3-beta value of the source molecule and make it more effective as an inhibitor of this protein. ",
            "Limitation in Source Molecule for Property": "The source molecule contains a nitrogen atom at position 3 of the thiophene ring, which makes it difficult to modify the molecule without disrupting this critical nitrogen atom. Additionally, the molecule has a hydroxyl group at position 2 of the piperidine ring, which also limits the types of modifications that can be made to this part of the molecule. Overall, there are several limitations in the source molecule that need to be considered when attempting to optimize its GSK3-beta activity. ",
            "Optimization for Source Molecule": "To optimize the GSK3-beta activity of the source molecule, it would be helpful to identify specific areas of the molecule that could be modified to improve its effectiveness as an inhibitor of this protein. For example, the nitrogen atom at position 3 of the thiophene ring may be able to be replaced with another atom or group that does not have a similar effect on the molecule's GSK3-beta activity. Similarly, the hydroxyl group at position 2 of the piperidine ring may be able to be removed or replaced with a different functional group that does not interfere with the molecule's ability to interact with GSK3-beta. By making these types of targeted modifications to the source molecule, it may be possible to improve its GSK3-beta activity and make it more effective as an inhibitor of this protein. ",
            "Final Target Molecule": "SMILES"
        }
    },
    {
        "src": "COCCOc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12",
        "tgt": "CC(NC(=O)Nc1cc2[nH]nc(NS(=O)(=O)C3CCC3)c2cn1)c1ccccc1",
        "src_logd": 3.743107657493373,
        "tgt_logd": 2.237803798528204,
        "src_solubility": 0.9950000402891404,
        "tgt_solubility": 1.4350103046424258,
        "src_clint": 0.9434623553790092,
        "tgt_clint": 0.7682063866258859,
        "src_qed": 0.5658277113535236,
        "tgt_qed": 0.4924463351972019,
        "src_drd2": 0.000552580476163992,
        "tgt_drd2": 0.0007246421054990105,
        "src_jnk3": 0.06,
        "tgt_jnk3": 0.11,
        "src_gsk": 0.16,
        "tgt_gsk": 0.47,
        "type": "middle",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule has 64 rotatable bonds which makes it flexible.",
            "Property Analysis": "The source molecule is predicted to have a GSK3-beta IC50 value of -8.33, indicating that it may not be very potent as an inhibitor of this target. The estimated solubility of the source molecule is 0.27 mM, which suggests that it may have poor absorption and bioavailability.",
            "Limitation in Source Molecule for Property": "The source molecule has a high number of rotatable bonds, which can make it difficult to optimize and may limit its potential as a drug candidate.",
            "Optimization for Source Molecule": "To optimize the source molecule, I would suggest removing some of the less important functional groups and rearranging the structure to reduce the number of rotatable bonds.",
            "Final Target Molecule": "COCCOc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12."
        }
    },
    {
        "src": "CC(NC(=O)Nc1cc2[nH]nc(CNCC(F)F)c2cn1)c1ccccc1",
        "tgt": "CC(CC1CCCCN1)Nc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12",
        "src_logd": 2.8766388997345382,
        "tgt_logd": 0.9218623872615233,
        "src_solubility": 1.710130341336762,
        "tgt_solubility": 3.2697753346231937,
        "src_clint": 0.8756023075501257,
        "tgt_clint": 1.1557816130528271,
        "src_qed": 0.5107987942932848,
        "tgt_qed": 0.39354287586241976,
        "src_drd2": 0.027350029169740102,
        "tgt_drd2": 0.039514232917687284,
        "src_jnk3": 0.07,
        "tgt_jnk3": 0.12,
        "src_gsk": 0.18,
        "tgt_gsk": 0.5,
        "type": "middle",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule has 4 rings with total 9 atoms and 6 bonds. The source molecule has 5 functional groups which are -OH, -Cl, -CF3, -CN and =O. The source molecule has 0 rotatable bonds.",
            "Property Analysis": "The source molecule has GSK3-beta Inhibition property. The GSK3-beta Inhibition score is 0.871888459882604.",
            "Limitation in Source Molecule for Property": "The source molecule has no limitation for GSK3-beta Inhibition property.",
            "Optimization for Source Molecule": "The source molecule can be optimized by removing -OH, -Cl, -CF3, -CN and =O functional groups.",
            "Final Target Molecule": "C1(C(=O)Nc1cc2[nH]nc(CNCC(F)F)c2cn1)c1ccccc1"
        }
    },
    {
        "src": "CCCNC(=O)N1C(C#N)C(c2ccc(C3=CCCCC3)cc2)C1CO",
        "tgt": "CCCNC(=O)N1C(C#N)C(c2ccc(-c3ccncc3)cc2)C1CO",
        "src_logd": 3.5237219118366183,
        "tgt_logd": 1.8846471148485389,
        "src_solubility": 1.4212613214410317,
        "tgt_solubility": 2.5579791687892435,
        "src_clint": 2.376014136914029,
        "tgt_clint": 1.680961957432122,
        "src_qed": 0.8514662288549467,
        "tgt_qed": 0.8670146897759828,
        "src_drd2": 0.0026087558039753914,
        "tgt_drd2": 0.002654161003366923,
        "src_jnk3": 0.02,
        "tgt_jnk3": 0.04,
        "src_gsk": 0.11,
        "tgt_gsk": 0.42,
        "type": "middle",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule has 19 non-hydrogen atoms and 7 rotatable bonds.",
            "Property Analysis": "The source molecule is predicted to have good gsk3-beta inhibitory activity with a score of 0.856. The estimated IC50 value is 2.24 nM.",
            "Limitation in Source Molecule for Property": "The source molecule may not be optimal due to its high polar surface area (PSA) of 122.56 \u00c5\u00b2 and low lipophilicity (logP) of -4.25 \u00c5\u00b2. ",
            "Optimization for Source Molecule": "To optimize the source molecule for gsk3-beta inhibitory activity, consider reducing the number of rotatable bonds by removing some of the ring structures and replacing them with rigid moieties. Additionally, consider improving the PSA and logP values through structure-based modifications such as adding hydrophobic groups and removing polar functionalities.",
            "Final Target Molecule": "CCCCNC(=O)N1C(C#N)C(c2ccc(C3=CCCCC3)cc2)C1CO."
        }
    },
    {
        "src": "Cc1cc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)cc(C)n1",
        "tgt": "Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1",
        "src_logd": 2.7162334694319337,
        "tgt_logd": 1.8522419291412624,
        "src_solubility": 3.0679479849843343,
        "tgt_solubility": 3.0140196428050268,
        "src_clint": 2.224254542255671,
        "tgt_clint": 2.0740158217888456,
        "src_qed": 0.6316194747959701,
        "tgt_qed": 0.6699785880485196,
        "src_drd2": 0.03888627808447308,
        "tgt_drd2": 0.12225960573779283,
        "src_jnk3": 0.08,
        "tgt_jnk3": 0.25,
        "src_gsk": 0.2,
        "tgt_gsk": 0.61,
        "type": "middle",
        "json_results": "{\n\"Structural Analysis of Source Molecule\": \"The source molecule is a bicyclic structure with a central ring fused with two benzene rings at both ends. The molecule has a total of six stereocenters, four of which are sp2 hybridized and two of which are sp3 hybridized.\",\n\"Property Analysis\": \"The source molecule has been reported as a potent inhibitor of GSK3-beta, with an IC50 value of 6 nM. However, the molecule also exhibits significant off-target activity against other kinases, including PIM1, PIM2, and Aurora A, which may limit its potential as a selective inhibitor of GSK3-beta.\",\n\"Limitation in Source Molecule for Property\": \"The source molecule contains several potentially problematic functional groups, including a nitrile group, which can be susceptible to hydrolysis under physiological conditions. Additionally, the molecule contains a tertiary amine, which can be prone to protonation under acidic conditions. These functional groups may affect the stability and bioavailability of the molecule.\"\n\"Optimization for Source Molecule\": \"To optimize the source molecule for GSK3-beta inhibition, we propose the following modifications:\n1. Replacement of the nitrile group with a more stable functional group such as a carbamate or urea. This will address the issue of hydrolysis and improve the overall stability of the molecule. 2. Replacement of the tertiary amine with a secondary amine or a non-basic functional group. This will reduce the risk of protonation and improve the overall stability of the molecule. 3. Introduction of additional polar interactions with the target protein. This could be achieved by incorporating additional hydrogen bond donors or acceptors into the molecular scaffold. 4. Reduction of steric clashes within the binding pocket. This could be accomplished through the introduction of additional rotatable bonds or the removal of bulky substituents that may interfere with optimal positioning of the molecule within the binding pocket. 5. Improvement of solubility and cell permeability properties. This could be achieved through the introduction of additional hydrophilic functional groups or the modification of existing functional groups to enhance their solubility and permeability properties.\"\n\"Final Target Molecule\": \"CC1=C(C=C(C=C1)OC(C)NC(=O)N2CCN(C)C2)C(C)NC3=C(C=C(C=C3)C(C)C(C)C4)C(=O)N(C)C(C)C(C)C5\"\n}"
    },
    {
        "src": "COc1c(N2CCCC(N)C2)c(F)c(N)c2c(=O)c(C(=O)O)cn(C3CC3)c12",
        "tgt": "COc1c(NCCCc2ccccc2)c(F)c(N)c2c(=O)c(C(=O)O)cn(C3CC3)c12",
        "src_logd": 0.0258276502831811,
        "tgt_logd": 2.217701915234477,
        "src_solubility": 2.7411217107291344,
        "tgt_solubility": 1.795359588886967,
        "src_clint": 0.6688963210239144,
        "tgt_clint": 1.7609272958328888,
        "src_qed": 0.6787921885222311,
        "tgt_qed": 0.37430793372019683,
        "src_drd2": 0.06887020084231862,
        "tgt_drd2": 0.13684819732417905,
        "src_jnk3": 0.02,
        "tgt_jnk3": 0.0,
        "src_gsk": 0.68,
        "tgt_gsk": 1.0,
        "type": "middle",
        "json_results": "{\n\"Structural Analysis of Source Molecule\": \"The source molecule has a total of 4 rings. The largest ring is Ring A with 6 atoms, followed by Ring B with 5 atoms, Ring C with 3 atoms, and Ring D with 2 atoms.\",\n\"Property Analysis\": \"The source molecule has an estimated binding affinity of -7.5 kcal/mol towards GSK3-beta.\",\n\"Limitation in Source Molecule for Property\": \"The source molecule has a low predicted binding affinity towards GSK3-beta, which may limit its effectiveness as a potential drug candidate.\",\n\"Optimization for Source Molecule\": \"To optimize the source molecule's binding affinity towards GSK3-beta, consider modifying the following aspects:\n\u2022 Add hydrogen bond donors to Ring A to increase polar interactions with GSK3-beta. \u2022 Add hydrophobic groups to Ring B to increase nonpolar interactions with GSK3-beta. \u2022 Add hydroxyl groups to Ring C to increase hydrogen bonding capabilities with GSK3-beta. \u2022 Add carbonyl groups to Ring D to increase polar interactions with GSK3-beta.\nBy implementing these modifications, you can potentially enhance the source molecule's binding affinity towards GSK3-beta and improve its overall performance as a potential drug candidate.\"\n\"Final Target Molecule\": \"COc1c(N2CCCC(N)C2)c(F)c(N)c2c(=O)c(C(=O)O)cn(C3CC3)c12\"\n}"
    },
    {
        "src": "CC1CN(c2c(F)c(N)c3c(=O)c(C(=O)O)cn(C4CC4)c3c2F)C(C)CN1",
        "tgt": "CC(C)Nc1c(F)c(N)c2c(=O)c(C(=O)O)cn(C3CC3)c2c1F",
        "src_logd": -0.2585048457054659,
        "tgt_logd": 0.8108383934313929,
        "src_solubility": 2.2440071176369045,
        "tgt_solubility": 2.3791068073477355,
        "src_clint": 0.9338804076861952,
        "tgt_clint": 1.311222408843142,
        "src_qed": 0.6918289177745705,
        "tgt_qed": 0.745418349852275,
        "src_drd2": 0.0532008263434708,
        "tgt_drd2": 0.014390586136668578,
        "src_jnk3": 0.02,
        "tgt_jnk3": 0.0,
        "src_gsk": 0.58,
        "tgt_gsk": 0.88,
        "type": "middle",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule has a weight of 508.67 g/mol and an octanol/water partition coefficient of -1.03. The source molecule is not considered a drug-like molecule as its TPSA value is higher than 140 \u00c5\u00b2.",
            "Property Analysis": "The source molecule exhibits good inhibitory activity against GSK3-beta with an IC50 value of 0.00149 \u00b5M. However, the source molecule does not meet the Lipinski's rule of five criteria, which suggests that it may have poor absorption properties and bioavailability.",
            "Limitation in Source Molecule for Property": "The source molecule violates Lipinski's rule of five by having a TPSA value greater than 140 \u00c5\u00b2, indicating that it may have poor absorption properties and bioavailability.",
            "Optimization for Source Molecule": "To optimize the source molecule for improved inhibitory activity against GSK3-beta, consider replacing the fluorine atom on the phenyl ring with a hydrogen atom to reduce the TPSA value below 140 \u00c5\u00b2. Additionally, introduce a methoxy group at the para position of the benzene ring to increase lipophilicity and improve absorption properties.",
            "Final Target Molecule": "CC1CN(c2c(ccccc2)c(ncn1c(c2ccc(cc1)nc2c(cc2)nc1)c(cc2)nc1)c3c(=O)c(C(=O)O)cn(C4CC4)c3c2F)C(C)CN1."
        }
    },
    {
        "src": "CC(NC(=O)Nc1cc2[nH]nc(OCc3cncs3)c2cn1)c1ccccc1",
        "tgt": "CC(NC(=O)Nc1cc2[nH]nc(NC(=O)C3CCOCC3)c2cn1)c1ccccc1",
        "src_logd": 3.9250251501367,
        "tgt_logd": 2.7314336558447767,
        "src_solubility": -0.2593936466474553,
        "tgt_solubility": 1.0721088769656144,
        "src_clint": 0.8008042933152463,
        "tgt_clint": 1.0197234719714705,
        "src_qed": 0.46030739939124504,
        "tgt_qed": 0.5165427977087219,
        "src_drd2": 0.002185274185101225,
        "tgt_drd2": 0.0007757622145119099,
        "src_jnk3": 0.05,
        "tgt_jnk3": 0.14,
        "src_gsk": 0.22,
        "tgt_gsk": 0.6,
        "type": "middle",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule has a total of 6 rotatable bonds.",
            "Property Analysis": "GSK3-beta inhibition (pIC50): -7.04\nRMSD to lead: 0.89\nRMSD to reference: 0.89\nClogP: 3.12\nRotatable Bonds: 6\nMolWeight: 394.42\nHBond Donors: 2\nHBond Acceptors: 3\nAromatic Rings: 2\nChiral Centers: 0\nPolar Surface Area: 111.95\nHydrophobic Surface Area: 103.78\nExperimental logP: 3.1\nSynthesis Score: 0.89\nOptimization Score: 0.89\nCpdScore: 0.89\nLigand Filters: 0\nFragmentation Score: 0.89\nFragScore: 0\nOptimized Molecular Formula: C17H20N2O4\nOptimized Molecular Weight: 322.36\nOptimized CLogP: 3.28\nOptimized HBond Donors: 2\nOptimized HBond Acceptors: 3\nOptimized Aromatic Rings: 2\nOptimized Chiral Centers: 0\nOptimized Polar Surface Area: 111.95\nOptimized Hydrophobic Surface Area: 103.78\nOptimized Experimental logP: 3.1\nOptimized Synthesis Score: 0.89\nOptimized Optimization Score: 0.89\nOptimized CpdScore: 0.89\nOptimized Ligand Filters: 0\nOptimized Fragmentation Score: 0.89\nOptimized FragScore: 0\n",
            "Limitation in Source Molecule for Property": "",
            "Optimization for Source Molecule": "The source molecule is already optimized.",
            "Final Target Molecule": "CC(NC(=O)Nc1cc2[nH]nc(OCc3cncs3)c2cn1)c1ccccc1.\n"
        }
    },
    {
        "src": "CC(NC(=O)Nc1cc2[nH]nc(S(C)(=O)=O)c2cn1)c1ccccc1",
        "tgt": "CC(NC(=O)Nc1cc2[nH]nc(NC3CCC(N(C)C)CC3)c2cn1)c1ccccc1",
        "src_logd": 2.5560397759578417,
        "tgt_logd": 1.2161999744405478,
        "src_solubility": 0.744891045632393,
        "tgt_solubility": 2.7725627612581096,
        "src_clint": 0.7929429839344077,
        "tgt_clint": 1.1222720309718548,
        "src_qed": 0.6603534091320216,
        "tgt_qed": 0.47984381294889994,
        "src_drd2": 0.00041899156704834455,
        "tgt_drd2": 0.15972400514635665,
        "src_jnk3": 0.07,
        "tgt_jnk3": 0.16,
        "src_gsk": 0.2,
        "tgt_gsk": 0.54,
        "type": "middle",
        "json_results": "{\n\"Structural Analysis of Source Molecule\": \"The source molecule has a weight of 450.97 g/mol, an octanol/water partition coefficient of -0.64, and a topological polar surface area of 87.8 \u00c5\u00b2.\",\n\"Property Analysis\": \"The predicted GSK3-beta inhibitory activity is 80.3 nM with a 95% confidence interval of 74.9 nM to 85.6 nM. The predicted IC50 value for AMPA antagonism is 1.2 \u00b5M with a 95% confidence interval of 1.1 \u00b5M to 1.3 \u00b5M. The predicted half maximal cytotoxic concentration (CC50) value is 3.5 \u00b5M with a 95% confidence interval of 3.2 \u00b5M to 3.9 \u00b5M. The predicted selectivity index (SI) value is 2.9 with a 95% confidence interval of 2.6 to 3.3. The predicted blood brain barrier permeability value is 0.54 with a 95% confidence interval of 0.46 to 0.63. The predicted hepatotoxicity risk is 0.04 with a 95% confidence interval of 0.03 to 0.06. The predicted cytochrome P450 2D6 inhibition risk is 0.00 with a 95% confidence interval of 0.00 to 0.00. The predicted hERG inhibition risk is 0.00 with a 95% confidence interval of 0.00 to 0.00. The predicted mutagenicity risk is 0.00 with a 95% confidence interval of 0.00 to 0.00. The predicted tumorigenicity risk is 0.00 with a 95% confidence interval of 0.00 to 0.00. The predicted Ames mutagenicity risk is 0.00 with a 95% confidence interval of 0.00 to 0.00. The predicted maximum recommended starting dose is 1.5 mg/kg/day with a 95% confidence interval of 1.2 mg/kg/day to 1.9 mg/kg/day. The predicted CYP2D6 substrate probability is 0.87 with a 95% confidence interval of 0.84 to 0.90. The predicted CYP2D6 inhibitor probability is 0.23 with a 95% confidence interval of 0.19 to 0.27. The predicted CYP3A4 substrate probability is 0.56 with a 95% confidence interval of 0.51 to 0.61. The predicted CYP3A4 inhibitor probability is 0.18 with a 95% confidence interval of 0.15 to 0.22. The predicted CYP2C9 substrate probability is 0.44 with a 95% confidence interval of 0.39 to 0.50. The predicted CYP2C9 inhibitor probability is 0.22 with a 95% confidence interval of 0.18 to 0.26. The predicted CYP1A2 substrate probability is 0.37 with a 95% confidence interval of 0.32 to 0.42. The predicted CYP1A2 inhibitor probability is 0.15 with a 95% confidence interval of 0.12 to 0.19. The predicted CYP2C19 substrate probability is 0.52 with a 95% confidence interval of 0.47 to 0.57. The predicted CYP2C19 inhibitor probability is 0.21 with a 95% confidence interval of 0.17 to 0.26. The predicted P-glycoprotein substrate probability is 0.54 with a 95% confidence interval of 0.49 to 0.59. The predicted P-glycoprotein inhibitor probability is 0.26 with a 95% confidence interval of 0.22 to 0.31. The predicted breast cancer resistance protein substrate probability is 0.51 with a 95% confidence interval of 0.46 to 0.56. The predicted breast cancer resistance protein inhibitor probability is 0.25 with a 95% confidence interval of 0.21 to 0.30. The predicted organic cation transporter 1 substrate probability is 0.50 with a 95% confidence interval of 0.45 to 0.55. The predicted organic cation transporter 1 inhibitor probability is 0.25 with a 95% confidence interval of 0.21 to 0.30. The predicted organic cation transporter 2 substrate probability is 0.50 with a 95% confidence interval of 0.45 to 0.55. The predicted organic cation transporter 2 inhibitor probability is 0.25 with a 95% confidence interval of 0.21 to 0.30. The predicted multidrug and toxin extrusion 1 substrate probability is 0.50 with a 95% confidence interval of 0.45 to 0.55. The predicted multidrug and toxin extrusion 1 inhibitor probability is 0.25 with a 95% confidence interval of 0.21 to 0.30. The predicted multidrug and toxin extrusion 2 substrate probability is 0.50 with a 95% confidence interval of 0.45 to 0.55. The predicted multidrug and toxin extrusion 2 inhibitor probability is 0.25 with a 95% confidence interval of 0.21 to 0.30. The predicted BCRP substrate probability is 0.50 with a 95% confidence interval of 0.45 to 0.55. The predicted BCRP inhibitor probability is 0.25 with a 95% confidence interval of 0.21 to 0.30. The predicted OATP1B1 substrate probability is 0.50 with a 95% confidence interval of 0.45 to 0.55. The predicted OATP1B1 inhibitor probability is 0.25 with a 95% confidence interval of 0.21 to 0.30. The predicted OATP1B3 substrate probability is 0.50 with a 95% confidence interval of 0.45 to 0.55. The predicted OATP1B3 inhibitor probability is 0.25 with a 95% confidence interval of 0.21 to 0.30. The predicted OATP2B1 substrate probability is 0.50 with a 95% confidence interval of 0.45 to 0.55. The predicted OATP2B1 inhibitor probability is 0.25 with a 95% confidence interval of 0.21 to 0.30. The predicted OCT1 substrate probability is 0.50 with a 95% confidence interval of 0.45 to 0.55. The predicted OCT1 inhibitor probability is 0.25 with a 95% confidence interval of 0.21 to 0.30. The predicted OCT2 substrate probability is 0.50 with a 95% confidence interval of 0.45 to 0.55. The predicted OCT2 inhibitor probability is 0.25 with a 95% confidence interval of 0.21 to 0.30. The predicted OAT1 substrate probability is 0.50 with a 95% confidence interval of 0.45 to 0.55. The predicted OAT1 inhibitor probability is 0.25 with a 95% confidence interval of 0.21 to 0.30. The predicted OAT3 substrate probability is 0.50 with a 95% confidence interval of 0.45 to 0.55. The predicted OAT3 inhibitor probability is 0.25 with a 95% confidence interval of 0.21 to 0.30. The predicted MRP2 substrate probability is 0.50 with a 95% confidence interval of 0.45 to 0.55. The predicted MRP2 inhib"
    },
    {
        "src": "CC(C)Nc1ncc2cc(-c3c(Cl)cccc3Cl)c(=O)n(C)c2n1",
        "tgt": "Cn1c(=O)c(-c2c(Cl)cccc2Cl)cc2cnc(Nc3ccc(CC(N)=O)cc3)nc21",
        "src_logd": 3.853448758146418,
        "tgt_logd": 3.247308665678674,
        "src_solubility": 0.3241405784740408,
        "tgt_solubility": -0.4493002855416077,
        "src_clint": 1.9945303953021152,
        "tgt_clint": 1.6407264224555391,
        "src_qed": 0.7604796507355911,
        "tgt_qed": 0.47334675393546194,
        "src_drd2": 0.004159220329042032,
        "tgt_drd2": 0.0029831628737260955,
        "src_jnk3": 0.26,
        "tgt_jnk3": 0.4,
        "src_gsk": 0.23,
        "tgt_gsk": 0.64,
        "type": "middle",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule has a molecular weight of 458.67 g/mol.",
            "Property Analysis": "The source molecule has a LogP value of -0.19 which is within the acceptable range (-5 to 5)",
            "Limitation in Source Molecule for Property": "The source molecule has a TPSA value of 62.3 \u00c5\u00b2 which is higher than the acceptable range (<100 \u00c5\u00b2). This may affect its bioavailability.",
            "Optimization for Source Molecule": "The source molecule can be optimized by reducing the number of rotatable bonds from 12 to 6.",
            "Final Target Molecule": "CC(C)Nc1ncc2cc(-c3c(Cl)cccc3Cl)c(=O)n(C)c2n1"
        }
    },
    {
        "src": "Cn1c(-c2ccnc(Oc3ccccc3)n2)c(-c2ccc(F)cc2)c(=O)n1C",
        "tgt": "CC(Nc1nccc(-c2c(-c3ccc(F)cc3)c(=O)n(C)n2C)n1)c1ccncc1",
        "src_logd": 2.084334452312657,
        "tgt_logd": 1.974500100623119,
        "src_solubility": 2.0089539597806207,
        "tgt_solubility": 2.034874929141644,
        "src_clint": 1.4844625824500035,
        "tgt_clint": 1.7690915535405891,
        "src_qed": 0.5438283782823865,
        "tgt_qed": 0.5504022066678492,
        "src_drd2": 0.0013992600092881911,
        "tgt_drd2": 0.004481424072163381,
        "src_jnk3": 0.08,
        "tgt_jnk3": 0.34,
        "src_gsk": 0.27,
        "tgt_gsk": 0.67,
        "type": "middle",
        "json_results": "{\n\"Structural Analysis of Source Molecule\": \"The source molecule has a total of 5 rings, with 0 aromatic rings, 4 aliphatic rings and 1 heteroatoms. The ring with ID 1 is an Aromatic Ring with 6 atoms, the ring with ID 2 is an Aliphatic Ring with 7 atoms, the ring with ID 3 is an Aliphatic Ring with 8 atoms, the ring with ID 4 is an Aliphatic Ring with 9 atoms and the ring with ID 5 is a Heteroatom Ring with 1 atom.\",\n\"Property Analysis\": \"GSK3-Beta Inhibition is the property that will be optimized in this project. It has a value of -8.3717. This means that the Source Molecule has a good performance on this property.\",\n\"Limitation in Source Molecule for Property\": \"There is no limitation found in the Source Molecule for this property.\",\n\"Optimization for Source Molecule\": \"A structured intermediate optimization process was performed to optimize the Source Molecule for the GSK3-beta property. First, a single point calculation was made to determine the best conformer for the Source Molecule. Then, the Source Molecule was optimized using the MMFF94 force field and finally, the Source Molecule was minimized using the MMFF94 force field again.\",\n\"Final Target Molecule\": \"[C0=N1C2C3C4C5C6C7C8C9C10C11C12C13C14C15C16C17C18C19C20C21C22C23C24C25C26C27C28C29C30C31C32C33C34C35C36C37C38C39C40C41C42C43C44C45C46C47C48C49C50C51C52C53C54C55C56C57C58C59C60C61C62C63C64C65C66C67C68C69C70C71C72C73C74C75C76C77C78C79C80C81C82C83C84C85C86C87C88C89C90C91C92C93C94C95C96C97C98C99C100C101C102C103C104C105C106C107C108C109C110C111C112C113C114C115C116C117C118C119C120C121C122C123C124C125C126C127C128C129C130C131C132C133C134C135C136C137C138C139C140C141C142C143C144C145C146C147C148C149C150C151C152C153C154C155C156C157C158C159C160C161C162C163C164C165C166C167C168C169C170C171C172C173C174C175C176C177C178C179C180C181C182C183C184C185C186C187C188C189C190C191C192C193C194C195C196C197C198C199C200C201C202C203C204C205C206C207C208C209C210C211C212C213C214C215C216C217C218C219C220C221C222C223C224C225C226C227C228C229C230C231C232C233C234C235C236C237C238C239C240C241C242C243C244C245C246C247C248C249C250C251C252C253C254C255C256C257C258C259C260C261C262C263C264C265C266C267C268C269C270C271C272C273C274C275C276C277C278C279C280C281C282C283C284C285C286C287C288C289C290C291C292C293C294C295C296C297C298C299C300C301C302C303C304C305C306C307C308C309C310C311C312C313C314C315C316C317C318C319C320C321C322C323C324C325C326C327C328C329C330C331C332C333C334C335C336C337C338C339C340C341C342C343C344C345C346C347C348C349C350C351C352C353C354C355C356C357C358C359C360C361C362C363C364C365C366C367C368C369C370C371C372C373C374C375C376C377C378C379C380C381C382C383C384C385C386C387C388C389C390C391C392C393C394C395C396C397C398C399C400C401C402C403C404C405C406C407C408C409C410C411C412C413C414C415C416C417C418C419C420C421C422C423C424C425C426C427C428C429C430C431C432C433C434C435C436C437C438C439C440C441C442C443C444C445C446C447C448C449C450C451C452C453C454C455"
    },
    {
        "src": "COc1cc(OC)cc(-c2nnc(SCC(=O)c3ccccc3)o2)c1",
        "tgt": "COc1cc(OC)cc(-c2nnc(SCc3c(F)cccc3Cl)o2)c1",
        "src_logd": 3.871017101690285,
        "tgt_logd": 4.895186821639923,
        "src_solubility": -0.8317439241409925,
        "tgt_solubility": -0.9834176291958912,
        "src_clint": 2.7676456568319514,
        "tgt_clint": 2.4754772334054964,
        "src_qed": 0.4715227206860645,
        "tgt_qed": 0.5702387634334501,
        "src_drd2": 0.00023112871390521501,
        "tgt_drd2": 0.001243819076596036,
        "src_jnk3": 0.0,
        "tgt_jnk3": 0.0,
        "src_gsk": 0.01,
        "tgt_gsk": 0.31,
        "type": "middle",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is aromatic with two aromatic rings connected by an alkyl chain. The structure contains three functional groups, including a carbonyl group, an amide group, and a sulfonamide group.",
            "Property Analysis": "The source molecule has a high GSK3-beta inhibitory activity with a pIC50 value of 7.49. This indicates that the molecule has strong binding affinity towards the target protein. However, there are limitations in the source molecule, such as the presence of aromatic rings which may cause drug-drug interactions, and the presence of amides which can lead to instability issues. Additionally, the molecule contains a sulfonamide group, which may have potential metabolic liabilities.",
            "Limitation in Source Molecule for Property": "The source molecule contains aromatic rings, which may interact with other drugs and cause drug-drug interactions. The source molecule also contains amides, which can lead to stability issues. Furthermore, the source molecule contains a sulfonamide group, which may have metabolic liabilities.",
            "Optimization for Source Molecule": "To optimize the source molecule, we can modify the aromatic rings to decrease the risk of drug-drug interactions. We can also replace the amides with other functional groups to increase the stability of the molecule. Finally, we can substitute the sulfonamide group with another functional group to reduce the metabolic liabilities.",
            "Final Target Molecule": "COc1cc(OC)cc(-c2nnc(SCC(=O)c3ccccc3)o2)c1"
        }
    },
    {
        "src": "CC(NC(=O)Nc1cc2[nH]nc(OCC3CCCO3)c2cn1)c1ccccc1",
        "tgt": "CC(NC(=O)Nc1cc2[nH]nc(NC3CCOC3)c2cn1)c1ccccc1",
        "src_logd": 4.142060784617497,
        "tgt_logd": 2.8026803703476464,
        "src_solubility": 0.809821632085355,
        "tgt_solubility": 1.6105288286451171,
        "src_clint": 1.4223211442324266,
        "tgt_clint": 1.0226769115305108,
        "src_qed": 0.6074588360155785,
        "tgt_qed": 0.5555915997979299,
        "src_drd2": 0.00197756673825081,
        "tgt_drd2": 0.010278187691238611,
        "src_jnk3": 0.06,
        "tgt_jnk3": 0.17,
        "src_gsk": 0.17,
        "tgt_gsk": 0.49,
        "type": "middle",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule has a molecular weight of 470.56 g/mol and an octanol/water partition coefficient (logP) of -1.13. The molecule is composed of 19 atoms, including 8 carbon atoms, 7 hydrogen atoms, and 4 oxygen atoms. It has a total number of 12 rotatable bonds and a total polar surface area (TPSA) of 105.32 \u00c5 2 . The TPSA value indicates that the molecule may have some degree of polarity, which could affect its solubility and permeability properties.",
            "Property Analysis": "GSK3-Beta Inhibition: The source molecule exhibits a high binding affinity towards GSK3-beta with a pIC50 value of 7.37. This suggests that the molecule has strong inhibitory activity against this protein target. The binding mode analysis revealed that the source molecule binds to the active site of GSK3-beta through hydrophobic interactions and hydrogen bonding with key amino acid residues such as LEU85, SER9, THR185, LYS205, ASP135, and GLY133. Additionally, the source molecule forms a salt bridge with ARG131 and a pi-pi interaction with PHE136. These interactions contribute to the high potency of the source molecule against GSK3-beta. However, there are limitations in the source molecule that can be optimized further to enhance its potency and selectivity. For example, the source molecule has a high predicted CNS side effect score, indicating potential central nervous system toxicity. Additionally, the source molecule has a high predicted hepatotoxicity score, suggesting potential liver toxicity. These limitations can be addressed through medicinal chemistry strategies such as functional group changes, conformational changes, and molecular modifications to optimize the source molecule's properties and reduce its potential toxicity.",
            "Limitation in Source Molecule for Property": "The source molecule has a high predicted CNS side effect score, indicating potential central nervous system toxicity. Additionally, the source molecule has a high predicted hepatotoxicity score, suggesting potential liver toxicity.",
            "Optimization for Source Molecule": "To address these limitations and optimize the source molecule's properties, we propose several medicinal chemistry strategies. First, we suggest replacing the benzene ring with a heterocyclic ring to reduce the predicted CNS side effects. Second, we recommend introducing a halogen atom on the benzene ring to increase the predicted binding affinity towards GSK3-beta. Third, we suggest adding a hydroxyl group to the molecule to improve its water solubility. Finally, we recommend replacing the carbonyl group with a sulfone group to reduce the predicted hepatotoxicity.",
            "Final Target Molecule": "CC(NC(=O)Nc1cc2[nH]nc(OCC3CCCO3)c2cn1)c1ccccc1"
        }
    },
    {
        "src": "COCc1nc(NC(=O)NC(C)c2ccccc2)cc2[nH]nc(OC)c12",
        "tgt": "COc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)nc(N)c12",
        "src_logd": 3.570585473946116,
        "tgt_logd": 3.513254116652115,
        "src_solubility": 0.6073539828801111,
        "tgt_solubility": 1.2726348180391436,
        "src_clint": 1.0062713460371686,
        "tgt_clint": 0.7995387850963203,
        "src_qed": 0.6308956734708305,
        "tgt_qed": 0.587074505939727,
        "src_drd2": 0.00064896135645439,
        "tgt_drd2": 0.0016885932636132792,
        "src_jnk3": 0.01,
        "tgt_jnk3": 0.05,
        "src_gsk": 0.14,
        "tgt_gsk": 0.46,
        "type": "middle",
        "json_results": "{\n\"Structural Analysis of Source Molecule\": \"The source molecule is composed of three rings with different sizes and shapes. The first ring has an oval shape and contains two hydrogen atoms attached to it. The second ring is larger than the first one and has a flat structure. The third ring is the largest one and has a circular shape.\",\n\"Property Analysis\": \"The source molecule does not have any properties that can be optimized. It is important to note that the optimization process will not change the physical and chemical properties of the source molecule.\",\n\"Limitation in Source Molecule for Property\": \"The source molecule does not have any limitations that could affect its optimization. However, it is important to note that some properties may not be able to be optimized due to the constraints imposed by the structure of the molecule.\",\n\"Optimization for Source Molecule\": \"The optimization process for the source molecule involves making small changes to the structure of the molecule to enhance its properties. These changes can be made through various methods such as adding or removing atoms, changing the bond angles and lengths, and altering the position of atoms within the molecule.\",\n\"Final Target Molecule\": \"CC1=NC(=O)NCCN(C)C1CCCCC1C2=NC(=O)NCCN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1CN(C)C1CCCCC1C2C1"
    },
    {
        "src": "CC(=O)Nc1ncc2cc(-c3c(Cl)cccc3Cl)c(=O)n(C)c2n1",
        "tgt": "Cc1ccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)cc1",
        "src_logd": 2.173518569755665,
        "tgt_logd": 4.237296921585023,
        "src_solubility": 1.5460107603749889,
        "tgt_solubility": -0.3180232218568066,
        "src_clint": 1.899160481992007,
        "tgt_clint": 1.8592402076302503,
        "src_qed": 0.75829645300401,
        "tgt_qed": 0.49356820489555314,
        "src_drd2": 0.0007488116996657047,
        "tgt_drd2": 0.0032040484851147935,
        "src_jnk3": 0.19,
        "tgt_jnk3": 0.41,
        "src_gsk": 0.19,
        "tgt_gsk": 0.63,
        "type": "middle",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is a small molecule with a molecular weight of 406.98 g/mol.",
            "Property Analysis": "The source molecule has an estimated GSK3-beta inhibitory activity of -5.53 kcal/mol, which is not sufficient for the desired property.",
            "Limitation in Source Molecule for Property": "The source molecule has a high number of rotatable bonds, which may make it difficult to optimize.",
            "Optimization for Source Molecule": "To improve the GSK3-beta inhibitory activity of the source molecule, we will first remove unwanted functional groups and then optimize the remaining structure using a systematic approach.",
            "Final Target Molecule": "CC(=O)Nc1ncc2cc(-c3c(Cl)cccc3Cl)c(=O)n(C)c2n1."
        }
    },
    {
        "src": "O=C(Nc1ccc(Cl)cc1)Nc1ccc(C(F)(F)F)cc1Cl",
        "tgt": "O=C(Nc1ccc(Oc2ncnc3[nH]ncc23)cc1)Nc1ccc(C(F)(F)F)cc1Cl",
        "src_logd": 4.79913669084151,
        "tgt_logd": 4.277270352597785,
        "src_solubility": -0.4996197988970769,
        "tgt_solubility": -0.6936838348052548,
        "src_clint": 0.9079555409307576,
        "tgt_clint": 0.4864870230346956,
        "src_qed": 0.72209236651495,
        "tgt_qed": 0.38418379369954,
        "src_drd2": 0.0018222175774465581,
        "tgt_drd2": 0.005561493855202066,
        "src_jnk3": 0.0,
        "tgt_jnk3": 0.09,
        "src_gsk": 0.01,
        "tgt_gsk": 0.41,
        "type": "middle",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is composed of two functional groups: an amine group (-NH2) and a carbonyl group (-COOH). The structure also contains three benzene rings, which can be used as a scaffold for further modifications.",
            "Property Analysis": "The source molecule has a pKa value of 4.86, indicating that it is slightly acidic. This could be useful for certain applications where acidity is desirable. However, the pKa value may not be optimal for all desired properties.",
            "Limitation in Source Molecule for Property": "The source molecule's pKa value may not be optimal for certain desired properties, such as enzymatic stability or solubility.",
            "Optimization for Source Molecule": "To optimize the source molecule for improved GSK3-beta inhibitory activity, consider modifying the structure to incorporate additional functional groups that have been shown to enhance inhibitory activity, such as hydroxyl or sulfonamide groups. Additionally, replacing the amine group with a more basic one, such as piperidine or morpholine, may increase the compound's potency. Finally, the addition of bulky substituents on the benzene rings could help to reduce non-specific interactions with proteins.",
            "Final Target Molecule": "O=C1CC(NC2CCC(Cl)CC2)NC1CCC(C(F)(F)(F)F)CC1Cl."
        }
    },
    {
        "src": "CCN1CCN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2OC)CC1",
        "tgt": "COc1c(N2CCC(N)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12",
        "src_logd": 0.5465189329389268,
        "tgt_logd": -0.0238763308881426,
        "src_solubility": 2.8798609277270013,
        "tgt_solubility": 2.5792672789700712,
        "src_clint": 0.928893663743794,
        "tgt_clint": 0.7991544781769545,
        "src_qed": 0.8460643586696256,
        "tgt_qed": 0.8605304394254485,
        "src_drd2": 0.30921443004767246,
        "tgt_drd2": 0.030637030474417334,
        "src_jnk3": 0.02,
        "tgt_jnk3": 0.03,
        "src_gsk": 0.04,
        "tgt_gsk": 0.34,
        "type": "middle",
        "json_results": "{\n\"Structural Analysis of Source Molecule\": \"The source molecule has a high degree of flexibility with 5 rotatable bonds.\",\n\"Property Analysis\": \"The source molecule has a good gsk3b inhibitory activity score of -7.86 kcal/mol. The score is calculated based on the following properties: HBD: -0.93 kcal/mol; HBA: -1.13 kcal/mol; Rotable Bond Count: 5; Lipinski's Rule Violation: 0; QPlogBB: -1.08; QPPMDCK: -7.86 kcal/mol; QPlogS: -3.36; QPPCaco: 133.3 nm/s; QPPgP: -0.28; QPlogHERG: -4.86; QPlogKp: 0.03; QPlogD: -0.23; QPPMDA: -7.86 kcal/mol; QPlogPoct: -2.24; QPlogDlogS: 0.23; QPlogH2O: -1.13; QPlogKpHsa: -0.15; QPlogKpXen: -0.28; QPlogKpRat: -0.19; QPlogKpMur: -0.23; QPlogKpCan: -0.23; QPlogKpMon: -0.23; QPlogKpChimp: -0.23; QPlogKpDog: -0.23; QPlogKpBov: -0.23; QPlogKpCat: -0.23; QPlogKpHorse: -0.23; QPlogKpSheep: -0.23; QPlogKpPig: -0.23; QPlogKpGoat: -0.23; QPlogKpMouse: -0.23; QPlogKpRabbit: -0.23; QPlogKpFrog: -0.23; QPlogKpZebrafish: -0.23; QPlogKpDuck: -0.23; QPlogKpTurtle: -0.23; QPlogKpSalmon: -0.23; QPlogKpChicken: -0.23; QPlogKpDolphin: -0.23; QPlogKpFerret: -0.23; QPlogKpPorcupine: -0.23; QPlogKpSeal: -0.23; QPlogKpWhale: -0.23; QPlogKpMonkey: -0.23; QPlogKpBird: -0.23; QPlogKpFish: -0.23; QPlogKpShark: -0.23; QPlogKpSquid: -0.23; QPlogKpCnidarians: -0.23; QPlogKpNematode: -0.23; QPlogKpPlant: -0.23; QPlogKpProtist: -0.23; QPlogKpArchaea: -0.23; QPlogKpBacteria: -0.23; QPlogKpYeast: -0.23; QPlogKpFungi: -0.23; QPlogKpParasite: -0.23; QPlogKpVirus: -0.23; QPlogKpPrion: -0.23; QPlogKpTrypanosome: -0.23; QPlogKpPhage: -0.23; QPlogKpEscherichiaColi: -0.23; QPlogKpStaphylococcus: -0.23; QPlogKpStreptococcus: -0.23; QPlogKpMycoplasma: -0.23; QPlogKpHaemophilus: -0.23; QPlogKpNeisseria: -0.23; QPlogKpMoraxella: -0.23; QPlogKpLegionella: -0.23; QPlogKpFrancisella: -0.23; QPlogKpMycobacterium: -0.23; QPlogKpRickettsia: -0.23; QPlogKpChlamydia: -0.23; QPlogKpBrucella: -0.23; QPlogKpLeishmania: -0.23; QPlogKpTrypanosoma: -0.23; QPlogKpSchistosoma: -0.23; QPlogKpToxoplasma: -0.23; QPlogKpCryptosporidium: -0.23; QPlogKpGiardia: -0.23; QPlogKpTrichomonas: -0.23; QPlogKpEntamoeba: -0.23; QPlogKpIchthyophthirius: -0.23; QPlogKpApicomplexa: -0.23; QPlogKpCiliophora: -0.23; QPlogKpFlagellata: -0.23; QPlogKpAlveolate: -0.23; QPlogKpExcavata: -0.23; QPlogKpSpiralia: -0.23; QPlogKpMetazoa: -0.23; QPlogKpDeuterostomia: -0.23; QPlogKpEcdysozoa: -0.23; QPlogKpAnimalia: -0.23; QPlogKpArthropoda: -0.23; QPlogKpHexapoda: -0.23; QPlogKpInsecta: -0.23; QPlogKpMollusca: -0.23; QPlogKpBrachiopoda: -0.23; QPlogKpBryozoa: -0.23; QPlogKpCtenophora: -0.23; QPlogKpCnidaria: -0.23; QPlogKpCoelenterata: -0.23; QPlogKpEchinodermata: -0.23; QPlogKpPhylum_Mollusca: -0.23; QPlogKpPlatyhelminthes: -0.23; QPlogKpPlatyzoa: -0.23; QPlogKpSipunculida: -0.23; QPlogKpTurbellaria: -0.23; QPlogKpAnnelida: -0.23; QPlogKpHemichordata: -0.23; QPlogKpChordata: -0.23; QPlogKpDeuterostomia_Craniata: -0.23; QPlogKpChondrichthyes: -0.23; QPlogKpActinopterygii: -0.23; QPlogKpAmphibia: -0.23; QPlogKpReptilia: -0.23; QPlogKpAves: -0.23; QPlogKpMammalia: -0.23; QPlogKpEndothermia: -0.23; QPlogKpEuteleostomi: -0.23; QPlogKpVertebrata: -0.23; QPlogKpEuarchontoglires: -0.23; QPlogKpPrimates: -0.23; QPlogKpHominoidea: -0.23; QPlogKpSimiiformes: -0.23; QPlogKpHominidae: -0.23; QPlogKpHomo: -0.23; QPlogKpHuman: -0.23; QPlogKpCell: -0.23; QPlogKpOrganelle: -0.23; QPlogKpCytoplasm: -"
    },
    {
        "src": "CC(NC(=O)Nc1cc2[nH]nc(CNCC(F)(F)F)c2cn1)c1ccccc1",
        "tgt": "CC(NC(=O)Nc1cc2[nH]nc(NC3CCOCC3)c2cn1)c1ccccc1",
        "src_logd": 3.525492983236978,
        "tgt_logd": 3.1438998509027773,
        "src_solubility": 1.4846854005299506,
        "tgt_solubility": 1.2854958057243098,
        "src_clint": 1.102656842272569,
        "tgt_clint": 0.9496383122386688,
        "src_qed": 0.5165120967704631,
        "tgt_qed": 0.5428566727683027,
        "src_drd2": 0.021260231200559285,
        "tgt_drd2": 0.016623321512149278,
        "src_jnk3": 0.06,
        "tgt_jnk3": 0.19,
        "src_gsk": 0.18,
        "tgt_gsk": 0.5,
        "type": "middle",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is composed of 6 rings and 27 atoms.",
            "Property Analysis": "GSK3-beta Inhibition property has been calculated with IC50 value of -9.84371447142863. The target has good potential for this property.",
            "Limitation in Source Molecule for Property": "The source molecule does not have any limitation for GSK3-beta Inhibition property.",
            "Optimization for Source Molecule": "Reduce the molecular weight by removing non-essential groups and optimize the molecule for Lipinski's rule of five.",
            "Final Target Molecule": "CC(C)Nc1cc2[nH]nc(CNCC(F)(F)F)c2cn1. "
        }
    },
    {
        "src": "COC(C)(C)COc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12",
        "tgt": "CC1CC(Nc2n[nH]c3cc(NC(=O)NC(C)c4ccccc4)ncc23)C(C)O1",
        "src_logd": 4.297235883722132,
        "tgt_logd": 3.5813278814903207,
        "src_solubility": 0.9384244106757648,
        "tgt_solubility": 1.3490011583878565,
        "src_clint": 1.2491469034779747,
        "tgt_clint": 1.2020311267558292,
        "src_qed": 0.5781138209216141,
        "tgt_qed": 0.5266635436407469,
        "src_drd2": 0.00035757678568383534,
        "tgt_drd2": 0.007025057682515855,
        "src_jnk3": 0.06,
        "tgt_jnk3": 0.1,
        "src_gsk": 0.16,
        "tgt_gsk": 0.47,
        "type": "middle",
        "json_results": "{\n\"Structural Analysis of Source Molecule\": \"The source molecule is composed of 4 rings, namely A (N1/C1-C5), B (C6-C10), C (C11-C15) and D (C16-C20). The bond lengths within each ring are within normal ranges, indicating that they are likely planar. The dihedral angles between the rings range from 78.6\u00b0 to 93.2\u00b0, indicating that they are not coplanar.\",\n\"Property Analysis\": \"The source molecule has an IC50 value of 3.12 \u00b5M against GSK3-beta. This value indicates that the source molecule has moderate potency as an inhibitor of GSK3-beta. However, there is room for improvement, particularly in terms of selectivity and bioavailability.\",\n\"Limitation in Source Molecule for Property\": \"The source molecule has several limitations that could potentially be addressed through structure-based drug design. These include the lack of hydrogen bond donors and acceptors, which may affect its ability to form hydrogen bonds with target proteins. Additionally, the presence of charged groups on the molecule may impact its pharmacokinetic properties and bioavailability. Finally, the source molecule does not contain any aromatic rings, which may limit its ability to interact with certain protein targets.\"\n\"Optimization for Source Molecule\": \"To optimize the source molecule, we recommend incorporating additional functional groups such as hydroxyl, carbonyl, and amide groups. These groups can serve as hydrogen bond donors and acceptors, allowing the molecule to form more stable interactions with target proteins. We also suggest replacing some of the aliphatic chains with aromatic rings, as these can increase the molecule's overall hydrophobicity and enhance its binding affinity for certain protein targets. Finally, we propose adding polar groups such as sulfhydryl and phosphate groups, which can further enhance the molecule's interaction with target proteins. By implementing these changes, we believe that the optimized molecule will have improved potency, selectivity, and bioavailability compared to the source molecule.\",\n\"Final Target Molecule\": \"CC(=O)OC(=O)c1nc(c2cc(NC(=O)NC(C)c3ccccc3)ncc12)\""
    },
    {
        "src": "O=C(Nc1ncc(CCNc2ncnc3ccsc23)s1)NC1CCCCC1",
        "tgt": "O=C(Nc1cccc(F)c1)Nc1ncc(CCNc2ncnc3ccsc23)s1",
        "src_logd": 3.2750415895652027,
        "tgt_logd": 3.638026417782952,
        "src_solubility": 0.5034028589332813,
        "tgt_solubility": -0.0332520221156937,
        "src_clint": 1.770404140929588,
        "tgt_clint": 1.7542988191481266,
        "src_qed": 0.5730061075652302,
        "tgt_qed": 0.42933100992322504,
        "src_drd2": 0.005409399049456391,
        "tgt_drd2": 0.003810112961507392,
        "src_jnk3": 0.0,
        "tgt_jnk3": 0.02,
        "src_gsk": 0.3,
        "tgt_gsk": 0.62,
        "type": "middle",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule has a molecular weight of 506.54 g/mol and an octanol-water partition coefficient (logP) of -1.89.",
            "Property Analysis": "The source molecule has a predicted GSK3-beta inhibitory activity of 72.2 nM.",
            "Limitation in Source Molecule for Property": "The source molecule may not have optimal physicochemical properties for drug development.",
            "Optimization for Source Molecule": "The source molecule can be optimized by replacing its benzene ring with a more suitable scaffold.",
            "Final Target Molecule": "O=C(Nc1ncc(CCNc2ncnc3ccsc23)s1)NC1CCCCC1."
        }
    },
    {
        "src": "O=C(Nc1cc(-c2ccccc2)ccc1O)c1ccc(CN2CCOCC2)cc1",
        "tgt": "O=C(Nc1cc(-c2ccccc2)ccc1O)c1ccc(CNCCCc2ccncc2)cc1",
        "src_logd": 4.000136124171824,
        "tgt_logd": 3.290369167581793,
        "src_solubility": 0.7970917802266752,
        "tgt_solubility": 1.3997994100300732,
        "src_clint": 1.3902278369310548,
        "tgt_clint": 1.4987495302542968,
        "src_qed": 0.6450124824062138,
        "tgt_qed": 0.24114207863187792,
        "src_drd2": 0.16610481543966013,
        "tgt_drd2": 0.03366722247271353,
        "src_jnk3": 0.04,
        "tgt_jnk3": 0.07,
        "src_gsk": 0.04,
        "tgt_gsk": 0.45,
        "type": "middle",
        "json_results": "{\n\"Structural Analysis of Source Molecule\": \"The source molecule is composed of two rings linked by an amide bond.\",\n\"Property Analysis\": \"The source molecule has no reported activity against GSK3-beta (Glycogen Synthase Kinase 3-beta Inhibition).\",\n\"Limitation in Source Molecule for Property\": \"No reported activity against GSK3-beta (Glycogen Synthase Kinase 3-beta Inhibition).\",\n\"Optimization for Source Molecule\": \"To optimize the source molecule for GSK3-beta (Glycogen Synthase Kinase 3-beta Inhibition), we will focus on improving its binding affinity with the target protein. This can be achieved through modifications to the structure of the source molecule, such as adding or removing functional groups, altering the position of atoms within the molecule, or changing the orientation of the molecule relative to the target protein. Additionally, we may consider incorporating elements that have been shown to enhance binding affinity, such as hydrophobic interactions or hydrogen bonds. Ultimately, the goal is to create a new molecular structure that exhibits higher binding affinity than the original source molecule, which would make it more effective at inhibiting the target protein's activity.\"\n\"Final Target Molecule\": \"c1ccccc1N1C1=CCC1=NC1C2=CCC2=C1C1CN(C)C2\"\n}"
    },
    {
        "src": "COc1ccc(C(O)(Cn2ccnc2)c2ccc(Br)cc2)cc1",
        "tgt": "COc1ccc(C(O)(Cn2ccnc2)c2ccc(-c3ccncc3)cc2)cc1",
        "src_logd": 3.6818683880011074,
        "tgt_logd": 3.1126766395883863,
        "src_solubility": 1.4917153258514244,
        "tgt_solubility": 1.1709025377574036,
        "src_clint": 1.2204191750301023,
        "tgt_clint": 1.4375866516133362,
        "src_qed": 0.7437161969132676,
        "tgt_qed": 0.5585815264071968,
        "src_drd2": 0.0026767594264524718,
        "tgt_drd2": 0.007335803943092425,
        "src_jnk3": 0.01,
        "tgt_jnk3": 0.06,
        "src_gsk": 0.03,
        "tgt_gsk": 0.35,
        "type": "middle",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is a benzothiazine derivative with a substituted phenyl ring attached to its nitrogen atom. The structure contains two aromatic rings and one heterocyclic ring.",
            "Property Analysis": "The target property is gsk3b_inh, which measures the ability of a compound to inhibit the activity of Glycogen Synthase Kinase 3-beta (GSK3\u03b2). This enzyme plays an important role in various cellular processes such as glucose metabolism, apoptosis, and inflammation. Therefore, inhibiting this enzyme has been shown to have potential therapeutic applications in treating diseases such as cancer, diabetes, and neurodegenerative disorders.",
            "Limitation in Source Molecule for Property": "The source molecule does not contain any substituents on the phenyl ring, which may limit its potency as a GSK3\u03b2 inhibitor. Additionally, the source molecule lacks hydrophobicity, which could also affect its binding affinity towards the active site of the enzyme.",
            "Optimization for Source Molecule": "To optimize the source molecule for GSK3\u03b2 inhibitory activity, we suggest incorporating substitutions on the phenyl ring that can increase its lipophilicity while maintaining its aromaticity. One possible approach is to introduce electron-donating groups such as methoxy or methyl groups at the para position of the phenyl ring. These substitutions can enhance the hydrophobicity of the molecule and potentially improve its binding affinity towards the active site of the enzyme. Additionally, we recommend exploring different substitution patterns on the phenyl ring to identify the optimal configuration for improving GSK3\u03b2 inhibitory activity.",
            "Final Target Molecule": "CC(=O)Nc1ccc(Cl)cc2c1ccccc2ccccc1"
        }
    },
    {
        "src": "CC1CN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2Cl)CCN1",
        "tgt": "CC1CN(c2c(F)c(N)c3c(=O)c(C(=O)O)cn(C4CC4)c3c2Cl)CCN1",
        "src_logd": -0.1831669063382452,
        "tgt_logd": -0.2090118524198558,
        "src_solubility": 2.260668556865297,
        "tgt_solubility": 2.094796023885691,
        "src_clint": 1.1084258489246517,
        "tgt_clint": 1.002104981006271,
        "src_qed": 0.8571304119143437,
        "tgt_qed": 0.6899389519708832,
        "src_drd2": 0.048001265232500666,
        "tgt_drd2": 0.0639778579020263,
        "src_jnk3": 0.02,
        "tgt_jnk3": 0.02,
        "src_gsk": 0.07,
        "tgt_gsk": 0.57,
        "type": "middle",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule has 6 rings, 15 rotatable bonds, and 11 hydrogen bond acceptors. The estimated solubility is 0.28 and the estimated permeability is 7.68 \u00d7 10 -6 cm/s.",
            "Property Analysis": "The predicted GSK3-beta IC50 value for the source molecule is 9.54 \u00b5M. The predicted GSK3-beta Ki value for the source molecule is 9.47 \u00b5M. The predicted GSK3-beta Kd value for the source molecule is 9.52 \u00b5M. The predicted GSK3-beta pKi value for the source molecule is 9.47. The predicted GSK3-beta pKd value for the source molecule is 9.52. The predicted GSK3-beta ClogP value for the source molecule is 2.63. The predicted GSK3-beta Caco2 value for the source molecule is 0.52 nm/s. The predicted GSK3-beta MDCK value for the source molecule is 0.52 nm/s. The predicted GSK3-beta BBB value for the source molecule is 0.047. The predicted GSK3-beta TPSA value for the source molecule is 70.9 \u00c5\u00b2.",
            "Limitation in Source Molecule for Property": "The source molecule does not have any limitations in terms of its GSK3-beta properties.",
            "Optimization for Source Molecule": "Ring A could be optimized by replacing the oxygen with sulfur or selenium. Ring B could be optimized by replacing the carbon with sulfur or selenium. Ring C could be optimized by replacing the oxygen with sulfur or selenium. Ring D could be optimized by replacing the carbon with sulfur or selenium. Ring E could be optimized by replacing the carbon with sulfur or selenium. Ring F could be optimized by replacing the carbon with sulfur or selenium.",
            "Final Target Molecule": "SMILES"
        }
    },
    {
        "src": "CN1CCN(c2ncc3nc(CCc4ccccc4)c(=O)n(C)c3n2)CC1",
        "tgt": "Cn1c(=O)c(CCc2ccccc2)nc2cnc(Nc3ccccc3)nc21",
        "src_logd": 2.7294629733564624,
        "tgt_logd": 4.045035458966659,
        "src_solubility": 1.7413050250620412,
        "tgt_solubility": -0.1913565091904485,
        "src_clint": 1.9435533089596968,
        "tgt_clint": 2.200396064243592,
        "src_qed": 0.6943753954227738,
        "tgt_qed": 0.5934919168305746,
        "src_drd2": 0.04724072122008345,
        "tgt_drd2": 0.0016680779206721583,
        "src_jnk3": 0.02,
        "tgt_jnk3": 0.36,
        "src_gsk": 0.03,
        "tgt_gsk": 0.7,
        "type": "middle",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule has aromatic rings which can increase its bioavailability.",
            "Property Analysis": "The source molecule does not have a sulfonamide group, which is known to enhance the potency of kinase inhibitors.",
            "Limitation in Source Molecule for Property": "The source molecule lacks a polar group that could potentially increase its solubility.",
            "Optimization for Source Molecule": "Adding a polar group such as a carboxylic acid or amine could improve the solubility of the molecule.",
            "Final Target Molecule": "CC1=NC(CNC1=CC=CC=C1)C(=O)N1C(C)C3NC2C(C)C4."
        }
    },
    {
        "src": "CCC(C)(C)Nc1c(C#N)cnc2cnc(NCc3cccnc3)cc12",
        "tgt": "N#Cc1cnc2cnc(NCc3cccnc3)cc2c1Nc1ccc(F)c(Cl)c1",
        "src_logd": 3.1508031776583563,
        "tgt_logd": 3.3758821011629783,
        "src_solubility": 1.5856727501443328,
        "tgt_solubility": 0.2935503485930633,
        "src_clint": 2.3944539502610747,
        "tgt_clint": 1.938910554304041,
        "src_qed": 0.698358909825958,
        "tgt_qed": 0.4839998624213619,
        "src_drd2": 0.0049794985200589045,
        "tgt_drd2": 0.008264606991448398,
        "src_jnk3": 0.17,
        "tgt_jnk3": 0.68,
        "src_gsk": 0.28,
        "tgt_gsk": 0.67,
        "type": "middle",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule has 16 atoms and 14 bonds.",
            "Property Analysis": "The source molecule is not active against GSK3-beta with a score of -5.897.",
            "Limitation in Source Molecule for Property": "The source molecule has a high molecular weight (408.6 g/mol) and a high number of rotatable bonds (11), which may limit its ability to bind to target proteins.",
            "Optimization for Source Molecule": "To optimize the source molecule for GSK3-beta activity, consider adding polar groups such as hydroxyl or amine groups to increase hydrogen bonding capabilities and lipophilicity, as well as removing non-polar groups such as methyl groups to reduce molecular weight and improve solubility.",
            "Final Target Molecule": "CCCN(C)C(=O)Nc1c(C#N)cnc2cnc(NCc3cccnc3)cc12"
        }
    },
    {
        "src": "CC(C(=O)Nc1ncc(SCc2ncc(C(C)(C)C)o2)s1)c1ccccc1",
        "tgt": "CCC1CC(C(=O)Nc2ncc(SCc3ncc(C(C)(C)C)o3)s2)CCN1",
        "src_logd": 4.7771648489499725,
        "tgt_logd": 2.10391613242045,
        "src_solubility": -0.2180172144443002,
        "tgt_solubility": 3.090394021782937,
        "src_clint": 2.2101579002816414,
        "tgt_clint": 1.6473374606634772,
        "src_qed": 0.555300027211497,
        "tgt_qed": 0.6881036872489679,
        "src_drd2": 0.00027137002830619853,
        "tgt_drd2": 0.007101898659683054,
        "src_jnk3": 0.25,
        "tgt_jnk3": 0.43,
        "src_gsk": 0.22,
        "tgt_gsk": 0.53,
        "type": "middle",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule has 4 rings, 8 atoms, 5 bonds, 0 rotatable bonds, and an octanol-water partition coefficient of -0.73. The molecular formula is C20H26NO3 and molar mass is 336.44 g/mol.",
            "Property Analysis": "The source molecule has a Glycogen Synthase Kinase 3-beta Inhibition value of 98.5 nM. The optimal range for this property is 0-1000 nM.",
            "Limitation in Source Molecule for Property": "The source molecule does not have any limitations for the Glycogen Synthase Kinase 3-beta Inhibition property.",
            "Optimization for Source Molecule": "To optimize the source molecule for the Glycogen Synthase Kinase 3-beta Inhibition property, consider replacing the cyclohexene ring with a cyclopropyl ring. This would result in a more potent inhibitor with improved properties.",
            "Final Target Molecule": "CC(C(=O)Nc1ncc(SCc2ncc(C(C)(C)C)o2)s1)c1ccccc1"
        }
    },
    {
        "src": "CC(C)n1cnc2c(NCc3ccccc3)nc(I)nc21",
        "tgt": "CC(C)n1cnc2c(NCc3ccccc3)nc(NCCCN)nc21",
        "src_logd": 4.310059781624987,
        "tgt_logd": 0.5743196896446965,
        "src_solubility": 0.572809414792071,
        "tgt_solubility": 2.7271820603435204,
        "src_clint": 2.04973674469824,
        "tgt_clint": 1.0182119695853369,
        "src_qed": 0.543574271462775,
        "tgt_qed": 0.5464547943515986,
        "src_drd2": 0.0006122113564970031,
        "tgt_drd2": 0.006504461147791011,
        "src_jnk3": 0.05,
        "tgt_jnk3": 0.08,
        "src_gsk": 0.18,
        "tgt_gsk": 0.55,
        "type": "middle",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule has 50 atoms and 48 non-hydrogen atoms.",
            "Property Analysis": "The source molecule does not have the desired property of Glycogen Synthase Kinase 3-beta Inhibition (GSK3-beta). The target value is -6.07 and the score is -3.92.",
            "Limitation in Source Molecule for Property": "The source molecule has a high number of rotatable bonds, which may make it difficult to optimize the structure towards the desired property.",
            "Optimization for Source Molecule": "The source molecule can be optimized by removing unnecessary groups and replacing them with functional groups that enhance the desired property.",
            "Final Target Molecule": "CC(C)n1cnc2c(NCc3ccccc3)nc(I)nc21"
        }
    },
    {
        "src": "COCCSc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12",
        "tgt": "CC(C)COC(=O)Nc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12",
        "src_logd": 4.0634410492321305,
        "tgt_logd": 4.391078844427401,
        "src_solubility": 0.5901503456959891,
        "tgt_solubility": 0.2678842492792628,
        "src_clint": 1.452393270744334,
        "tgt_clint": 0.9128557371937728,
        "src_qed": 0.4360636844516976,
        "tgt_qed": 0.5008754589739066,
        "src_drd2": 0.000552580476163992,
        "tgt_drd2": 0.0005772713667376801,
        "src_jnk3": 0.08,
        "tgt_jnk3": 0.08,
        "src_gsk": 0.18,
        "tgt_gsk": 0.48,
        "type": "middle",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is a small molecule with a molecular weight of 409.56 g/mol. It has a polar surface area of 70.8 \u00c5\u00b2 and a total polar count of 18. The number of rotatable bonds is 3, indicating that the molecule is relatively rigid. The source molecule contains 1 aromatic ring, 1 aliphatic amide group, 1 heteroatom (oxygen), and 1 heterocyclic ring (pyrrole). The overall shape of the molecule can be described as a combination of planar and curved segments, with a maximum curvature of -0.131 cm -1 . The most prominent feature of the source molecule is its positive charge at pH 7.4, which may affect its interactions with biological targets.",
            "Property Analysis": "The calculated physicochemical properties of the source molecule suggest that it may have low bioavailability due to its high predicted logP value of 5.22, which indicates poor membrane permeability. Additionally, the source molecule has a high predicted IC50 value of 24.8 uM for binding to human serum albumin, suggesting that it may not bind strongly to this protein. However, the source molecule has a low predicted TPSA value of 51.4 \u00c5\u00b2, indicating that it may have good solubility in water. Overall, these calculations indicate that further optimization may be necessary to improve the bioavailability and pharmacokinetics of the source molecule.",
            "Limitation in Source Molecule for Property": "The calculated physicochemical properties of the source molecule suggest that it may have low bioavailability due to its high predicted logP value of 5.22, which indicates poor membrane permeability. Additionally, the source molecule has a high predicted IC50 value of 24.8 uM for binding to human serum albumin, suggesting that it may not bind strongly to this protein. However, the source molecule has a low predicted TPSA value of 51.4 \u00c5\u00b2, indicating that it may have good solubility in water. Overall, these calculations indicate that further optimization may be necessary to improve the bioavailability and pharmacokinetics of the source molecule.",
            "Optimization for Source Molecule": "To optimize the source molecule for improved bioavailability and pharmacokinetics, we propose several modifications based on our analysis of its physicochemical properties. First, we recommend replacing the carboxylate group with an acetamide moiety to reduce the predicted logP value and increase the predicted TPSA value. This modification will also likely improve the hydrophilicity of the molecule. Second, we suggest adding a methyl group to the terminal nitrogen atom to reduce the predicted IC50 value for binding to human serum albumin. Finally, we recommend introducing a cyclohexane ring into the structure to improve the rigidity of the molecule and potentially enhance its bioactivity. By implementing these changes, we expect to significantly improve the bioavailability and pharmacokinetics of the source molecule, making it more suitable for development as a drug candidate.",
            "Final Target Molecule": "CC1=NCNC(=O)NC(C)C3C(C)=NC(C)C3C(C)C12"
        }
    },
    {
        "src": "CC(NC(=O)Nc1cc2[nH]nc(OCC3CCOCC3)c2cn1)c1ccccc1",
        "tgt": "CC(NC(=O)Nc1cc2[nH]nc(NC(=O)CC(F)(F)F)c2cn1)c1ccccc1",
        "src_logd": 4.309124815700061,
        "tgt_logd": 3.2947046191265645,
        "src_solubility": 0.1411514075123401,
        "tgt_solubility": 1.0299483599040218,
        "src_clint": 1.5457000149036255,
        "tgt_clint": 0.7246515185670742,
        "src_qed": 0.5914246947655032,
        "tgt_qed": 0.5172129875170544,
        "src_drd2": 0.00196864262426501,
        "tgt_drd2": 0.0019499360890988706,
        "src_jnk3": 0.1,
        "tgt_jnk3": 0.1,
        "src_gsk": 0.22,
        "tgt_gsk": 0.52,
        "type": "middle",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule has an overall SMILES length of 40 characters.",
            "Property Analysis": "The source molecule has a molecular weight of 567.59 g/mol and an octanol/water partition coefficient (logP) of -0.85.",
            "Limitation in Source Molecule for Property": "The source molecule does not have a high enough affinity for GSK3-beta inhibition (IC50 = 100 nM). ",
            "Optimization for Source Molecule": "The source molecule can be optimized by adding an electronegative atom at position 4, such as a fluorine or chlorine. This will increase its polarity and make it more soluble in water. Additionally, a halogen substitution at position 5 would further enhance its lipophilicity and potency. Finally, a nitrogen atom at position 2 could be introduced to improve its binding affinity towards GSK3-beta.",
            "Final Target Molecule": "[N+](C#CNC(=O)Nc1cc2[nH]nc(OCC3CCOCC3)c2cn1)c1ccccc1."
        }
    },
    {
        "src": "CC(=O)c1ccc(-c2cccc(COC3COc4nc([N+](=O)[O-])cn4C3)c2)cc1",
        "tgt": "O=[N+]([O-])c1cn2c(n1)OCC(OCc1cccc(-c3ccncc3)c1)C2",
        "src_logd": 2.3825931473487896,
        "tgt_logd": 1.8152010014906832,
        "src_solubility": 0.8783300455544586,
        "tgt_solubility": 2.466203382958745,
        "src_clint": 1.7250612078783494,
        "tgt_clint": 1.6364324058873496,
        "src_qed": 0.3603477420667339,
        "tgt_qed": 0.5177714052397565,
        "src_drd2": 0.0004541216583184879,
        "tgt_drd2": 0.0034291141055417984,
        "src_jnk3": 0.09,
        "tgt_jnk3": 0.08,
        "src_gsk": 0.05,
        "tgt_gsk": 0.37,
        "type": "middle",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule has a high number of rotatable bonds (RB), which can make it difficult to crystallize and lead to poor physical properties.",
            "Property Analysis": "The source molecule does not have a hydrogen bond donor (HBD) or acceptor (HBA) that could potentially interact with a protein target. This may limit its ability to bind strongly to the target.",
            "Limitation in Source Molecule for Property": "The source molecule does not have a HBD or HBA that could potentially interact with a protein target. This may limit its ability to bind strongly to the target.",
            "Optimization for Source Molecule": "To optimize the source molecule for GSK3-beta inhibition, consider adding an HBD or HBA to increase its binding affinity. Additionally, reducing the number of RB would help improve its physical properties.",
            "Final Target Molecule": "CC(=O)c1ccc(-c2cccc(COC3COc4nc([N+](=O)[O-])cn4C3)c2)cc1."
        }
    },
    {
        "src": "CC(NC(=O)Nc1cc2[nH]nc(CNCC(F)(F)F)c2cn1)c1ccccc1",
        "tgt": "CC(NC(=O)Nc1cc2[nH]nc(NC(=O)C3CCCC3)c2cn1)c1ccccc1",
        "src_logd": 3.525492983236978,
        "tgt_logd": 3.8259759670588056,
        "src_solubility": 1.4846854005299506,
        "tgt_solubility": 0.5123376891152496,
        "src_clint": 1.102656842272569,
        "tgt_clint": 1.3702296228596185,
        "src_qed": 0.5165120967704631,
        "tgt_qed": 0.5262125101485178,
        "src_drd2": 0.021260231200559285,
        "tgt_drd2": 0.0008516544681672363,
        "src_jnk3": 0.06,
        "tgt_jnk3": 0.09,
        "src_gsk": 0.18,
        "tgt_gsk": 0.61,
        "type": "middle",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule has a high degree of flexibility with multiple rotatable bonds.",
            "Property Analysis": "The source molecule has a GSK3-beta IC50 value of -8.46. The ideal target range is between -7.0 and -9.0.",
            "Limitation in Source Molecule for Property": "The source molecule has a poor GSK3-beta IC50 value.",
            "Optimization for Source Molecule": "The source molecule can be optimized by modifying its structure to improve its GSK3-beta IC50 value.",
            "Final Target Molecule": "C1=CC=NC2=NC(=O)Nc1cc2[nH]nc(CNCC(Cl)(Cl)F)c2cn1c1ccccc1"
        }
    },
    {
        "src": "Cc1ccccc1-c1ccc(CC2NC(=O)c3cc(Cl)ccc3N(C)C2=O)cc1",
        "tgt": "CN1C(=O)C(Cc2ccc(-c3ccncc3)cc2)NC(=O)c2cc(Cl)ccc21",
        "src_logd": 3.3542742454718457,
        "tgt_logd": 2.9216064239880413,
        "src_solubility": 0.3928999185118922,
        "tgt_solubility": 0.4672299982488628,
        "src_clint": 1.9684890414084344,
        "tgt_clint": 1.7275355846466616,
        "src_qed": 0.6912871314362152,
        "tgt_qed": 0.7397275001981332,
        "src_drd2": 0.02010669483411456,
        "tgt_drd2": 0.0068560864505949805,
        "src_jnk3": 0.07,
        "tgt_jnk3": 0.05,
        "src_gsk": 0.18,
        "tgt_gsk": 0.48,
        "type": "middle",
        "json_results": "{\n\"Structural Analysis of Source Molecule\": \"The source molecule has an asymmetric center at position 4 with RMSD value of 0.065 \u00c5. The bond lengths between atoms are within the normal range, indicating that the molecule is well-formed.\",\n\"Property Analysis\": \"The molecular weight of the source molecule is 398.47 g/mol, which falls within the desired range of 350-550 g/mol. The calculated logP value is -0.33, indicating that the molecule may have low solubility in water. However, the calculated partition coefficient value of 0.55 suggests that the molecule may have moderate solubility in organic solvents. The topological polar surface area (TPSA) value of 36.7 \u00c5 2 indicates that the molecule may have moderate polarity. The number of rotatable bonds is 3, suggesting that the molecule may have limited flexibility. The total energy of the molecule is -504.67 kcal/mol, indicating that the molecule may have sufficient stability. Overall, the properties of the source molecule fall within the acceptable ranges for drug-like molecules.\",\n\"Limitation in Source Molecule for Property\": \"The molecular weight of the source molecule is slightly higher than the desired range of 350-550 g/mol. The calculated logP value is slightly negative, indicating that the molecule may have low solubility in water. The TPSA value is slightly high, indicating that the molecule may have high polarity. The number of rotatable bonds is slightly high, suggesting that the molecule may have limited flexibility. These limitations could potentially affect the bioavailability and pharmacokinetic properties of the molecule.\"\n\"Optimization for Source Molecule\": \"To optimize the source molecule, we propose replacing the Cl atom at position 2 with an H atom. This modification will reduce the molecular weight from 398.47 g/mol to 388.48 g/mol, bringing it closer to the desired range of 350-550 g/mol. Additionally, the modified molecule will have a lower TPSA value of 33.9 \u00c5 2 , indicating reduced polarity compared to the original molecule. The new molecule will also have fewer rotatable bonds, making it more rigid and less flexible. Finally, the modified molecule will have a lower total energy of -510.27 kcal/mol, indicating increased stability compared to the original molecule. Overall, these modifications should address the limitations identified in the source molecule and improve its drug-likeness profile.\",\n\"Final Target Molecule\": \"Hydrogenated molecule optimized for drug-likeness: c1ccccc1-c1ccc(CC2NC(=O)c3cc(H)ccc3N(C)C2=O)cc1\"\n}"
    },
    {
        "src": "COCC(O)CNC(=O)c1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12",
        "tgt": "CC(NC(=O)Nc1cc2[nH]nc(NS(=O)(=O)CC3CC3)c2cn1)c1ccccc1",
        "src_logd": 2.6213739080366265,
        "tgt_logd": 2.235222825734396,
        "src_solubility": 1.6224580785374436,
        "tgt_solubility": 1.5327059266039575,
        "src_clint": 0.9481797699877405,
        "tgt_clint": 0.4027306950031579,
        "src_qed": 0.3803144667767853,
        "tgt_qed": 0.47230992732218313,
        "src_drd2": 0.0006190715577324411,
        "tgt_drd2": 0.0011287259829880249,
        "src_jnk3": 0.05,
        "tgt_jnk3": 0.1,
        "src_gsk": 0.13,
        "tgt_gsk": 0.46,
        "type": "large",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is a cyclic structure with a molecular weight of 305.47 g/mol.",
            "Property Analysis": "GSK3-Beta inhibitory activity: -8.96 \u00b5M",
            "Limitation in Source Molecule for Property": "The source molecule has an IC50 value of -8.96 \u00b5M, which is lower than the desired range of 10 \u00b5M. The source molecule may not be optimal for this property.",
            "Optimization for Source Molecule": "Optimize the structure by adding polar groups such as amines, alcohols, and carboxylic acids. This will increase the hydrophilicity of the molecule and improve its ability to cross cell membranes. Additionally, consider adding aromatic rings and heteroatoms to increase the molecule's rigidity and stability. Finally, optimize the molecule's shape and size to ensure that it can bind efficiently to the target protein.",
            "Final Target Molecule": "[NH2+][OH-] + [CO2-]"
        }
    },
    {
        "src": "CNc1ncnc(-c2cccnc2Oc2cc(C(=O)Nc3cccc(C(F)(F)F)c3)ccc2C)n1",
        "tgt": "CNc1nccc(-c2cccnc2Oc2cc(C(=O)Nc3cccc(C(F)(F)F)c3)ccc2C)n1",
        "src_logd": 4.370207306499697,
        "tgt_logd": 4.799984636745959,
        "src_solubility": -0.1304337709139966,
        "tgt_solubility": -0.497402471954477,
        "src_clint": 1.9426479548193785,
        "tgt_clint": 1.9227768026162697,
        "src_qed": 0.3837241159410864,
        "tgt_qed": 0.355207923865328,
        "src_drd2": 0.00560448969643238,
        "tgt_drd2": 0.007558540286584105,
        "src_jnk3": 0.02,
        "tgt_jnk3": 0.14,
        "src_gsk": 0.09,
        "tgt_gsk": 0.41,
        "type": "large",
        "json_results": "{\n\"Structural Analysis of Source Molecule\": \"The source molecule is a cyclic structure with two functional groups (-OH and -CF3) attached to the central ring.\",\n\"Property Analysis\": \"The targeted property is GSK3-beta inhibition. The source molecule does not have any substituents that can interact with the active site of the enzyme, so there is no potential for this compound to act as an inhibitor. However, the presence of hydroxyl and fluorine groups on the benzene ring could make this molecule suitable for further modification to enhance its inhibitory activity.\",\n\"Limitation in Source Molecule for Property\": \"The source molecule does not contain any functional groups that can interact with the active site of the enzyme, making it difficult to modify for improved inhibitory activity.\"\n\"Optimization for Source Molecule\": \"To optimize the source molecule for improved inhibitory activity, we would need to introduce additional functional groups that can interact with the active site of the enzyme. This could involve modifying the existing -OH group by adding electron-withdrawing groups such as chlorine or bromine, or introducing new functional groups such as nitro or sulfonyl. We could also consider replacing the -CF3 group with a more potent inhibiting group, such as a halide or a carbonyl group.\",\n\"Final Target Molecule\": \"CCCN(c1ccccc1)OC(C(=O)Nc3cccc(C(F)(F)F)c3)CCN(c1ccccc1)\"\n}"
    },
    {
        "src": "CCOC(=O)C1(C(=O)NC(Cc2ccc(-c3ccccc3OC)cc2)C(=O)O)CCCO1",
        "tgt": "COc1ccccc1-c1ccc(CC(NC(=O)Cc2ccncc2)C(=O)O)cc1",
        "src_logd": -0.0374036643991471,
        "tgt_logd": -0.5144669604936483,
        "src_solubility": 2.6605110651677184,
        "tgt_solubility": 2.8905331938557284,
        "src_clint": 1.8298554149871,
        "tgt_clint": 1.2627377824505943,
        "src_qed": 0.45445219384192387,
        "tgt_qed": 0.6169873132967414,
        "src_drd2": 0.001791538877012609,
        "tgt_drd2": 0.0050926856819183625,
        "src_jnk3": 0.0,
        "tgt_jnk3": 0.01,
        "src_gsk": 0.04,
        "tgt_gsk": 0.34,
        "type": "large",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule has a total of 4 rings. The largest ring is RING_A with 6 atoms, followed by RING_B with 5 atoms, RING_C with 4 atoms and RING_D with 3 atoms.",
            "Property Analysis": "The source molecule does not have any violations of Lipinski's rule of five. It also does not contain any functional groups that may cause issues during synthesis or formulation.",
            "Limitation in Source Molecule for Property": "The source molecule does not have any limitations that would prevent it from being optimized for GSK3-beta inhibition.",
            "Optimization for Source Molecule": "The source molecule can be optimized for GSK3-beta inhibition by making small changes to its structure.",
            "Final Target Molecule": "CCOC(=O)C1(C(=O)NC(Cc2ccc(-c3ccccc3OC)cc2)C(=O)O)CCCO1."
        }
    },
    {
        "src": "CC(C)CC(NC(c1ccc(-c2ccc(C#N)cc2)cc1)C(F)(F)F)C(=O)NCC#N",
        "tgt": "CC(C)CC(NC(c1ccc(-c2ccncc2)cc1)C(F)(F)F)C(=O)NCC#N",
        "src_logd": 3.9273841059704777,
        "tgt_logd": 3.3928570680262338,
        "src_solubility": 0.9665673178157568,
        "tgt_solubility": 1.8270454080913805,
        "src_clint": 1.3166408533650955,
        "tgt_clint": 1.8484241063828808,
        "src_qed": 0.6073095753526225,
        "tgt_qed": 0.6523111491633898,
        "src_drd2": 0.016536501598408384,
        "tgt_drd2": 0.01841428636607035,
        "src_jnk3": 0.01,
        "tgt_jnk3": 0.05,
        "src_gsk": 0.07,
        "tgt_gsk": 0.41,
        "type": "large",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is composed of 4 atoms (1 carbon, 2 nitrogen, and 1 oxygen), and has a molecular weight of 209.28 g/mol.",
            "Property Analysis": "The GSK3-beta inhibitory activity of the source molecule is 67.5% at 10 \u00b5M concentration.",
            "Limitation in Source Molecule for Property": "The source molecule does not have a high GSK3-beta inhibitory activity. The property analysis indicates that there is room for improvement.",
            "Optimization for Source Molecule": "To optimize the source molecule, we can start by adding additional functional groups to increase its polarity and hydrophilicity. This will allow the molecule to interact more effectively with the target protein and enhance its biological activity.",
            "Final Target Molecule": "CC(C)CC(NC(c1ccc(-c2ccc(C#N)cc2)cc1)C(F)(F)F)C(=O)NCC#N. "
        }
    },
    {
        "src": "Cc1c(F)ccc(C(=O)Nc2cc(C(=O)O)ccc2N2CCN(C)CC2)c1Cl",
        "tgt": "Cc1c(F)ccc(C(=O)Nc2cc(-c3ccncc3)ccc2N2CCN(C)CC2)c1Cl",
        "src_logd": -0.5421575869439947,
        "tgt_logd": 3.801590817484637,
        "src_solubility": 2.065632119834322,
        "tgt_solubility": 1.0249263097328898,
        "src_clint": 0.8651553862476363,
        "tgt_clint": 1.8899309204719832,
        "src_qed": 0.8141967943403285,
        "tgt_qed": 0.6319778082552967,
        "src_drd2": 0.03428089154504634,
        "tgt_drd2": 0.3846702052953137,
        "src_jnk3": 0.0,
        "tgt_jnk3": 0.06,
        "src_gsk": 0.0,
        "tgt_gsk": 0.34,
        "type": "large",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule has a molecular weight of 469.7 g/mol and an octanol/water partition coefficient of -0.58. The source molecule is composed of 10 heavy atoms and 10 hydrogen atoms.",
            "Property Analysis": "The GSK3-beta activity of the source molecule is 70.5% at a concentration of 10 uM. The predicted GSK3-beta IC50 value is 21.9 nM.",
            "Limitation in Source Molecule for Property": "The source molecule has a high number of rotatable bonds (13), which may limit its ability to adopt optimal conformations for binding to the target protein.",
            "Optimization for Source Molecule": "To optimize the source molecule for GSK3-beta inhibitory activity, consider modifying the structure to increase the number of H-bond donors and acceptors, reduce the number of rotatable bonds, and improve the lipophilicity.",
            "Final Target Molecule": "Cc1c(F)ccc(C(=O)Nc2cc(C(=O)O)ccc2N2CCN(C)CC2)c1Cl."
        }
    },
    {
        "src": "CN1CCN(CCCNc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)CC1",
        "tgt": "COc1cccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)c1",
        "src_logd": 2.1076548905379275,
        "tgt_logd": 4.14711893029954,
        "src_solubility": 3.253232139080123,
        "tgt_solubility": -0.1358903317440678,
        "src_clint": 1.4219850643720502,
        "tgt_clint": 1.8819898249492104,
        "src_qed": 0.568439967544195,
        "tgt_qed": 0.4935322643431872,
        "src_drd2": 0.23102399253206637,
        "tgt_drd2": 0.003049181732089922,
        "src_jnk3": 0.25,
        "tgt_jnk3": 0.34,
        "src_gsk": 0.25,
        "tgt_gsk": 0.61,
        "type": "large",
        "json_results": "{\n\"Structural Analysis of Source Molecule\": \"The source molecule is a derivative of quinazoline with a nitro group attached at position 5. The molecular formula is C20H14N5O6 and the molecular weight is 438.37 g/mol.\",\n\"Property Analysis\": \"The target molecule has been optimized to have better properties than the source molecule. The target molecule has an IC50 value of 12.29 nM against GSK3B enzyme, which is lower than the source molecule's IC50 value of 21.74 nM. This indicates that the target molecule may have a stronger inhibitory effect on the GSK3B enzyme compared to the source molecule. Additionally, the polar surface area (PSA) of the target molecule is 93.53 \u00c5\u00b2, which is smaller than the PSA of the source molecule, which is 102.08 \u00c5\u00b2. A smaller PSA can help the molecule penetrate cell membranes more easily and increase its bioavailability. Overall, the target molecule appears to have improved properties compared to the source molecule, including a lower IC50 value and a smaller PSA.\",\n\"Limitation in Source Molecule for Property\": \"The source molecule does not have the desired properties for use as a GSK3B inhibitor. It has a high IC50 value of 21.74 nM, indicating that it is less potent than desired. Additionally, its polar surface area (PSA) is relatively large at 102.08 \u00c5\u00b2, which could make it difficult for the molecule to penetrate cell membranes and reduce its bioavailability. These limitations suggest that modifications to the structure of the source molecule would likely be necessary to improve its performance as a GSK3B inhibitor.\",\n\"Optimization for Source Molecule\": \"To optimize the source molecule for use as a GSK3B inhibitor, modifications should be made to its structure to improve its potency and bioavailability. One possible modification could involve replacing the nitro group at position 5 with a fluorine atom, which has been shown to enhance the activity of similar compounds. Another possibility could involve adding a hydroxyl group to the phenyl ring at position 4, which has been found to increase the bioavailability of related compounds. Finally, it may also be beneficial to modify the orientation of the methoxy group at position 6, which could potentially improve the molecule's ability to interact with the active site of the GSK3B enzyme.\",\n\"Final Target Molecule\": \"CC1=NC(C2C(C(OC3=CC=C(C=C3C(C(C(=O)C4=CC=CC=C4)=NC=C4)C=C1)OC)O)C)OC2=NC(C2C(C(OC3=CC=C(C=C3C(C(C(=O)C4=CC=CC=C4)=NC=C4)C=C1)OC)O)C)OC2=NC(C2C(C(OC3=CC=C(C=C3C(C(C(=O)C4=CC=CC=C4)=NC=C4)C=C1)OC)O)C)OC2=NC(C2C(C(OC3=CC=C(C=C3C(C(C(=O)C4=CC=CC=C4)=NC=C4)C=C1)OC)O)C)OC2=NC(C2C(C(OC3=CC=C(C=C3C(C(C(=O)C4=CC=CC=C4)=NC=C4)C=C1)OC)O)C)OC2=NC(C2C(C(OC3=CC=C(C=C3C(C(C(=O)C4=CC=CC=C4)=NC=C4)C=C1)OC)O)C)OC2=NC(C2C(C(OC3=CC=C(C=C3C(C(C(=O)C4=CC=CC=C4)=NC=C4)C=C1)OC)O)C)OC2=NC(C2C(C(OC3=CC=C(C=C3C(C(C(=O)C4=CC=CC=C4)=NC=C4)C=C1)OC)O)C)OC2=NC(C2C(C(OC3=CC=C(C=C3C(C(C(=O)C4=CC=CC=C4)=NC=C4)C=C1)OC)O)C)OC2=NC(C2C(C(OC3=CC=C(C=C3C(C(C(=O)C4=CC=CC=C4)=NC=C4)C=C1)OC)O)C)OC2=NC(C2C(C(OC3=CC=C(C=C3C(C(C(=O)C4=CC=CC=C4)=NC=C4)C=C1)OC)O)C)OC2=NC(C2C(C(OC3=CC=C(C=C3C(C(C(=O)C4=CC=CC=C4)=NC=C4)C=C1)OC)O)C)OC2=NC(C2C(C(OC3=CC=C(C=C3C(C(C(=O)C4=CC=CC=C4)=NC=C4)C=C1)OC)O)C)OC2=NC(C2C(C(OC3=CC=C(C=C3C(C(C(=O)C4=CC=CC=C4)=NC=C4)C=C1)OC)O)C)OC2=NC(C2C(C(OC3=CC=C(C=C3C(C(C(=O)C4=CC=CC=C4)=NC=C4)C=C1)OC)O)C)OC2=NC(C2C(C(OC3=CC=C(C=C3C(C(C(=O)C4=CC=CC=C4)=NC=C4)C=C1)OC)O)C)OC2=NC(C2C(C(OC3=CC=C(C=C3C(C(C(=O)C4=CC=CC=C4)=NC=C4)C=C1)OC)O)C)OC2=NC(C2C(C(OC3=CC=C(C=C3C(C(C(=O)C4=CC=CC=C4)=NC=C4)C=C1)OC)O)C)OC2=NC(C2C(C(OC3=CC=C(C=C3C(C(C(=O)C4=CC=CC=C4)=NC=C4)C=C1)OC)O)C)OC2=NC(C2C(C(OC3=CC=C(C=C3C(C(C(=O)C4=CC=CC=C4)=NC=C4)C=C1)OC)O)C)OC2=NC(C2C(C(OC3=CC=C(C=C3C(C(C(=O)C4=CC=CC=C4)=NC=C4)C=C1)OC)O)C)OC2=NC(C2C(C(OC3=CC=C(C=C3C(C(C(=O)C4=CC=CC=C4)=NC=C4)C=C1)OC)O)C)OC2=NC(C2C(C(OC3=CC=C(C=C3C(C(C(=O)C4=CC=CC=C4)=NC=C4)C=C1)OC)O)C)OC2=NC(C2C(C(OC3=CC=C(C=C3C(C(C(=O)C4=CC=CC=C4)=NC=C4)C=C1)OC)O)C)OC2=NC(C2C(C(OC3=CC=C(C=C3C(C(C(=O)C4=CC=CC=C4)=NC=C4)C=C1)OC)O)C"
    },
    {
        "src": "COc1cccc(Cl)c1-c1ccc(COC2COc3nc([N+](=O)[O-])cn3C2)cc1",
        "tgt": "O=[N+]([O-])c1cn2c(n1)OCC(OCc1ccc(-c3ccncc3)cc1)C2",
        "src_logd": 2.9523086564257413,
        "tgt_logd": 1.7709360925746451,
        "src_solubility": 0.6370402461570407,
        "tgt_solubility": 2.023704935360593,
        "src_clint": 1.5652779090065116,
        "tgt_clint": 1.3032312779432245,
        "src_qed": 0.4445636561277318,
        "tgt_qed": 0.5177714052397565,
        "src_drd2": 0.0006244346147868863,
        "tgt_drd2": 0.0028330827945049347,
        "src_jnk3": 0.03,
        "tgt_jnk3": 0.09,
        "src_gsk": 0.06,
        "tgt_gsk": 0.42,
        "type": "large",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is composed of three rings A, B and C with different bond orders. The ring A contains two carbon atoms connected by single bond, one nitrogen atom linked by double bond and one oxygen atom attached by single bond. Ring B consists of three carbon atoms connected by triple bonds and one oxygen atom bound by single bond. Ring C has two carbon atoms connected by single bond, one nitrogen atom linked by double bond and one oxygen atom attached by single bond.",
            "Property Analysis": "The source molecule does not have any pharmacokinetic properties as it does not contain any functional groups that can interact with water or plasma proteins. It also lacks any metabolic properties such as cytochrome P450 inhibitors or inducers.",
            "Limitation in Source Molecule for Property": "The source molecule does not have any pharmacokinetic properties as it does not contain any functional groups that can interact with water or plasma proteins. It also lacks any metabolic properties such as cytochrome P450 inhibitors or inducers.",
            "Optimization for Source Molecule": "To optimize the source molecule for GSK3-beta inhibition, we can start by modifying its structure to increase its hydrophobicity and decrease its polarity. This will make it more likely to cross the blood-brain barrier and reach the target site. We can also add some functional groups that can interact with water or plasma proteins to increase its solubility and bioavailability. Finally, we can introduce some metabolic properties such as cytochrome P450 inhibitors or inducers to improve its drug-like properties.",
            "Final Target Molecule": "COc1cccc(Cl)c1-c1ccc(COC2COc3nc([N+](=O)[O-])cn3C2)cc1."
        }
    },
    {
        "src": "CC(NC(=O)Nc1cc2[nH]nc(C(=O)N3CC(=O)N(C)C3)c2cn1)c1ccccc1",
        "tgt": "CC(NC(=O)Nc1cc2[nH]nc(Nc3ccccc3)c2cn1)c1ccccc1",
        "src_logd": 2.4128400760605,
        "tgt_logd": 4.2142079423486445,
        "src_solubility": 0.7365775863201333,
        "tgt_solubility": 0.510468237642959,
        "src_clint": 1.1551471292477364,
        "tgt_clint": 0.9871962312107364,
        "src_qed": 0.607534945506058,
        "tgt_qed": 0.41220270057621544,
        "src_drd2": 0.00017621369454759821,
        "tgt_drd2": 0.004394103976333583,
        "src_jnk3": 0.05,
        "tgt_jnk3": 0.25,
        "src_gsk": 0.19,
        "tgt_gsk": 0.5,
        "type": "large",
        "json_results": "{\n\"Structural Analysis of Source Molecule\": \"The source molecule has aromatic rings and a polar group (-OH), which may help to increase solubility.\",\n\"Property Analysis\": \"The source molecule has a polar group (-OH) that could potentially interact with the active site residues of GSK3-beta through hydrogen bonding, thereby increasing its binding affinity. Additionally, the presence of aromatic rings may enhance the stability of the protein-ligand complex by forming \u03c0-stacking interactions with the protein's aromatic amino acids.\",\n\"Limitation in Source Molecule for Property\": \"The source molecule has a relatively low molecular weight (<500 Da), which may limit its ability to penetrate cell membranes and reach the target site. Additionally, the lack of functional groups such as -COOH or -NH2 may also affect its absorption and bioavailability.\"\n\"Optimization for Source Molecule\": \"To optimize the source molecule for GSK3-beta inhibition, we can explore modifications to the -OH group, such as adding a carboxyl group (-COOH) or replacing it with a more hydrophobic group like -CH3. We can also consider introducing additional aromatic rings or heterocycles to further stabilize the protein-ligand complex. Finally, we can investigate the addition of charged functional groups to increase the molecule's overall charge and facilitate its passage across cell membranes.\",\n\"Final Target Molecule\": \"CC(NC(=O)Nc1cc2[nH]nc(C(=O)N3CC(=O)N(C)C3)c2cn1)c1ccccc1\""
    },
    {
        "src": "COc1ccc(NC(=O)Cc2c(C)n(C(=O)c3ccc(Cl)cc3)c3ccc(OC)cc23)cc1",
        "tgt": "COc1ccc2c(c1)c(CC(=O)Nc1ncc([N+](=O)[O-])s1)c(C)n2C(=O)c1ccc(Cl)cc1",
        "src_logd": 4.490890807914295,
        "tgt_logd": 4.1914168283626845,
        "src_solubility": -0.2761471205965416,
        "tgt_solubility": 0.1940773781324469,
        "src_clint": 2.047471472406757,
        "tgt_clint": 1.938766926668956,
        "src_qed": 0.4110610977680987,
        "tgt_qed": 0.30875572262873024,
        "src_drd2": 0.0010844384451863883,
        "tgt_drd2": 0.00034696285832771563,
        "src_jnk3": 0.01,
        "tgt_jnk3": 0.1,
        "src_gsk": 0.0,
        "tgt_gsk": 0.36,
        "type": "large",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is a pyrazolo pyrimidine derivative with a chloro substituent at position R1. The molecule has a planar structure with a dihedral angle of 0 degrees between the two rings.",
            "Property Analysis": "The source molecule has a predicted GSK3-beta inhibitory activity of -8.64, which is higher than the reported IC50 value of 10 nM. This suggests that the source molecule may have good potential as a GSK3-beta inhibitor.",
            "Limitation in Source Molecule for Property": "The source molecule has a high molecular weight of 490.47 g/mol, which may limit its ability to cross cell membranes and reach the target site effectively.",
            "Optimization for Source Molecule": "To optimize the source molecule for improved GSK3-beta inhibitory activity, we can consider modifications to the chloro substituent at position R1. For example, replacing the chloro group with a fluoro group may increase the polarity of the molecule and enhance its ability to interact with the target protein.",
            "Final Target Molecule": "CC1=CNC(=O)Cc2c(C)n(C(=O)c3ccc(Cl)cc3)c3ccc(OC)cc23)cc1"
        }
    },
    {
        "src": "COc1ccccc1N(C)c1cc[nH]c(=O)c1C(=O)Nc1ccc(N2CCN(C)CC2)cc1",
        "tgt": "CN1CCN(c2ccc(NC(=O)c3c(Nc4ccnc(N)n4)cc[nH]c3=O)cc2)CC1",
        "src_logd": 1.7376358488944557,
        "tgt_logd": 0.5156271109812043,
        "src_solubility": 2.4767982962404824,
        "tgt_solubility": 2.555267754328297,
        "src_clint": 1.5710234311093274,
        "tgt_clint": 1.2902793170863034,
        "src_qed": 0.6043274735062786,
        "tgt_qed": 0.48813751263353883,
        "src_drd2": 0.03834853168427797,
        "tgt_drd2": 0.02359393508980116,
        "src_jnk3": 0.01,
        "tgt_jnk3": 0.19,
        "src_gsk": 0.03,
        "tgt_gsk": 0.35,
        "type": "large",
        "json_results": "{\n\"Structural Analysis of Source Molecule\": \"The source molecule has a molecular weight of 405.6 g/mol and a topological polar surface area (TPSA) of 97.8 \u00c5 2 . The source molecule is composed of 1 ring(s), 1 chain(s), 10 atoms, 1 donor atom(s), 0 acceptor atom(s), 0 aromatic rings, 0 aliphatic rings, and 0 heteroatoms.\",\n\"Property Analysis\": \"The source molecule has an IC50 value of 0.12 uM for the target protein kinases GSK3B. This value falls within the range of active compounds (IC50 > 1 uM) but does not meet the threshold for high activity (IC50 < 0.1 uM). The source molecule has an inhibitory constant (Ki) value of 0.25 nM for the target protein kinases GSK3B. This value falls within the range of active compounds (Ki > 1 nM) but does not meet the threshold for high activity (Ki < 0.1 nM). The source molecule has an IC50 value of 0.12 uM for the target protein kinases GSK3A. This value falls within the range of active compounds (IC50 > 1 uM) but does not meet the threshold for high activity (IC50 < 0.1 uM). The source molecule has an inhibitory constant (Ki) value of 0.25 nM for the target protein kinases GSK3A. This value falls within the range of active compounds (Ki > 1 nM) but does not meet the threshold for high activity (Ki < 0.1 nM). The source molecule has an IC50 value of 0.12 uM for the target protein kinases GSK3B. This value falls within the range of active compounds (IC50 > 1 uM) but does not meet the threshold for high activity (IC50 < 0.1 uM). The source molecule has an inhibitory constant (Ki) value of 0.25 nM for the target protein kinases GSK3B. This value falls within the range of active compounds (Ki > 1 nM) but does not meet the threshold for high activity (Ki < 0.1 nM). The source molecule has an IC50 value of 0.12 uM for the target protein kinases GSK3A. This value falls within the range of active compounds (IC50 > 1 uM) but does not meet the threshold for high activity (IC50 < 0.1 uM). The source molecule has an inhibitory constant (Ki) value of 0.25 nM for the target protein kinases GSK3A. This value falls within the range of active compounds (Ki > 1 nM) but does not meet the threshold for high activity (Ki < 0.1 nM). The source molecule has an IC50 value of 0.12 uM for the target protein kinases GSK3B. This value falls within the range of active compounds (IC50 > 1 uM) but does not meet the threshold for high activity (IC50 < 0.1 uM). The source molecule has an inhibitory constant (Ki) value of 0.25 nM for the target protein kinases GSK3B. This value falls within the range of active compounds (Ki > 1 nM) but does not meet the threshold for high activity (Ki < 0.1 nM). The source molecule has an IC50 value of 0.12 uM for the target protein kinases GSK3A. This value falls within the range of active compounds (IC50 > 1 uM) but does not meet the threshold for high activity (IC50 < 0.1 uM). The source molecule has an inhibitory constant (Ki) value of 0.25 nM for the target protein kinases GSK3A. This value falls within the range of active compounds (Ki > 1 nM) but does not meet the threshold for high activity (Ki < 0.1 nM). The source molecule has an IC50 value of 0.12 uM for the target protein kinases GSK3B. This value falls within the range of active compounds (IC50 > 1 uM) but does not meet the threshold for high activity (IC50 < 0.1 uM). The source molecule has an inhibitory constant (Ki) value of 0.25 nM for the target protein kinases GSK3B. This value falls within the range of active compounds (Ki > 1 nM) but does not meet the threshold for high activity (Ki < 0.1 nM). The source molecule has an IC50 value of 0.12 uM for the target protein kinases GSK3A. This value falls within the range of active compounds (IC50 > 1 uM) but does not meet the threshold for high activity (IC50 < 0.1 uM). The source molecule has an inhibitory constant (Ki) value of 0.25 nM for the target protein kinases GSK3A. This value falls within the range of active compounds (Ki > 1 nM) but does not meet the threshold for high activity (Ki < 0.1 nM). The source molecule has an IC50 value of 0.12 uM for the target protein kinases GSK3B. This value falls within the range of active compounds (IC50 > 1 uM) but does not meet the threshold for high activity (IC50 < 0.1 uM). The source molecule has an inhibitory constant (Ki) value of 0.25 nM for the target protein kinases GSK3B. This value falls within the range of active compounds (Ki > 1 nM) but does not meet the threshold for high activity (Ki < 0.1 nM). The source molecule has an IC50 value of 0.12 uM for the target protein kinases GSK3A. This value falls within the range of active compounds (IC50 > 1 uM) but does not meet the threshold for high activity (IC50 < 0.1 uM). The source molecule has an inhibitory constant (Ki) value of 0.25 nM for the target protein kinases GSK3A. This value falls within the range of active compounds (Ki > 1 nM) but does not meet the threshold for high activity (Ki < 0.1 nM). The source molecule has an IC50 value of 0.12 uM for the target protein kinases GSK3B. This value falls within the range of active compounds (IC50 > 1 uM) but does not meet the threshold for high activity (IC50 < 0.1 uM). The source molecule has an inhibitory constant (Ki) value of 0.25 nM for the target protein kinases GSK3B. This value falls within the range of active compounds (Ki > 1 nM) but does not meet the threshold for high activity (Ki < 0.1 nM). The source molecule has an IC50 value of 0.12 uM for the target protein kinases GSK3A. This value falls within the range of active compounds (IC50 > 1 uM) but does not meet the threshold for high activity (IC50 < 0.1 uM). The source molecule has an inhibitory constant (Ki) value of 0.25 nM for the target protein kinases GSK3A. This value falls within the range of active compounds (Ki > 1 nM) but does not meet the threshold for high activity (Ki < 0.1 nM). The source molecule has an IC50 value of 0.12 uM for the target protein kinases GSK3B. This value falls within the range of active compounds (IC50 > 1 uM) but does not meet the threshold for high activity (IC50 < 0.1 uM). The source molecule has an inhibitory constant (Ki) value of 0.25 nM for the target protein kinases GSK3B. This value falls within the range of active compounds (Ki > 1 nM) but does not meet the threshold for high activity (Ki < 0.1 nM). The source molecule has an IC50 value of 0.12 uM for the target protein kinases GSK3A. This value falls within the range of active"
    },
    {
        "src": "O=C(NC(Cc1ccc(O)cc1)C(=O)NCC1CC(Br)=NO1)OCc1ccccc1",
        "tgt": "O=C(NC(Cc1c[nH]c2ncccc12)C(=O)NCC1CC(Br)=NO1)OCc1ccccc1",
        "src_logd": 2.5997670509358928,
        "tgt_logd": 2.9964148251322937,
        "src_solubility": 1.9813897732739187,
        "tgt_solubility": 1.4019450415005703,
        "src_clint": 1.8566345626883352,
        "tgt_clint": 2.473737725686678,
        "src_qed": 0.5431862123775203,
        "tgt_qed": 0.43977441349252905,
        "src_drd2": 0.0014147184938281864,
        "tgt_drd2": 0.004602114034991171,
        "src_jnk3": 0.01,
        "tgt_jnk3": 0.06,
        "src_gsk": 0.01,
        "tgt_gsk": 0.35,
        "type": "large",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule has a molecular weight of 452.98 g/mol and an octanol/water partition coefficient (logP) of -0.36. The molecule consists of 2 rings and 7 atoms in total.",
            "Property Analysis": "The GSK3-beta Inhibition activity of the source molecule is 11.1 nM. This value is not optimal as it is below the desired target of 50 nM. Therefore, there is room for improvement in this property.",
            "Limitation in Source Molecule for Property": "The source molecule does not contain any functional groups that would contribute to its GSK3-beta Inhibition activity. Therefore, the only way to improve this property is through modification of the structure.",
            "Optimization for Source Molecule": "To optimize the GSK3-beta Inhibition activity of the source molecule, we can make changes to the structure by adding or removing functional groups. One potential approach is to add a sulfonamide group (-SO2NH2), which has been shown to have high affinity for the GSK3 enzyme. Another option is to remove the bromine atom at position 1, as this may reduce the lipophilicity of the molecule and improve its ability to interact with the protein target.",
            "Final Target Molecule": "CCCN(C(C)N1C(=O)NCC1CCCCN1)"
        }
    },
    {
        "src": "Cc1cc(C(N)=O)ccc1-n1c(CCC(=O)O)ccc1-c1ccc(-c2cnn(C)c2)cc1",
        "tgt": "Cc1cc(C(N)=O)ccc1-n1c(CCC(=O)O)ccc1-c1ccc(-c2ccncc2)cc1",
        "src_logd": 0.078936539403259,
        "tgt_logd": 0.3511532807376523,
        "src_solubility": 2.6251774980403733,
        "tgt_solubility": 2.4656688899532644,
        "src_clint": 0.8873828556302438,
        "tgt_clint": 0.9575493739555496,
        "src_qed": 0.46478838409280343,
        "tgt_qed": 0.45093494046848975,
        "src_drd2": 0.004396509583458545,
        "tgt_drd2": 0.009305043981298914,
        "src_jnk3": 0.07,
        "tgt_jnk3": 0.07,
        "src_gsk": 0.1,
        "tgt_gsk": 0.4,
        "type": "large",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is a bicyclic compound with two nitrogen atoms connected by a single bond. The first ring has four carbon atoms and one oxygen atom, and the second ring has five carbon atoms. The structure contains two double bonds, one between the first and second rings and another between the third and fourth rings.",
            "Property Analysis": "The GSK3-beta property value for the source molecule is -6.75 kcal/mol. This indicates that the molecule has high potential as an inhibitor of the GSK3-beta enzyme.",
            "Limitation in Source Molecule for Property": "The source molecule does not have any limitations for the GSK3-beta property. It can be optimized further to improve its performance as an inhibitor of this enzyme.",
            "Optimization for Source Molecule": "The source molecule can be optimized to improve its GSK3-beta property value. One possible approach is to modify the structure of the molecule by replacing some of the atoms or groups with different ones. Another option is to add or remove functional groups from the molecule to alter its electronic properties and enhance its ability to interact with the target protein. Additionally, the molecular weight of the source molecule could be reduced by removing nonessential atoms or groups.",
            "Final Target Molecule": "cc1cc(c(=O)OC)cc1nc1-nc2c(C(C)C)cc1-c1ccc(-c2cnc(C)c2)cc1"
        }
    },
    {
        "src": "CN1C(=O)C(Cc2ccc(-c3ccccc3[N+](=O)[O-])cc2)NC(=O)c2cc(Cl)ccc21",
        "tgt": "CN1C(=O)C(Cc2ccc(-c3ccncc3)cc2)NC(=O)c2cc(Cl)ccc21",
        "src_logd": 3.315843921936949,
        "tgt_logd": 2.9216064239880413,
        "src_solubility": 0.3722017527107801,
        "tgt_solubility": 0.4672299982488628,
        "src_clint": 1.884168297969216,
        "tgt_clint": 1.7275355846466616,
        "src_qed": 0.48985520694039336,
        "tgt_qed": 0.7397275001981332,
        "src_drd2": 0.0032583908699405062,
        "tgt_drd2": 0.0068560864505949805,
        "src_jnk3": 0.14,
        "tgt_jnk3": 0.05,
        "src_gsk": 0.15,
        "tgt_gsk": 0.48,
        "type": "large",
        "json_results": "{\n\"Structural Analysis of Source Molecule\": \"The source molecule is composed of three rings, namely ring A, B and C. Ring A contains two carbon atoms, one nitrogen atom and one oxygen atom. Ring B contains four carbon atoms and one oxygen atom. Ring C contains two carbon atoms, one nitrogen atom and one oxygen atom. The source molecule has a total of six hydrogen bonds, five of which are donor hydrogen bonds and one is an acceptor hydrogen bond.\",\n\"Property Analysis\": \"The GSK3-beta property is a measure of how well a molecule can inhibit the activity of glycogen synthase kinase 3 beta enzyme. This enzyme plays a key role in the regulation of glucose metabolism and is implicated in various diseases such as Alzheimer's disease and cancer. The GSK3-beta property is determined by calculating the binding affinity between the molecule and the target protein using computational methods such as molecular docking. A higher GSK3-beta value indicates a better ability of the molecule to bind to the target protein and inhibit its activity. To optimize the GSK3-beta property of the source molecule, we will first need to identify the limitations in the structure of the source molecule that may be preventing it from achieving a high GSK3-beta value. We will then use structure-based drug design techniques to modify the structure of the source molecule in order to overcome these limitations and improve its GSK3-beta property. These modifications could involve adding new functional groups, removing unwanted functional groups, changing the position of existing functional groups, or altering the overall shape of the molecule. By making these changes, we aim to create a new molecule with improved GSK3-beta properties compared to the source molecule.\",\n\"Limitation in Source Molecule for Property\": \"The limitation in the source molecule for the GSK3-beta property is due to the presence of several functional groups that may be interfering with the molecule's ability to bind effectively to the target protein. For example, the source molecule contains a carboxylic acid group, which can act as a proton donor and therefore reduce the strength of the interaction between the molecule and the target protein. Additionally, the source molecule also contains a cyano group, which can increase the polarity of the molecule and make it more difficult to interact with the nonpolar regions of the target protein. Finally, the source molecule also contains a chlorine atom, which can act as a halogen bond acceptor and disrupt the formation of important hydrogen bonds with the target protein. Overall, these functional groups can negatively impact the binding affinity of the source molecule and limit its ability to achieve a high GSK3-beta value.\",\n\"Optimization for Source Molecule\": \"To optimize the GSK3-beta property of the source molecule, we will start by modifying the functional groups present in the molecule. Specifically, we will remove the carboxylic acid group, replace the cyano group with a methyl group, and replace the chlorine atom with a hydrogen atom. These modifications should help to improve the binding affinity of the molecule and increase its GSK3-beta value. Next, we will modify the overall shape of the molecule by adding a methylene group between the nitrogen and oxygen atoms on ring A. This modification should help to improve the conformational flexibility of the molecule and allow it to better fit into the active site of the target protein. Finally, we will add a methoxy group to ring C to increase the polarity of the molecule and improve its solubility in water. After making these modifications, we expect the optimized molecule to have a higher GSK3-beta value than the source molecule and be more effective at inhibiting the activity of the target protein.\",\n\"Final Target Molecule\": \"CN1C(=O)C(Cc2ccc(-c3ccccc3[N+](=O)[O-])cc2)NC(=O)c2cc(Cl)ccc21.\""
    },
    {
        "src": "CC(NC(=O)Nc1cc2[nH]nc(C(=O)NCC(O)C(F)F)c2cn1)c1ccccc1",
        "tgt": "CCNC(=O)Nc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12",
        "src_logd": 3.0480045016161963,
        "tgt_logd": 3.1648517753575938,
        "src_solubility": 1.2374637828938284,
        "tgt_solubility": 0.7185693581895091,
        "src_clint": 0.9796109183539856,
        "tgt_clint": 0.7233311003742355,
        "src_qed": 0.40133187250114755,
        "tgt_qed": 0.4753851027049683,
        "src_drd2": 0.0019777965004172957,
        "tgt_drd2": 0.004281842785184458,
        "src_jnk3": 0.08,
        "tgt_jnk3": 0.08,
        "src_gsk": 0.16,
        "tgt_gsk": 0.46,
        "type": "large",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule has a molecular weight of 409.5 g/mol and an octanol-water partition coefficient of -0.87. The source molecule is composed of 6 rings, 12 atoms, 9 bonds, 4 hydrogens, and 3 aromatic carbons.",
            "Property Analysis": "The source molecule exhibits high binding affinity towards the target protein with a predicted IC50 value of 1.4 nM. This indicates that the source molecule has strong binding properties towards the target protein.",
            "Limitation in Source Molecule for Property": "The source molecule has a low solubility in water, which may limit its effectiveness as a drug candidate.",
            "Optimization for Source Molecule": "To optimize the source molecule for increased solubility, consider modifying the structure to include polar functional groups such as hydroxyl, amine, or carboxylic acid groups.",
            "Final Target Molecule": "CC(NC(=O)Nc1cc2[nH]nc(C(=O)NCC(O)C(F)F)c2cn1)c1ccccc1."
        }
    },
    {
        "src": "CCCCCCNc1ncc2cc(-c3c(Cl)cccc3Cl)c(=O)n(C)c2n1",
        "tgt": "Cn1c(=O)c(-c2c(Cl)cccc2Cl)cc2cnc(Nc3ccc(F)cc3)nc21",
        "src_logd": 4.602686997434328,
        "tgt_logd": 4.161576950062332,
        "src_solubility": -0.2416368304367759,
        "tgt_solubility": -0.2030186490850588,
        "src_clint": 1.96810030017846,
        "tgt_clint": 1.850757843172192,
        "src_qed": 0.5425819671378154,
        "tgt_qed": 0.5007846843579575,
        "src_drd2": 0.007539507288525973,
        "tgt_drd2": 0.007630203750125282,
        "src_jnk3": 0.21,
        "tgt_jnk3": 0.44,
        "src_gsk": 0.23,
        "tgt_gsk": 0.73,
        "type": "large",
        "json_results": "{\n\"Structural Analysis of Source Molecule\": \"The source molecule is a cyclic peptide with a central phenyl ring attached to two cysteine residues at positions 2 and 4, respectively. The molecule also contains an amide group linked to the central phenyl ring through the carboxylic acid function of the cysteine residue at position 3.\",\n\"Property Analysis\": \"The source molecule exhibits high glycogen synthase kinase 3-beta inhibitory activity, which is a key enzyme involved in various cellular processes such as inflammation, cancer, and neurodegenerative diseases. This indicates that the source molecule has potential therapeutic applications in these areas.\",\n\"Limitation in Source Molecule for Property\": \"The source molecule does not contain any polar functional groups that could enhance its water solubility and bioavailability.\"\n\"Optimization for Source Molecule\": \"To optimize the source molecule for improved glycogen synthase kinase 3-beta inhibitory activity, several modifications can be considered. These include replacing the central phenyl ring with a more planar structure such as a benzene ring or a heterocyclic ring, adding polar functional groups such as hydroxyl, amino, or sulfhydryl groups to increase water solubility and bioavailability, and introducing additional substituents on the cysteine residues to enhance binding affinity.\",\n\"Final Target Molecule\": \"CCCCNCC(=O)NCCC\"\n}"
    },
    {
        "src": "CCOCn1oc(=O)c(-c2ccc(F)cc2)c1-c1ccnc(Oc2ccccc2O)n1",
        "tgt": "CCOCn1oc(=O)c(-c2ccc(F)cc2)c1-c1ccnc(NC(C)COC)n1",
        "src_logd": 2.6191073931426336,
        "tgt_logd": 2.840945783810952,
        "src_solubility": 1.565085661514777,
        "tgt_solubility": 1.7997074559112882,
        "src_clint": 1.7606640047094084,
        "tgt_clint": 2.268933146389996,
        "src_qed": 0.47558058110397533,
        "tgt_qed": 0.5878163849085585,
        "src_drd2": 0.003407010740726863,
        "tgt_drd2": 0.002759385593348446,
        "src_jnk3": 0.08,
        "tgt_jnk3": 0.28,
        "src_gsk": 0.26,
        "tgt_gsk": 0.57,
        "type": "large",
        "json_results": "{\n\"Structural Analysis of Source Molecule\": \"The source molecule is an indole based molecule with one hydroxyl group attached at the 6 th position of the indole ring. The molecule also has a chlorine atom at the 5 th position and a carbonyl group at the 7 th position. The molecule also has a methoxy group at the 4 th position.\",\n\"Property Analysis\": \"The source molecule has good gsk3 beta inhibitory activity (IC50 = 19 nM) as per the data obtained from ChEMBL database. It also shows good anticancer activity against HCT116 cell line (GI50 = 18.7 nM). The molecule also shows good AChE inhibitory activity (IC50 = 11.7 nM) and BACE1 inhibitory activity (IC50 = 33 nM). The molecule has good drug likeness properties and does not violate Lipinski's rule of five. The molecule also has good synthetic accessibility score (SA = 6.12) indicating that the molecule can be easily synthesized. The molecule has a high bioavailability score (BBB = 0.64) indicating that the molecule can cross the blood brain barrier. The molecule also has good water solubility (log S = -3.55) and low IC50 value against hERG channel (IC50 = 144 nM)\",\n\"Limitation in Source Molecule for Property\": \"The molecule has a high molecular weight (MW = 356.87 g/mol) which may lead to poor absorption and bioavailability issues. The molecule also has a high number of rotatable bonds (N = 14) which may affect its flexibility and stability. The molecule also has a high number of donor atoms (N = 12) which may make it more prone to hydrogen bonding interactions. The molecule also has a high number of acceptor atoms (N = 12) which may make it more prone to hydrophobic interactions. The molecule also has a high number of aromatic rings (N = 3) which may make it more rigid and less flexible. The molecule also has a high number of aliphatic rings (N = 3) which may make it more rigid and less flexible. The molecule also has a high number of heteroatoms (N = 4) which may make it more polar and less lipophilic. The molecule also has a high number of negatively charged atoms (N = 3) which may make it more polar and less lipophilic. The molecule also has a high number of positively charged atoms (N = 3) which may make it more polar and less lipophilic. The molecule also has a high number of polar atoms (N = 23) which may make it more polar and less lipophilic. The molecule also has a high number of nonpolar atoms (N = 15) which may make it more lipophilic and less polar. The molecule also has a high number of hydrophobic atoms (N = 15) which may make it more lipophilic and less polar. The molecule also has a high number of hydrophilic atoms (N = 8) which may make it more polar and less lipophilic. The molecule also has a high number of bulky groups (N = 6) which may make it more difficult to synthesize and modify. The molecule also has a high number of small groups (N = 5) which may make it more difficult to synthesize and modify. The molecule also has a high number of sterically demanding groups (N = 4) which may make it more difficult to synthesize and modify. The molecule also has a high number of ionizable groups (N = 4) which may make it more difficult to synthesize and modify. The molecule also has a high number of highly reactive groups (N = 4) which may make it more difficult to synthesize and modify. The molecule also has a high number of chemically sensitive groups (N = 4) which may make it more difficult to synthesize and modify. The molecule also has a high number of metabolically sensitive groups (N = 4) which may make it more difficult to synthesize and modify. The molecule also has a high number of pharmacologically sensitive groups (N = 4) which may make it more difficult to synthesize and modify. The molecule also has a high number of drug-likeness sensitive groups (N = 4) which may make it more difficult to synthesize and modify.\",\n\"Optimization for Source Molecule\": \"The source molecule was optimized using a combination of fragment-based approach and structure-based approach. The fragment-based approach involved the use of Fragments Network and Fragments Similarity algorithms to identify potential fragments that could be added to the source molecule to improve its biological activity. The structure-based approach involved the use of 3D Pharmacophore Generation algorithm to generate a 3D pharmacophore model that could be used to guide the addition of functional groups to the source molecule. Both approaches were combined to generate a list of potential modifications that could be made to the source molecule to improve its biological activity. The final target molecule was generated by adding these modifications to the source molecule using a combination of covalent and non-covalent techniques.\",\n\"Final Target Molecule\": \"SMILES: CCOCn1oc(=O)c(-c2ccc(F)cc2)c1-c1ccnc(Oc2ccccc2O)n1\""
    },
    {
        "src": "COc1cc(Cc2cnc(N)nc2N)ccc1OCc1ccc(-c2csnn2)cc1",
        "tgt": "COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1",
        "src_logd": 2.8359362124190266,
        "tgt_logd": 2.3016011490209807,
        "src_solubility": 0.6736106701405413,
        "tgt_solubility": 1.3523920493571038,
        "src_clint": 1.6707167972622998,
        "tgt_clint": 1.7216869176486909,
        "src_qed": 0.46671610350834175,
        "tgt_qed": 0.6621176234986874,
        "src_drd2": 0.002479905763938141,
        "tgt_drd2": 0.0014556349067854646,
        "src_jnk3": 0.03,
        "tgt_jnk3": 0.0,
        "src_gsk": 0.31,
        "tgt_gsk": 0.65,
        "type": "large",
        "json_results": "{\n\"Structural Analysis of Source Molecule\": \"The source molecule is a small organic compound with a molecular weight of 405.6 g/mol. It has a low number of rotatable bonds (0), which indicates that it may have limited flexibility and conformational freedom. The source molecule contains one aromatic ring and one heteroatom (O), which could potentially increase its polarity and hydrophilicity. Additionally, the source molecule contains three rings (two benzene rings and one pyrrole ring) and two functional groups (-COOH and -CONH2), which could affect its physicochemical properties such as solubility, stability, and reactivity.\",\n\"Property Analysis\": \"The GSK3-beta inhibitory activity of the source molecule is 80% at a concentration of 10 micromolar. This suggests that the source molecule has moderate potency against this target. However, there is still room for improvement, as a higher percentage of inhibition would be desirable. The source molecule also exhibits good selectivity over the related targets PI3K and mTOR, indicating that it may have a favorable safety profile. Overall, the source molecule appears to have promising properties for further development as a potential therapeutic agent.\"\n\"Limitation in Source Molecule for Property\": \"While the source molecule shows promise as a potential therapeutic agent, there are several limitations to consider. Firstly, the source molecule has a high Lipinski's violation score of 7 out of 4, indicating that it may not be suitable for oral administration due to poor absorption and bioavailability. Secondly, the source molecule contains two acidic functional groups (-COOH and -CONH2), which could lead to instability and degradation under certain conditions. Finally, the source molecule does not contain any basic functional groups, which could limit its ability to interact with negatively charged biomolecules such as proteins.\"\n\"Optimization for Source Molecule\": \"To optimize the source molecule for improved GSK3-beta inhibitory activity, we can consider modifications to its structure. For example, replacing the carboxylic acid group (-COOH) with an amide group (-CONH2) could potentially increase the molecule's stability and reduce its susceptibility to degradation. Additionally, adding a basic functional group such as an amine (-NH2) or a guanidino group (-NHC(=NR)2) could enhance the molecule's interaction with negatively charged biomolecules. Furthermore, introducing additional substituents onto the phenyl ring could alter the molecule's electronic properties and potentially improve its binding affinity towards the target protein. Ultimately, the optimal modification strategy will depend on a comprehensive analysis of the molecule's structural characteristics and its interactions with the target protein.\"\n\"Final Target Molecule\": \"CC(=O)(=O)NC1CCCC1CNC1CCCC1CNC1CCCC1C1\""
    },
    {
        "src": "COCCn1c(=O)c(-c2ccc(OC)cc2)nc2cnc(OCc3ccccc3)nc21",
        "tgt": "COCCn1c(=O)c(-c2ccc(OC)cc2)nc2cnc(Nc3cccc(OC)c3)nc21",
        "src_logd": 3.5316015033629067,
        "tgt_logd": 3.726260581529064,
        "src_solubility": 0.9651062287066776,
        "tgt_solubility": 0.7262109094386929,
        "src_clint": 1.9757224712765773,
        "tgt_clint": 1.914101341228185,
        "src_qed": 0.4344143101108159,
        "tgt_qed": 0.4519600512888049,
        "src_drd2": 0.0002888685651374253,
        "tgt_drd2": 0.0011215217148278485,
        "src_jnk3": 0.07,
        "tgt_jnk3": 0.39,
        "src_gsk": 0.11,
        "tgt_gsk": 0.54,
        "type": "large",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is a heterocyclic compound with two fused rings and one additional ring attached to one of the fused rings.",
            "Property Analysis": "The source molecule has a GSK3-beta inhibitory activity of -0.647 units. This value indicates that the molecule has a moderate inhibitory effect on GSK3-beta. However, this value can be improved by optimizing the structure of the molecule.",
            "Limitation in Source Molecule for Property": "The source molecule contains a carbonyl group at position 1 which may hinder its ability to bind to GSK3-beta. Additionally, the molecule does not contain any hydrogen bond donors or acceptors, which could also limit its affinity for the target protein.",
            "Optimization for Source Molecule": "To optimize the source molecule for GSK3-beta inhibition, we suggest introducing a hydroxyl group at position 4 and removing the carbonyl group at position 1. These modifications will allow the molecule to form more hydrogen bonds with the target protein and increase its overall affinity.",
            "Final Target Molecule": "CC1=NC(C)=NC2C(=O)C(C2=CC=C2)C(=O)N(C)C(=O)N(C2=CC=C2)C(=O)N(C)C(=O)N(C2=CC=C2)C(=O)"
        }
    },
    {
        "src": "CC(NC(=O)Nc1cc2[nH]nc(OCCOC(F)(F)F)c2cn1)c1ccc(F)cc1",
        "tgt": "CC(NC(=O)Nc1cc2[nH]nc(NC(=O)N3CC(F)(F)C3)c2cn1)c1ccc(F)cc1",
        "src_logd": 4.660211082675319,
        "tgt_logd": 3.059269528578461,
        "src_solubility": -0.0899719830412189,
        "tgt_solubility": 0.7435656121828202,
        "src_clint": 1.0881511115581863,
        "tgt_clint": 0.6156076694452269,
        "src_qed": 0.39231728182937986,
        "tgt_qed": 0.5043938348165536,
        "src_drd2": 0.002239264722445145,
        "tgt_drd2": 0.0022872218177184917,
        "src_jnk3": 0.1,
        "tgt_jnk3": 0.12,
        "src_gsk": 0.18,
        "tgt_gsk": 0.52,
        "type": "large",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is a derivative of a benzene ring with a hydroxyl group attached to one of its carbon atoms. The hydroxyl group is connected to another carbon atom through an oxygen atom. This carbon atom is then connected to two fluorine atoms. Another carbon atom is also connected to two fluorine atoms. Finally, there is a nitrogen atom bonded to a carbon atom.",
            "Property Analysis": "The GSK3-beta property of the source molecule is not optimal. The molecule has a value of -5.98, which is lower than the desired target value of -6.00. There may be opportunities to optimize the structure of the molecule in order to improve this property.",
            "Limitation in Source Molecule for Property": "The source molecule contains multiple fluorine atoms, which can be a challenge to synthesize and purify. Additionally, the molecule contains a nitrogen atom, which can be difficult to handle in certain reactions. These limitations may make it more challenging to modify the molecule in order to achieve the desired property.",
            "Optimization for Source Molecule": "There are several potential modifications that could be made to the source molecule in order to improve its GSK3-beta property. For example, the fluorine atoms could be replaced with less electronegative groups such as chlorine or bromine. Alternatively, the nitrogen atom could be removed altogether. By making these changes, it may be possible to increase the overall electron density on the molecule and thereby enhance its ability to bind to the target protein.",
            "Final Target Molecule": "CC(NC(=O)Nc1cc2[nH]nc(OCCOC(F)(F)F)c2cn1)c1ccc(F)cc1"
        }
    },
    {
        "src": "Cn1c(=O)c(-c2c(Cl)cccc2Cl)cc2cnc(NCCCN3CCOCC3)nc21",
        "tgt": "COc1cccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)c1",
        "src_logd": 2.954245279848664,
        "tgt_logd": 4.14711893029954,
        "src_solubility": 1.9126198768475369,
        "tgt_solubility": -0.1358903317440678,
        "src_clint": 1.949086793965369,
        "tgt_clint": 1.8819898249492104,
        "src_qed": 0.5830057360670298,
        "tgt_qed": 0.4935322643431872,
        "src_drd2": 0.10334333193736699,
        "tgt_drd2": 0.003049181732089922,
        "src_jnk3": 0.28,
        "tgt_jnk3": 0.34,
        "src_gsk": 0.24,
        "tgt_gsk": 0.61,
        "type": "large",
        "json_results": {
            "Structural Analysis of Source Molecule": "The source molecule is composed of 4 rings with 65 atoms.",
            "Property Analysis": "GSK3-beta property is not predicted as it has no value.",
            "Limitation in Source Molecule for Property": "None detected.",
            "Optimization for Source Molecule": "Ring B could be replaced by another ring that can form hydrogen bond with GSK3-beta protein. Ring A can also be modified to enhance its binding affinity.",
            "Final Target Molecule": "CCCN3CCOCC3NC2CCCCN3CCOCC3"
        }
    }
]